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Observational studies: focus on leflunomide 
 
The view that randomized controlled trials are the ‘gold standard’ for evaluation and that 
observational methods have little additional value is widely accepted. According to some 
experts, the results of observational studies should not be used for defining evidence-based 
medical care. The major criticism of observational studies is that unrecognized confounding 
factors may influence the results [1]. However, results from a study comparing the results of 
observational and randomized, controlled studies in 19 different fields of medicine, suggest 
that observational studies usually do provide valid information [2].  
One of the major reasons to conduct observational studies is the potentially limited 
external validity of the results of the randomized controlled trial. To what extent are the 
results of the trial generalisable to a population not treated in the setting of a specific trial? 
Three potential reasons for limited external validity can be recognized. The first may be that 
the health care providers in the setting of clinical trials are unrepresentative, for example 
because they are innovators. Secondly, the patients included in the trials may have 
characteristics different from the patients treated outside the setting of the trial. Thirdly, the 
treatment in the trial may be atypical. For example, patients included in trials may receive 
different care due to intensified follow-up [1]. These aspects may introduce bias in the 
results of the trial, resulting in limited external validity.  
In the treatment of rheumatoid arthritis a number of therapeutical options are available. 
The potential algorithms to prescribe these medications change rapidly. New medications 
enter the market, medication is prescribed in combination therapy, in higher doses and 
earlier in the disease process. In combination with the development of practical tools for 
evaluating disease activity and response to treatment [3], these changing algorithms provide 
the rationale for studying treatment outcomes in observational studies in rheumatoid 
arthritis. 
In the last few years, on the basis of results from large randomized controlled trials, 
leflunomide, the tumor-necrosis alpha antagonists and anakinra (interleukin-1 receptor 
antagonist) were registered for the treatment of rheumatoid arthritis (RA) [4-9]. To estimate 
the additional value in daily practice, critical evaluation of treatment effects in observational 
studies in the setting of day-to-day care, complementary to the results of randomized 
controlled trials, may be considered as essential. 
Chapter 2 highlights aspects of the use of leflunomide for the treatment of RA in daily 
rheumatological practice. Chapter 2.1 describes a long-term follow-up study of patients with 
RA starting leflunomide therapy in the first four years after registration. The objective is to 
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study the effectiveness, incidence of adverse drug reactions and withdrawal from 
leflunomide in an outpatient population with RA in the setting of care-as-usual. Shortly after 
the registration of leflunomide for the treatment of RA a number of reports of severe 
hepatotoxicity were published. Although in these reports, besides leflunomide exposure, 
other potential factors for hepatotoxicity were present, hepatotoxicity became an important 
safety issue concerning leflunomide. In chapter 2.2 the incidence and severity of 
hepatotoxicity in terms of elevations of plasma liver enzyme activities in patients on 
leflunomide treatment is studied. Information on predictors for better survival of leflunomide 
use, at the start of leflunomide therapy may offer opportunities for treatment optimization. In 
chapter 2.3 possible predictors for better leflunomide survival are studied. From the long 
term follow-up data of patients treated with leflunomide for RA in two regions in the 
Netherlands (Twente and Friesland) a set of patient-, disease- and treatment characteristics 
were analysed to detect potential predictors.  
 
 
Therapeutic drug monitoring: focus on A77 1726, the active 
metabolite of leflunomide 
 
From randomized controlled trials with leflunomide it is known that a large proportion (up 
to 47%) of patients withdraw leflunomide therapy due to adverse effects and inefficacy within 
12 months after start of therapy [5,6]. Studies in clinical practice, outside the setting of 
randomized controlled trials, suggest even higher withdrawal rates [10-12]. For this reason 
optimization of leflunomide therapy is warranted. Therapeutic drug monitoring based on 
steady state serum concentrations of the active metabolite of leflunomide, A77 1726, may 
allow individualised dose adjustment and consequently increase clinical effectiveness. In 
phase II pharmacokinetic population modelling studies, a relationship between steady state 
A77 1726 serum concentrations < 13 mg/L and a reduced probability of clinical success is 
described [13]. However, information on A77 1726 serum concentrations is not incorporated 
in current clinical decision making in the rheumatological practice. For this reason, in 
chapter 3 the potential role of therapeutic drug monitoring in leflunomide treatment 
optimization is studied. 
In chapter 3.1 we describe the technical and clinical validation of a high-performance 
liquid chromatography method with ultraviolet detection for the analyses of A77 1726. Using 
this validated method, in chapter 3.2, the relationship between RA disease activity and the 
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Switching therapies: focus on parenteral gold therapy 
 
The market of rheumatoid arthritis treatment changes as new therapies are registered, 
and existing treatment options are withdrawn from the market. For patients using these 
withdrawn therapies, alternatives have to be found. A recent example is the withdrawal of 
aurothioglucose from the Dutch market due to insufficient quality of the raw material. 
Aurothiomalate was registered shortly after withdrawal of aurothioglucose and presented as 
the alternative preparation. Although never formally studied, some publications suggest that 
switching from aurothioglucose to aurothiomalate may be associated with the introduction of 
novel clinical problems [14,15].  
To study earlier suggestions of negative safety of the aqueous aurothiomalate 
preparation, we monitored patients switching from the oily aurothioglucose preparation 
Auromyose® to the aqueous aurothiomalate preparation Tauredon® in a national case series 
study in the Netherlands. Chapter 4 describes the results of the follow-up of a cohort of 
patients during the first year after switching from aurothioglucose to aurothiomalate. 
 
 
Drug safety: focus on drug-drug interactions with disease-modifying 
antirheumatic drugs 
 
When prescribing and administering drugs, drug related problems may occur. Drug 
related problems include medication errors (involving an error in the process of prescribing, 
dispensing or administering a drug, whether there are adverse consequences or not) and 
adverse drug reactions (any response to a drug which is noxious and unintended, and which 
occurs at doses normally used in man for prophylaxis, diagnosis or therapy of disease, or 
the modification of physiological function) [16].  
The possibility of drugs to influence each others safety or efficacy is known as a drug-
drug interaction (DDI). DDI may increase morbidity and mortality and may lead to hospital 
admission [17-19]. Due to ageing and the presence of comorbidity in the population with RA, 
patients are prone to polypharmacy and therefore are at risk for the adverse reactions due to 
DDI. 
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Many sources for information of DDI are available for health care providers, ranging from 
the summaries of product characteristics and product leaflets to text books and internet sites 
[20,21]. However, knowledge of a DDI between two drugs is no guarantee for timely 
recognition of the DDI or for taking the appropriate action to prevent the risk of an adverse 
outcome. Computerized drug interaction surveillance systems may be helpful in detecting 
and preventing DDI with clinical significance. However, many pharmacists and doctors 
experience these systems to yield a large number of alerts with questionable or unclear 
clinical significance (suboptimal specificity), fail to provide identifiable patient and medication 
risk factors, fail to detect all relevant DDI (suboptimal sensitivity) and to include a variable 
set of DDI [22-25]. These problems stress the importance of transparency and selectivity in 
choosing the DDI to be included in computerized drug interaction surveillance systems on 
the basis of a structured assessment procedure. 
Chapter 5 concerns the DDI aspect of drug safety. Chapter 5.1 describes the 
procedures for structured assessment of DDI and the translation of this assessment to the 
computerized drug interaction surveillance system by the Working Group on 
Pharmacotherapy and Drug Information in the Netherlands. Further, this chapter presents 
results of the revision of the complete computerized drug interaction surveillance system of 
the Royal Dutch Association for the Advancement of Pharmacy on the basis of these 
assessments. In chapter 5.2 an overview is given of potential DDI with disease-modifying 
antirheumatic drugs (DMARD), to assess the clinical relevance of potential DDI with 
DMARDs and to study the uniformity in assessment of clinical relevance between 
rheumatologists and hospital pharmacists. 
 
 
Objectives of the thesis  
 
The objective of this thesis is to study aspects of safety and effectiveness of 
pharmacotherapy in the treatment of rheumatoid arthritis, with focus on leflunomide and 
parenteral gold. Furthermore, in this thesis the assessment of the clinical relevance of drug-
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We prospectively studied the effectiveness, incidence of adverse drug reactions and 
withdrawal from leflunomide in an outpatient population with rheumatoid arthritis in a setting 
of care-as-usual.  
Methods 
In this prospective case series study, from outpatient medical records a standard dataset 
was collected including patient and disease characteristics, data on leflunomide use and 
adverse drug reactions.  
Results 
During the study period 136 rheumatoid arthritis patients started leflunomide. Median 
(range) follow-up duration was 317 (11-911) days. Sixty-five percent of patients experienced 
at least one adverse drug reaction related to leflunomide. During follow-up 76 patients (56%) 
withdrew from leflunomide treatment, mainly because of adverse drug reactions (29%) or 
lack of effectiveness (13%). The overall incidence density for withdrawal from leflunomide 
was 56.2 per 100 patient years. Complete data for calculating effectiveness using a 
validated disease activity score on 28 joints (DAS28) was available for 48, 36, and 35% of 
patients at 2, 6, and 12 months follow-up, respectively. Within a 12-month period after start 
of leflunomide treatment 76% of the evaluable patients were classified as moderate or good 
responder according to the DAS28 response criteria. 
Conclusions 
In the setting of care-as-usual rheumatoid arthritis patients starting leflunomide frequently 
experienced adverse drug reactions. More than half of the patients withdrew from 
leflunomide treatment within a year after start of leflunomide treatment, mainly because of 
adverse drug reactions. 




In January 2000 leflunomide was registered in The Netherlands for treating active 
rheumatoid arthritis (RA). Leflunomide represents a novel class of disease-modifying 
antirheumatic drugs (DMARDs), the isoxazole derivatives. The active metabolite, A77 1726, 
reversibly inhibits the enzyme dihydroorotate dehydrogenase, the rate limiting step in the de 
novo synthesis of pyrimidines [1]. Hypotheses on the pathogenesis of RA suggest an 
important role of activated T lymphocytes [2]. Since lymphocytes are dependent on de novo 
synthesis of pyrimidines for their cell division, proliferation of lymphocytes is inhibited by A77 
1726.  
Efficacy and safety of leflunomide has been demonstrated in randomized controlled trials 
that included over 1000 RA patients treated with leflunomide [3-10]. These trials 
demonstrate similar efficacy of leflunomide in suppressing RA as compared with 
sulfasalazine and methotrexate (MTX) after 6 months to two years of follow-up [3-7]. By 
inclusion of patients based on selection criteria and strict follow-up, the trial setting is 
different from daily clinical practice in rheumatology. This difference between research trial 
and day-to-day practice, may limit the validity of extrapolation of data from these trials to RA 
patients in daily practice [11]. Therefore, studies on clinical experience in daily practice with 
newly approved therapies are important to inform about potential discrepancies with the 
results from randomized controlled trials. 
In this study we evaluated the effectiveness, safety and withdrawal rates for leflunomide 





Patients and inclusion criteria 
All consecutive RA patients to whom leflunomide was prescribed de novo by their 
rheumatologist in the outpatient departments of rheumatology in Friesland (in the Northern 
part of the Netherlands) from January 2000 to June 2002 were included. The study was 
approved by the institutional review board of the Medical Centre Leeuwarden. Patients 
signed informed consent for collecting a standard dataset using outpatient medical records 
and were followed from the start of leflunomide until the end of the study, withdrawal from 
leflunomide or death.  
Patients were recorded as ‘lost-to-follow-up’ where the last visit to the outpatient 




The standard dataset, using outpatient medical records, consisted of patient 
characteristics, disease characteristics, adverse drug reactions (ADRs) and leflunomide use 
data. During the study period information on leflunomide treatment in combination with other 
DMARDs was scarce. However, to gain insight in combination of leflunomide with other 
DMARDs or systemic corticosteroids, data on co-medication were recorded in the study 
database. 
Intensity of follow-up of the patients during this study was similar to non-study patients, 
reflecting care-as-usual. Patients visited the rheumatologist on a routine basis at least every 
month up to 6 months after start of leflunomide treatment and every 2 months thereafter. 
During these visits a routine physical examination was conducted, parameters for calculation 
of the disease activity score on 28 joints (DAS28) were scored, and ADRs were collected. In 
case of intercurrent problems, patients contacted the outpatient department by telephone. In 
the outpatient medical records all telephone contacts were registered. 
An exception to the rule of care-as-usual was made for registration of parameters 
necessary for calculation of the Disease Activity Score using 28 joints (DAS28), a validated 
score for establishing disease activity and response to therapy in RA [12,13]. The DAS28 is 
calculated from four parameters: the number of swollen and tender joints from a total of 28 
joints, the erythrocyte sedimentation rate and the visual analogue score for general health 
as subjectively estimated by the patient. High, moderate or low disease activity is 
categorized as DAS28-scores >5.1, >3.2 but ≤5.1 and >2.6 but ≤3.2, respectively. Remission 
is categorized as DAS28-scores ≤ 2.6 [12]. Response to treatment according to DAS28 is 
defined by both the difference in DAS28 and the DAS28 achieved (Table 1).  
To avoid bias of DAS28 on treatment decisions during the study period, DAS28 was 
calculated from the individual parameters only at the end of the follow-up. Due to possible 
incompleteness of DAS28 data we predefined the category of evaluable patients for 
response on leflunomide treatment as patients for whom a DAS28 at start of leflunomide, and 
at least 1 follow-up DAS28 in the first 12 months of leflunomide treatment was available. 
DAS28-response was categorized comparing the DAS28 at start of leflunomide treatment with 
the lowest DAS28 achieved during the first 12 months. 
During each follow-up visit patients were asked about ADRs. When an ADR or abnormal 
biochemical parameter was encountered and judged by the rheumatologist or patient as 
possibly related to leflunomide, then the ADR was recorded. Different ADRs reported by one 
patient although possibly related to each other, were recorded as separate ADRs (for 
example weight loss in combination with loss of appetite, nausea or vomiting). Serious ADR  
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Table 1. Definition of DAS28 responder categories. 
 
DAS28-calculation: DAS28 = 0.56* √TJS28 + 0.28*√SJS28 + 0.70*ln ESR + 0.014 VASgeneral health 
 
 Change in DAS28 
DAS28 achieved >1.2 >0.6 -≤1.2 ≤0.6 
≤3.2 good moderate non 
>3.2- ≤5.1 moderate moderate non 
>5.1 moderate non non 
Legend: DAS28 = Disease Activity Score on 28 joints; ESR = Erythrocyte Sedimentation Rate (mm/hr); SJS28 = Swollen 




were predefined as fatal, life-threatening, permanently disabling or necessitating hospital 
admission. 
Withdrawal from leflunomide was defined as any reported discontinuation of leflunomide 
use. In the study database the reasons for withdrawal from leflunomide treatment were 
recorded using the information in the medical record. If no specific reason for withdrawal 
was mentioned, this was recorded in the study database as such.  
In case of restarting leflunomide, patients were not eligible for re-entry into this study. To 




The place of leflunomide in the sequence of DMARD therapy in RA is not standardised, 
and was left to the judgement of the individual rheumatologist. Leflunomide was prescribed 
in a dose as recommended by the manufacturer, i.e. loading dose of 100 mg daily for 3 





Access database software (Microsoft Corp.) was used for data collection, data validation 
and data selection. SPSS 10.0 for Windows (SPSS Inc, Chicago, Ill, USA) was used for 
statistical analysis. For survival analysis the Kaplan-Meier estimator was used to calculate 






All consecutive RA patients to whom leflunomide was prescribed during the study period 
were included, leading to a study population of 136 patients. Reasons for starting 
leflunomide were: ADRs on previous DMARD-therapy (n=26; 19%), ineffectiveness of 
previous DMARD (n=63; 46%) or a combination of these reasons (n=17; 13%). For 3 (2%) 
patients the specific reason for starting leflunomide was not registered in the files and 27 
patients (20%) started leflunomide as the first DMARD.  
Table 2 shows baseline demographic and clinical characteristics of our study population 
and characteristics from the populations from the major randomized controlled trials [3-5]. 
Median (range) follow-up duration was 317 (11-911) days. Three patients died during follow-
up from a natural cause, i.e. not related to leflunomide use and 8 patients were lost to follow-
up. 
Four patients (3%) started leflunomide in combination with MTX in order to bridge the 
first months, in which leflunomide was not expected to show optimal effectiveness. Three of 
these patients were withdrawn from MTX within 6 months after start of leflunomide as 
planned and 1 patient continued using the combination. For 15 patients (11%) another 
DMARD was added to leflunomide treatment (8x MTX, 5x hydroxychloroquine, 1x 
sulfasalazine, 1x infliximab) during follow-up. From these patients 7 withdrew from 
leflunomide (3x for reason of ADR (all MTX-combinations), 2x ineffectiveness (1 MTX and 1 
sulfasalazine combination) and 2x combination of ADR and ineffectiveness (both MTX-
combination)), 2 were lost to follow-up, 1 patient died. 
 
Effectiveness and adverse drug reactions 
Due to incomplete data for calculating DAS28, disease activity and response category 
data were not available for every patient at every visit. At baseline for 79 of 136 patients 
(58%) a DAS28 could be calculated. Complete DAS28-data were available for 48, 36, and 
35% of patients at 2, 6, and 12 months follow-up, respectively. 
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25 
Table 2. Baseline demographic and clinical characteristics of the present study 
population on leflunomide compared with [3-5]. 
 
Demographic characteristics Present study [3]1 [4] [5] 
Number of patients  136 133 182 501 
Age (yrs)     
Mean [SD] 65 [13] 58 [11] 54 [12] 58 [10] 
Range 27-89    
 > 65 years (%)  47   31 
Female (%) 66 76 73 71 
Rheumatoid factor positive (%) 80 79 65  
Duration of RA (yrs)     
Mean [SD] 9.7 [11.2] 7.6 [8.6] 7.0 [8.6] 3.7 [3.2] 
Range 0.1-60    
≤ 2 years (%) 33 38 39 44 
Previous DMARD treatment (%) 76 60 56 66 
DMARDs failed (n)     
Mean [SD] 1.7 [1.5] 1.2 0.8 [1.0] 1.1 [1.1] 
Range 0-6    
DAS28     
Mean [SD] 5.25 [1.01]    
Median [Range] 5.32 [2.4-8.4]    
Last DMARD prior to leflunomide (n(%))     
 Methotrexate 40 (30)    
Sulfasalazine 28 (22)    
Hydroxychloroquine 22 (17)    
Other 14 (10)    
Concomitant systemic corticosteroids (n(%)) 59 (43) 29 54 36 
< 7.5 mg prednisone equivalents daily 46 (33)    
≥ 7.5 mg prednisone equivalents daily 13 (10)    

















































Patients at risk 124   99  72 
Evaluable patients  
 n 60   36  25 
 % 48   36  35 
   




Ninety-eight percent of the evaluable patients had high or moderate disease activity 
according to DAS28 criteria at baseline. Two percent of the patients started leflunomide 
treatment with a baseline DAS28 ≤ 2.6. Responder categories according to DAS28-criteria at 
the 2, 6 and 12 month follow-up visits are shown in Figure 1. 
During follow-up in 89 patients (65%) at least one ADR was registered. Table 3 lists the 
ADRs reported by 3 or more patients (>2%) during follow-up. All patients reporting weight 
loss also report loss of appetite or diarrhea. Loss of appetite does not seem to be directly 
correlated to other gastrointestinal complaints, since only 3 of 6 patients who report loss of 
appetite also report diarrhea (3x) and/or nausea (1x). 
For one patient a serious adverse event was recorded leading to hospitalization. This 
patient, who was one of the 9 patients developing hypertension, suffered an ischemic 
cerebrovascular accident during leflunomide treatment. 
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Table 3. Percentage of patients reporting adverse drug reactions (>2% of patients in 
present study) and associated withdrawal rates, in comparison with [4,5]. 
 
 Present study [4] [5] 
 ADR Withdrawal ADR Withdrawal ADR Withdrawal 
 n % % %  %  
Withdrawal (per patient year follow-up)        
Overall   56.2  30  47 
ADR  29.6  19  22 
Ineffectiveness   12.6  7  4 
Combination of ADR and ineffectiveness   7.4     
Other   6.7  4  8 
        
ADR        
diarrhea 40 29.4 18.4 33.5 5.51 18 2 
nausea 15 11.0 5.9 20.92  11.2 1.2 
pruritus 10 7.4 4.4     
hypertension 9 6.6 4.4 11 1.1   
skin problems3 8 5.9 3.7  2.2 7.4 1.2 
alopecia 7 5.1 2.9 9.9 0.5 16.6 1.4 
gastrointestinal pain 7 5.1 2.2 13.7  5.6 0.8 
abnormal enzyme elevations4 6 4.4 3.7 11 7.1 5.4 1.6 
loss of appetite 6 4.4 2.2     
headache 4 2.9 1.5   6.2 0.6 
vomiting 3 2.2 2.2     
hoarseness 3 2.2 2.2     
weight loss 3 2.2 1.5     
mouth ulceration 3 2.2 0.7 6.0  3.0 0.2 
Legend: ADR = adverse drug reaction, ALT = Alanine AminoTransferase, AST = Aspartate AminoTransferase.  
1
 Withdrawal for all gastrointestinal ADR; 2 Nausea and vomiting; 3 ADR skin events reported (n): eczema (2), rash (2), 
psoriasis (1), urticaria (1), dry skin (1), not specified (1); 4 Abnormal plasma liver enzyme levels are defined as ALT or 
AST values > 2x upper limit of normal values, reference [5] > 3x upper limit of normal values. 
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Additionally, the following ADRs were reported with a frequency of <2% of the patient 
population: fatigue (n=2), polyuria, nocturnal enuresis, tinnitus, dry mouth, constipation, 
palpitations, dry eyes, lightheadedness, tremor, excessive perspiration, anxiety, swollen lips, 
muscle cramps in lower legs, coughing, nailfold laesions, thrombocytopaenia (nadir 75 x 
109/L), and dizziness (all n=1). 
 
Withdrawal from leflunomide 
During follow-up 76 patients (56%) withdrew from leflunomide treatment. Fifty percent of 
study patients withdrew from leflunomide within 405 days. The incidence density for 
withdrawal from leflunomide was 56.2 per 100 patient years. Figure 2 shows Kaplan-Meier 
estimates of the proportion of patients withdrawing from leflunomide during follow-up. 
Reasons for withdrawal from leflunomide were ADRs (n=40; 29%), ineffectiveness or loss of 
effectiveness (n=17; 13%) or a combination of ADR and insufficient effectiveness (n=10; 
7%). Two patients (1.5%) stopped leflunomide for comorbidity not related to leflunomide 
treatment (sepsis, toxic megacolon). For 7 patients (5%) no specific reason for stopping 







































At risk (n) 136                         91                          62                           48                          36                          17                           8                                       
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ADRs recorded for 3 or more (>2%) patients during follow-up in our study and two 
randomized controlled trials with 12 month follow-up data [4,5].  
Within 12 weeks after withdrawal from leflunomide 7 patients out of 76 (9%) restarted 
leflunomide and 6 of these patients were still on leflunomide treatment at the moment of 
closing the study database (January 2003). Reasons for stopping leflunomide before 
restarting at a later date were ADR for 4 patients, ineffectiveness for 1 patient, and a 





Data from randomized controlled trials are obtained from selected populations in the 
setting of a strict follow-up. A follow-up study of patient populations outside the setting of a 
randomized controlled trial is an important tool to learn about drug effectiveness and safety 
in daily clinical practice. Leflunomide has become available for the treatment of RA in a 
period of new treatment possibilities for RA and a changing treatment algorithm. Early 
treatment of RA with DMARDs [14], the availability of tumor necrosis factor-alpha 
antagonists [15,16] and the use of DMARDs in combination therapy [17] highlight the need 
for careful evaluation of new treatment options. In this study we followed an outpatient 
population that started leflunomide for the treatment of RA in the setting of care-as-usual. 
Some remarks should be made on the limitations of the present study. Firstly, for only 
35-58% of the patients on leflunomide therapy at every visit a DAS28-score could be 
calculated due to missing data. Although we expected some incompleteness of DAS28-data 
before start of the study and we prospectively defined patients that could be evaluated, the 
influence of missing data on overall response rates is not clear. The percentage of DAS28-
non-evaluable patients reflects one of the basic concepts of the study. In our study we follow 
an outpatient population of patients, consecutively starting leflunomide treatment for their RA 
in a setting of care-as-usual. Since optimization of completeness of DAS28 data would 
require serious interference with the concept of care-as-usual, and therefore with clinical 
decision making, it was explicitly decided at the start of the study not to interfere during 
follow-up.  
Secondly, this study was conducted in the period immediately following leflunomide 
licensing for the treatment of RA. The role of leflunomide in the treatment algorithm of RA is 
not yet defined and may well change in time. This is illustrated by the results of studies 
combining leflunomide with MTX [8,18]. This changing place of leflunomide in the treatment 
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of RA may have consequences for patient outcomes in terms of treatment effectiveness or 
safety and the applicability of our study results in the future.  
At baseline 98% of our evaluable study population had high or moderate RA disease 
activity according to DAS28-criteria [12]. This percentage reflects high adherence of the 
rheumatologists to the approved indication of leflunomide for adult patients with active RA. 
During the first 12 months of follow-up the percentage of non-responders per visit varied 
from 24-45%. Despite this large percentage of non-effective treatment, overall only 13% 
withdraw from leflunomide treatment because of ineffectiveness. This discrepancy may be 
explained by the fact that DAS28-scores are not used in routine clinical practice in our centre 
as key parameter for treatment effectiveness. Another explanation may be the strategy of 
postponing withdrawal in the expectation of effectiveness later during treatment. This 
strategy is supported by data from recent studies. Results of randomized controlled trials 
[3,4] show improvement of disease severity characteristics for an increasing percentage of 
the study population in the period from 3 to 6 months after start of leflunomide treatment. 
Dougados et al [19] in their 6 month follow-up data from the RELIEF study, show an 
increase of 56.0 to 77.1% in patients achieving a ‘definitive’ responder rate at week 12 and 
24 of leflunomide treatment, respectively. 
Comparison of our results with randomized controlled trials, Strand et al [4] and Emery et 
al. [5] in their studies found 52%, respectively 50.5% of patients reaching 20% improvement 
according to the criteria of the American College of Rheumatology (ACR20) after 12 months. 
In our study 76% of evaluable patients show moderate or good response at 12 month follow-
up according to DAS28-criteria. Although degrees of responder categories according to 
DAS28- and ACR20-criteria correlate well [20,21], comparison of our results with randomized 
controlled trials is not possible due to incompleteness of our data on DAS28-scores.  
In the past few years, despite the availability of leflunomide and the biologicals, the 
treatment algorithm for RA did not change significantly. Therefore, the place of leflunomide 
in the treatment strategy of RA in the past few years was often secondary to other DMARDs. 
Its place in therapy is reflected by the baseline characteristics of our study population.  
Compared with the population included in the randomized controlled trials on leflunomide 
our population is older, has a longer duration of RA, and is more frequently and more 
intensively treated with DMARDs before start of leflunomide. Major inclusion criteria from the 
randomized controlled trials were a duration of RA >4-6 months [4,5], an age over 18 years, 
active disease, and no concomitant DMARD-therapy [3-5]. Concomitant use of systemic 
corticosteroids (≤ 10 mg prednisolone daily or equivalent) was allowed if doses were stable 
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for 4 weeks previous to leflunomide start. In our study at baseline 89% of patients had a 
disease duration over 4 months, all patients were over 18 years of age (range 27-89), 98% 
had active disease and 86% used leflunomide as the only DMARD during complete follow-
up. In our population 30% of patients switched from MTX to leflunomide, in contrast, in the 
study by Strand et al [4] patients who were pretreated with MTX were not eligible. This 
pretreatment with MTX could influence comparability of data with the present study. 
However, MTX pretreatment as risk factor for early leflunomide withdrawal or reduced 
effectiveness has not been published to our knowledge. Overall, the in- and exclusion 
criteria used in the randomized controlled trials [3-5] are not different from the characteristics 
in the present study population. 
The ADR reported in our study are in general comparable with the ADR reported in 
randomized controlled trials. However, in our study hoarseness and loss of appetite 
(independent of other gastrointestinal complaints) are reported in >2% of patients. These 
ADRs are not reported in the randomized controlled trials [3-5].  
Compared with randomized controlled trials with approximately the same duration of 
follow-up as the present study [4,5] the overall withdrawal rate is high in our study, 56.2 per 
100 patient years. Withdrawal due to ADRs represent approximately 50% of the overall 
withdrawal rate both in our study and in the randomized controlled trials. 
Results of studies outside the setting of randomized controlled trials show high 
withdrawal rates for leflunomide treatment. Geborek et al [22] report withdrawal from 
leflunomide treatment of 78% of patients after 20 months follow-up. Siva et al [23] and 
Hajidiacos et al [24] report withdrawal rates of 63% and 78%, respectively, after 6 months of 
follow-up. After 12 months withdrawal rates of 48% [24] and 57% [25] have been reported. 
Wolfe et al [26] report failure rates of 55.5% per 100 patient years follow-up. The results 
from these observational studies and the present study suggest that the withdrawal rate 
from leflunomide treatment is higher in the setting of care-as-usual compared with 
randomized controlled trials. 
The high withdrawal rates demand optimization of the leflunomide treatment schedule 
and better recognition of patients at risk for treatment failure. Possibilities for improvement of 
the treatment schedule include omitting the loading dose, weekly dosing and/or titration of 
the leflunomide dose on the basis of the plasma concentrations of the active metabolite, A77 
1726.  
Siva et al [23] present evidence for the higher risk (odds ratio 2.0, confidence interval 
1.76-2.4) of leflunomide treatment failure after start with the 3x100 mg loading dose 
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compared with no loading or other loading schemes. Erra et al [27] in their study conclude a 
potential association between the loading dose and early adverse events. Several studies 
investigated weekly dosing of leflunomide [28,29]. Although these studies are small and 
have a short duration of follow-up, the results suggest that weekly dosing of leflunomide is 
effective and well tolerated.  
The relationship between mean steady-state plasma concentrations of A77 1726 and the 
probability of clinical success [30] suggest options for therapeutic drug monitoring and dose 
titration. Since leflunomide dosing is limited to 20 mg daily with possible dose reduction to 
10 mg [31], at the moment the possibilities for dose adjustment are scarce. On the basis of 
study results thus far, the abovementioned options for adaptation of the dosing schedule of 






Leflunomide offers an efficacious treatment option although the incidence of withdrawal 
from leflunomide therapy in the present study was high. ADRs are the most frequently 
encountered reason for withdrawal. The results of this study stress the importance of critical 
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Leflunomide is a novel disease-modifying antirheumatic drug. Because of reports on 
possible hepatotoxicity and adaptations in the recommendations for monitoring liver function 
during leflunomide treatment, we conducted a study to evaluate the incidence and severity 
of hepatotoxicity.  
Methods 
We included consecutive, rheumatoid arthritis patients starting treatment with leflunomide in 
the region of Friesland (The Netherlands) between January 2000 and January 2002. During 
follow-up patient characteristics, disease characteristics, and clinical and laboratory data on 
liver functions were registered. Severity of hepatotoxicity was categorized using the National 
Cancer Institute Common Toxicity Criteria, as moderate (grade 2), severe (grade 3) or life 
threatening (grade 4). 
Results 
101 patients were followed for a median period of 10 months (range 0.5-12). Grade 2 or 3 
elevations in any liver function blood test were recorded for 9 patients (8.9%). No grade 4 
elevations were recorded. Four patients (4%) showed grade 2-3 aminotransferase 
elevations. Due to grade 2 hepatotoxicity one patient (1%) was withdrawn from leflunomide 
treatment, and one patient continued leflunomide in a reduced dose. In eight of nine patients 
with grade 2-3 liver function blood tests, these elevated liver function tests occurred within 6 
months after starting leflunomide. None of the patients with grade 2 or 3 toxicity had a 
history of hepatic disease, eight patients concomitantly used potential hepatotoxic co-
medication. Eight (8%) patients used leflunomide in combination with methotrexate, one of 
these patients developed hepatotoxicity. No clinical signs of serious hepatotoxicity were 
recorded during follow-up.  
Discussion 
In 8.9% of the patients grade 2 or 3 hepatotoxicity was recorded within the first year after 
start of leflunomide therapy based on liver enzyme determinations. In the majority of the 
patients liver enzyme elevations occurred within the first 6 months of therapy and resolved 
during continued follow-up. None of the patients showed clinical signs of hepatotoxicity.  
Conclusion 
Under continued monitoring of liver functions hepatotoxicity during leflunomide use does not 
seem to be a major problem in our population. 




Leflunomide is an isoxazole-derived disease-modifying antirheumatic drug (DMARD). 
Leflunomide is a prodrug that is converted in the gastrointestinal tract and plasma to its 
active metabolite A77 1726. The primary mechanism of action of A77 1726 is inhibition of 
the enzyme dihydroorotate dehydrogenase, a key enzyme in the de novo pyrimidine 
synthesis. Activated T-lymphocytes, which are believed to play a central role in the 
pathogenesis of rheumatoid arthritis (RA), depend on de novo pyrimidine synthesis for 
proliferation. Efficacy and safety of leflunomide has been demonstrated in several 
randomized controlled trials [1-3].  
Elevated liver function tests during treatment with leflunomide in patients with RA have 
been reported in randomized controlled trials studying leflunomide monotherapy in 
comparison with methotrexate or sulfasalazine [1-3]. After registration of leflunomide, the 
European Agency for the Evaluation of Medicinal Products (EMEA) in 2001 published a 
Public Assessment on rare, serious cases of hepatotoxicity during use of leflunomide. 
Reasons for the publication of this Public Assessment were 15 cases with fatal outcome and 
reported liver failure, liver toxicity, hepatitis, cholestatic jaundice or increased liver function 
tests over more than 100,000 patient years of leflunomide exposure. In 10 of the 15 cases 
an hepatic event was not the immediate cause of death. The reported cases were 
complicated by associated factors possibly leading to poor outcome, such as pre-existing 
liver disease, pre-existing/concurrent illness or comorbidity (heart failure, infection/sepsis, 
pulmonary failure, pancreatitis) and other possibly hepatotoxic co-medication. 
The discussion on potential hepatotoxicity of leflunomide led to adaptations in the 
Summary of Product Characteristics and the package leaflet stressing the importance of 
monitoring of liver functions. The current recommendations are Alanine AminoTransferase 
(ALT) must be checked before initiation and at least at monthly intervals during the first 6 
months of treatment and every 8 weeks thereafter. For ALT elevations between 2- and 3-
fold the upper limit of normal (ULN) values (as defined by the local laboratory), dose 
reductions from 20 mg to 10 mg may be considered and monitoring must be performed 
weekly. If ALT elevations >2 x ULN persist or if ALT of >3 x ULN are present, leflunomide 
must be discontinued and washout initiated. 
Observational cohort studies performed after registration of a novel medication regimen 
can help to establish the effectiveness and safety of leflunomide in a setting similar to daily 
clinical practice. Therefore, to gain insight in the timing, frequency and severity of elevated 
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liver enzymes or clinical hepatotoxicity and to aid in clinical decision-making, we conducted 
a study on the incidence and severity of hepatotoxicity during leflunomide treatment in a 





Patients and inclusion criteria 
All consecutive RA patients who were prescribed leflunomide de novo by their 
rheumatologist in the outpatient departments of rheumatology in Friesland (in the Northern 
part of the Netherlands) from January 2000 to January 2002 were included. The human 
research committee approved the study, and written informed consent was received from all 
subjects in the study. Patients were followed from the moment they started leflunomide 
therapy for a period of 12 months, unless they withdrew from leflunomide therapy or died. 
The standard dataset consisted of patient characteristics, disease characteristics, 
parameters of disease activity (disease activity on 28 joints; DAS28) [4], and laboratory data 
on liver function.  
Intensity of follow-up of the patients during this study was not different from non-study 
patients in our outpatient departments of rheumatology, reflecting care-as-usual. Patients 
visited the rheumatologist every 4-8 weeks for the first 6 months after initiation of 
leflunomide therapy. Depending on the judgement of the rheumatologist the frequency of 
visits after 6 months was reduced to at least every 6 months. With laboratory controls, 
including hepatic enzyme determination, every 8 weeks. 
During visits a routine interview and physical examination, including collection of DAS28-
parameters, took place. In the case of problems the outpatient department of rheumatology 
could be reached by telephone. Every telephone contact was registered in the outpatient 
medical records. 
During follow-up visits patients were asked about adverse events. When an adverse 
event or an abnormal biochemical parameter was encountered and judged by the 
rheumatologist or patient as possibly related to leflunomide use, then the adverse event was 
recorded in the study database. All liver enzyme determinations during the 2-year study 
period were recorded and used for analysis. 
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Medication 
Leflunomide was prescribed by the participating rheumatologists on the basis of good 
clinical practice for their individual patients in a dose as recommended by the manufacturer: 
starting with a loading dose of 100 mg daily for 3 days, followed by 20 mg daily. 
 
Clinical and outcome measures 
Clinical data on hepatotoxicity (hepatitis, jaundice, (pre)coma hepaticum) were collected 
from outpatient and hospital medical records. Since the reports on hepatotoxicity of 
leflunomide involved both hepatocellular injury and cholestatic adverse events, laboratory 
data on the enzyme activities of Alanine AminoTransferase (ALT), Aspartate 
AminoTransferase (AST) as well as Alkaline Phosphatase (AP), Gamma 
GlutamylTranspeptidase (GT) and Total Bilirubin (TB) were collected. With respect to the 
moment of occurrence of the hepatotoxicity event, four time frames were defined, based on 
the start of leflunomide treatment.  
• Period I consisted of the time from 6 months prior to the start of leflunomide until the 
start of leflunomide.  
• Periods II consisted of the time period during leflunomide treatment from 1 week to 1 
month  
• Period III consisted of the time period during leflunomide treatment from 1-6 months 
• Period IV consisted of the time period during leflunomide treatment from 6-12 months 
after start of leflunomide.  
In the case of more than one known laboratory value for one parameter in a specific 
period the value most deviating from the ULN was recorded in the database. Laboratory 
values on liver enzyme activities were categorised according to the National Cancer Institute 
Common Toxicity Criteria (NCI-CTC, see Table 1). Primary outcome measures, with general 
NCI-CTC definitions, were grade 2 (moderate adverse event), grade 3 (severe and 
undesirable adverse event) or grade 4 (life-threatening or disabling adverse event) toxicity 
according to NCI-CTC.  
The ULN of a given liver enzyme activity is defined as the mean of the distribution + 2 
standard deviations of a presumably representative healthy population. It has to be taken 
into account that, by definition, 2.5% of healthy individuals will have an abnormal elevation 
of a given liver chemistry test [5]. For this reason, and the minor clinical relevance of grade 1 
enzyme activity elevations (NCI-CTC description: mild adverse event), we scored only grade 
2, 3 or 4 liver enzyme elevations. 
Chapter 2.2 
40 
Table 1. NCI-CTC categories for liver enzyme elevations. 
 
Toxicity grade (NCI-CTC)  
0 1 2 3 4 
Description1 WNL ≤ 2.5 x ULN >2.5-≤ 5 x ULN >5-≤ 20 x ULN > 20 x ULN 
Description for TB WNL - <1.5 x ULN ≥1.5-< 3 x ULN  ≥ 3 x ULN 
Clinical relevance of 
hepatotoxicity 
None Mild Moderate Severe Life-threatening/ 
disabling 
Legend: TB = total bilirubin, NCI-CTC = National Cancer Institute - Common Toxicity Criteria, ULN = upper limit of 
normal value, WNL=within normal limit. 1Description of NCI-CTC categories for alanine aminotransferase (ALT), 




For patients with grade 2-4 elevations of liver enzyme activities in any time period during 
leflunomide treatment (II-IV) the medical records were screened for pre-existent hepatic 
disease, or potential hepatotoxic co-medication. Co-medication was regarded as potentially 
hepatotoxic when liver toxicity was mentioned in Meyler’s Side Effects of Drugs [6]. Alcohol 
intake was not scored during the study. 
As AP and GT may behave as acute phase proteins and, therefore, may result from an 




Access database software (Microsoft Corp.) is used for data collection and selection. 





During the study period, clinical and laboratory data on hepatotoxicity are recorded for 
101 patients who began leflunomide therapy with a median follow-up of 10 (range 0.5-12) 
months (see Table 2). Due to variable follow-up (i.e. not all patients had liver enzyme levels 
determined  in all periods)  and withdrawal of leflunomide,  the number of patients  for whom 
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Table 2. Patient characteristics. 
 
Demographic characteristics  
Number of patients 101 
Age (yrs)  
Mean (SD) 65.1 (12.9) 
Range 27-89 
Female (%) 65 
Rheumatoid factor positive (%) 77 
Duration of RA (yrs)  
Mean (SD)  10.3 (11.9) 
Range 0.1-60 
  
Clinical characteristics  
Previous DMARD treatment (%) 82 
Number of previous DMARDs  
Mean ± SD 1.7 (1.4) 
Range 0-6 
Concomitant systemic corticosteroids (n(%))  
None 55 (54) 
< 7.5 mg prednisone equivalents daily 29 (29) 
≥ 7.5 mg prednisone equivalents daily 17 (17) 




liver function blood tests could be evaluated for periods I, II, III or IV vary from 101, 68, 81 
and 55, respectively.  
Of the 101 patients enrolled over the 2 years of the study, a total of 38 patients (38%) 
withdrew from leflunomide treatment. Reasons for withdrawal were given as: adverse drug 
reactions (n=23;23%; 22 of these withdrawals were due to non-hepatic events and one due 
to grade 2 elevations of liver enzymes), ineffectiveness (n=5;5%), combination of inadequate 
effectiveness and adverse drug reactions (n=7;7%) or other reasons (3;3%). 
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In total 997 liver function blood tests were recorded during the 2-year study period, with 
316, 190, 290 and 201 test results in periods I to IV, respectively. Throughout the 2-year 
study period no clinical signs of severe hepatotoxicity have been registered. 
During period I, before start of leflunomide treatment, no patients had grade 2 or 3 ALT 
or AST elevations and three patients had grade 2 or 3 AP and/or GT elevations. None of 
these latter patients show further elevation of AP/GT-activities during follow-up. 
In total, during follow-up 9 patients (8.9%; CI95 3.2-14.6%) show grade 2-3 elevations in 
liver enzyme activities (see Table 3). Of these, maximal deviations from ULN were grade 3 
elevations for 3 patients and grade 2 elevations for 6 patients. None of the patients with 
grade 3 elevations withdrew leflunomide therapy for the reason of hepatotoxicity. One of 
these patients showed spontaneous regression of ALT elevations in period III (grade 2) and 
period IV (grade 1); for two patients with grade 3 GT elevations, these elevations were 
present throughout complete follow-up. Abdominal ultrasound scans were performed for 2 of 
the 3 patients with grade 3 elevations, showing no evidence for pathology. No liver biopsies 
were performed for any of the patients with grade 3 elevations. No grade 4 toxicity was 
recorded.  
Concerning the potential risk factors accounted for, none of these patients with grade 2 
or 3 elevations have a history of hepatic disease or excessive alcohol consumption. Eight of 
the 9 patients with grade 2-3 elevations of liver enzyme activities have been treated with 
other potentially hepatotoxic co-medication concomitantly (6x diclofenac, 1x MTX and 1x 
flucloxacilline).  
During the 2-year study period 8 (8%) patients used leflunomide in combination with 
MTX. One of these patients developed grade 2 liver enzyme elevations (AP and GT) during 
combination therapy, which reverted to normal values under continued combination 
treatment without dose reduction of leflunomide or MTX.  
For two patients (2%) the prescription of leflunomide was altered. For one patient the 
daily leflunomide dose was reduced from 20 mg to 10 mg in period III, due to grade 1 activity 
elevations of ALT and AST. Transferase activities normalized after dose reduction, but 
leflunomide was withdrawn due to insufficient effectiveness after 8 months on therapy. For 
one patient leflunomide was withdrawn on the basis of grade 2 ALT-elevations in period III.  
Neither AP nor GT values correlate with DAS28-scores, showing correlation coefficients 
of 0.002 and 0.06, respectively. 
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Table 3. Characteristics of patients with grade 2 or 3 liver enzyme elevations. 
 




(months) Total1 Abnormal 2 Enzyme NCI3 Period 
Remarks 
1 12 7 1 GT 3 4  
2 12 12 6 AP (3x), GT (3x) 3 2  
3 12 16 2 ALT 3 3  
4 3 6 1 GT 2 2 Death, unrelated to treatment 
5 12 10 2 ALT/AST 2 3  
6 12 6 1 GT 2 3  
7 12 10 2 ALT/AP 2 3  
8 3 9 1 ALT 2 3 Withdrawn; hepatotoxicity 
9 2 7 1 AP 2 2 Withdrawn; mouth ulcerations 
Legend: ALT = alanine aminotransferase, AST = aspartate aminotransferase, AP = alkaline phosphatase and GT = 
gamma glutamyltranspeptidase. 1 Total number of liver enzyme determinations; 2 Total number of grade 2 or 3 






In previous, large, randomized, controlled trials abnormal plasma liver enzyme levels are 
recorded for patients treated with leflunomide. Emery et al report abnormal plasma liver 
enzyme levels in 5.4% of patients in their study during the first year of treatment [1]. Strand 
et al report aminotransferase elevations for 14.8% of patients on leflunomide, all of which 
are reversible under continued treatment or after treatment withdrawal [2]. The current 
surveillance of RA patients on leflunomide in the Netherlands gives a valuable estimate of 
the incidence of hepatotoxicity under conditions of care-as-usual and strict monitoring of 
liver function tests. In our population the occurrence of grade 2-3 liver enzyme elevations is 
8.9%. The incidence of grade 2-3 aminotransferase elevations during leflunomide treatment 
is 4%. The grade 2-3 elevations of liver enzyme function activities that are recorded in our 
study, regress to normal under ongoing leflunomide treatment for all except one patient.  
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Some remarks on the present study have to be made. First, the absence of clinical signs 
of severe hepatotoxicity and/or grade 4 liver enzyme elevations in our study does not mean 
that these events cannot occur. Based on our population size the upper limit of the 95% 
confidence interval of the probability of these events is 2,95%. 
Second, the present data do not allow comparison with hepatotoxicity during treatment 
with DMARDs other than leflunomide. In the setting of ‘care-as-usual’ this comparison 
cannot be made since the place of leflunomide in the treatment strategy of RA is different 
from the place of MTX or sulfasalazine. This may result in treatment of populations with 
different characteristics and potential confounding of treatment safety results. Despite this 
consideration the results of the surveillance of Cannon et al. do not show evidence of an 
increased risk of hepatotoxicity for patients receiving leflunomide compared with other 
DMARDs [7]. The surveillance of Wolfe et al., however, although not statistically significant, 
suggest that the rates of hepatic adverse events attributed to leflunomide and MTX were 
higher than those attributed to other DMARDs [8].  
Randomized, controlled trials offer direct comparison of hepatic safety of leflunomide 
versus other DMARDs in populations with comparable characteristics. Abnormal plasma 
liver enzyme levels during 12 months follow-up are reported for 5.4% and 16.3% of patients 
on leflunomide and MTX, respectively, in a randomized controlled trial of these two agents in 
patients with RA [1]. Aminotransferase elevations are reported in 14.8% and 11.5% of 
patients treated with leflunomide and MTX, respectively, during 12 months of follow-up [2]. 
In their recently published systematic review of controlled clinical trials Osiri et al. concluded 
that elevated liver function tests were not significantly different for the leflunomide-treated 
patients than for those treated with methotrexate (MTX) or sulfasalazine (SSZ) [9].  
Third, the duration of follow-up in our study, similar to the randomized controlled trials, is 
restricted to a maximum of 12 months [1-3]. A part of the population could not be followed 
up to this point. Thirty-eight percent of the patients withdrew from leflunomide therapy before 
12 months for reasons other than hepatotoxicity, and liver function tests were not available 
for the complete 12 month period for all patients. Early withdrawal and incompleteness of 
follow-up leads to 55 of 101 patients for which data on liver enzymes were available after 6 
months of follow-up. Furthermore, hepatotoxicity occurring after a period of 12 months is 
therefore not recorded in our study. Eight of the nine patients (89%) with grade 2-3 liver 
enzyme elevations in the present study show these elevations within 6 months after start of 
leflunomide treatment. In three randomized, controlled trials, ALT elevations >3x ULN 
occurred within 9 months after start of leflunomide treatment in 18 of 23 patients (78%) [1-3]. 
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Two-year follow-up data from these trial populations show no late toxicity or unexpected 
adverse events after longer duration of leflunomide treatment [10,11]. This suggests that the 
potential underestimation of liver enzyme activity elevations due to too short follow-up will be 
minimal. 
Fourth, in 8 of 9 patients with liver enzyme elevations potentially hepatotoxic co-
medication is used. Hepatotoxicity due to these co-medications or due to a combination of 
these co-medications with leflunomide cannot be excluded. 
Lastly, only 8% of the study patients use leflunomide in combination with MTX. 
Therefore, results of this study are not applicable for extrapolation to populations using 
leflunomide in combination therapy. Several studies report on the incidence of elevated liver 
enzyme activities in patients treated with leflunomide alone or in combination with MTX [12-
14]. Kremer et al. conclude that combination treatment of leflunomide and MTX can be used 
safely with appropriate monitoring of liver enzyme activity [13]. The combination of DMARDs 
in the treatment of RA may become more important, but information on the place of 
combination therapy in the treatment paradigm and the preferred combinations still is scarce 
[15]. Leflunomide monotherapy in RA will therefore remain an important treatment option, 






This study presents a critical evaluation and risk assessment on the incidence of 
hepatotoxicity during leflunomide use in an outpatient setting of care-as-usual. 
Hepatotoxicity during leflunomide treatment does not seem to present a major problem, 
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To determine factors predictive for leflunomide drug survival in an outpatient population with 
rheumatoid arthritis in a setting of care-as-usual.  
Methods 
A standard dataset was collected from medical records of consecutive outpatients on 
leflunomide treatment for rheumatoid arthritis between January 2000 and June 2003. The 
dataset consisted of patient-, disease- and treatment-characteristics at the start of 
leflunomide treatment, and data on leflunomide use.  
Results 
Leflunomide was started in 279 patients and 173 patients (62,0%) withdrew from treatment 
during follow-up. From univariate analysis, concomitant systemic corticosteroid use and an 
erythrocyte sedimentation rate < 35 mm/hr at start of leflunomide were found to be predictive 
for better leflunomide survival. Furthermore, the attending rheumatologist was correlated 
with leflunomide drug survival. Multivariate analysis suggested attending rheumatologist, 
concomitant systemic corticosteroid use and erythrocyte sedimentation rate < 35 mm/hr at 
start of leflunomide to be associated with leflunomide survival. 
Conclusions 
Concomitant systemic corticosteroid use, erythrocyte sedimentation rate at the start of 
treatment and attending rheumatologist were found to be predictive for leflunomide survival. 
Information on these predictors at the start of leflunomide therapy may offer opportunities for 
treatment optimization. 




Prescription of new drugs and treatment outcomes may be influenced by channelling 
bias. Channelling bias occurs when a patient is directed away from or toward a specific 
therapy because of underlying medical conditions or perceptions of the provider. This 
phenomenon has to be taken into account when extrapolating the results from randomized 
controlled trials (RCT) to the setting of care-as-usual, for example in the case of leflunomide 
treatment for rheumatoid arthritis (RA). 
In January 2000 leflunomide was registered for the treatment of active RA on the basis 
of results from RCTs including over 1000 patients [1-3]. Results of an observational study in 
patients with RA on leflunomide treatment showed that the characteristics of patients treated 
in a setting of care-as-usual differ from characteristics of the populations in RCTs suggesting 
channeling of the application of leflunomide [4]. Compared with the population included in 
the RCTs on leflunomide the population in this study had a higher age, had longer disease 
duration, and was more intensively treated with disease-modifying antirheumatic drugs 
(DMARDs) before starting leflunomide.  
Compared with RCTs, reporting withdrawal rates that varied from 30 to 47 per 100 
patient years [2,3], observational studies consistently showed higher withdrawal rates, 
suggesting that channeling influences treatment outcomes in clinical practice. Failure rates 
have been reported between 55.5% and 56.2% per 100 patient years follow-up [4,5]. 
Furthermore, Geborek et al [6] and Siva et al [7] reported withdrawal from leflunomide 
treatment of 78% of patients after 20 months and 63% after 6 months follow-up, 
respectively. The results from these observational studies suggested that the withdrawal 
rate from leflunomide treatment is higher in the setting of care-as-usual compared with RCT. 
Time remaining on therapy is a relevant factor in obtaining treatment effects, particularly 
in chronic diseases such as RA. To optimize leflunomide therapy, early recognition of factors 
predictive for longer treatment survival is of clinical importance. For this reason we 
performed a study to determine predictors for leflunomide withdrawal in an outpatient 






In two regions in the Netherlands (Friesland and Twente) with a total of approximately 
1,200,000 inhabitants, consecutive patients starting leflunomide for RA were followed. The 
study period started in January 2000, the moment leflunomide became available for 
prescription in the Netherlands, and ended in June 2003.  
 
Leflunomide prescription 
At the time this study was conducted the place of leflunomide in the sequence of 
DMARD therapy in RA was not standardised. Generally, methotrexate was regarded as the 
option of first choice, and anti-TNF-alpha therapy was available in cases with higher disease 
activity with proven failure of at least 2 DMARDs. Prescription of leflunomide therefore was 
left to the judgement of the attending rheumatologist. Leflunomide was prescribed in a dose 
as recommended by the manufacturer, i.e. a loading dose of 100 mg daily for 3 days, 




Data were collected at every routine visit of the patient to the rheumatologist. The 
standard dataset, using outpatient medical records, consisted of patient characteristics, 
disease characteristics, laboratory values and data on leflunomide prescription. Intensity of 




Some discontinuations of leflunomide use are temporary, for example in case of 
intercurrent disease or surgery, and are not related to adverse drug reactions or 
ineffectiveness of therapy. For this reason the withdrawal from leflunomide was defined as a 
reported discontinuation of leflunomide for a period longer than 12 weeks. Continuation of 
leflunomide therapy within this time frame was considered to be a continuation of the first 
treatment episode and patients were not recorded as ‘withdrawn from therapy’. In case of 
restarting leflunomide after a period over 12 weeks, patients were not eligible for re-entry 
into this study. 
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Predictors 
Possible predictors for survival of leflunomide treatment that are continuous variables 
were studied as continuous and as dichotomous variables. Translation to a dichotomous 
variable was performed by dividing the population in two groups of equal size.  
 
Statistical analysis 
SPSS 12.0.1 was used for data collection, data validation, data selection and statistical 
analysis. Kolmogorov-Smirnov analysis was used to test for normality. T-test and Mann 
Whitney tests were used where appropriate, to test for differences between group means of 
continuous variables. For comparison with respect to categorical variables Fisher’s exact 
test was used. Cumulative probability of survival was estimated using Kaplan-Meier curves.  
Differences in time-to-withdrawal for certain factors were investigated using log-rank 
tests or cox-proportional hazard models, for continuous and categorical variables, 
respectively. Forward stepwise conditional regression analysis was used for studying 
variable contribution in multivariate analysis. The independent variables in this analysis were 
selected on the basis of the univariate analysis. Variables with p < 0.10 in univariate analysis 






Twelve rheumatologists included a total of 279 patients, 140 from the Friesland and 139 
from the Twente region. With a median of 21 (range 2-49) patients starting leflunomide per 
rheumatologist. Baseline demographic and clinical characteristics of the population are 
shown in Table 1. The dataset was complete, except for 16 and 41 patients for whom no 
erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) at start of leflunomide 
treatment were recorded, respectively. 
Patients were followed for a median period of 9.6 months (range 0.1-38.9 months). In 
only 3 patients the 3-day 100-mg loading dose was omitted, they started with the daily 
maintenance dose of 20 mg. Ten patients started leflunomide treatment in combination with 
methotrexate. None of the patients started leflunomide in combination with other DMARDs. 
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Table 1. Baseline demographic and clinical characteristics1  
 
Characteristic  
Age (years) 62.6 [12.6] 
Female (%) 66.7 
IgM rheumatoid factor positive (%) 81.4 
RA disease duration (yrs ; median[range]) 10.0[0-60] 
Leflunomide as first DMARD (%) 9.7 
DMARDs prior to leflunomide (n; median[range]) 3.0 [0-11] 
Concomitant systemic corticosteroids (%) 43.0 
ESR start (mm/hr) 40 [26] 
CRP start (mg/L) 38 [33] 
Creatinine (micromoles/L) 78[22] 
Dose reduction (%)  16.8 
Legend: CRP start = C-reactive protein at the start of leflunomide therapy, DMARD = disease-modifying antirheumatic 
drug, ESR start = erythrocyte sedimentation rate at the start of leflunomide therapy, RA = rheumatoid arthritis. 1 Values 
represent mean[SD] unless stated otherwise. 
 
 
Populations in both centres differed with respect to age, RA disease duration, the 
number of DMARDs prescribed prior to the start of leflunomide, serum creatinine at start of 
leflunomide and the fraction of patients for which the leflunomide dose was reduced to 10 
mg during follow-up. Other variables did not show significant differences between the two 
centres. Centre is therefore taken into account as a covariate or stratifier for further 
analyses. Since attending rheumatologists work exclusively in one of the two centres, for 
analysis of the attending rheumatologist as potential predictor, centre is not taken into 
account as stratifier. 
 
Leflunomide survival 
Of the 279 patients included, 173 patients (62.0%) were withdrawn from leflunomide 
therapy, a withdrawal rate of 54.3 per 100 patient years. Seventeen patients were lost to 
follow-up. Figure 1 shows the Kaplan-Meier cumulative survival curve for all included 
patients. Figure 2 shows the Kaplan-Meier cumulative survival curves per centre. No 
significant differences in survival rates between both centres were found (p=0.20). 
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Legend: + = censored observation 
 
 
Predictors for longer leflunomide drug survival 
 
Independence of variables 
Since the characteristics of the population treated per rheumatologist may differ, the 
association between rheumatologist and patient age, ESR at start of leflunomide, CRP at 
start of leflunomide, duration of RA or number of DMARDs prior to leflunomide were studied. 
Rheumatologist was found to be associated with disease duration (p=0.01) and number of 
previous DMARDs (p<0.001).  
Rheumatoid factor status was not associated with systemic corticosteroid use at the start 
of leflunomide therapy. 
Systemic corticosteroid use was not associated with ESR at start (p=0.08) and IgM 
rheumatoid factor status (p=0.44). However, significant positive associations were found 
between systemic corticosteroid use and CRP at start (p<0.001, mean CRP at start with and 
without concomitant corticosteroids was 48 and 30 mg/L, respectively). 


































Legend: + = censored observation 
 
Uni- and multivariate analysis 
Gender, age, disease duration, IgM rheumatoid factor status, the number of previous 
DMARDs, serum creatinine, ESR and CRP at start of leflunomide were found not to be 
predictive for leflunomide survival.  
However, concomitant systemic corticosteroid use at the start of leflunomide, and ESR at 
start of leflunomide (dichotomous; <35 versus ≥ 35 mm/hr) were recognized as predicting 
variables for leflunomide survival (Table 2). Patients with concomitant systemic 
corticosteroid use at start of leflunomide showed better leflunomide survival (Hazard ratio 
95% [95CI] 1.35 [1.00-1.83]) compared with patients without concomitant systemic 
corticosteroids. Patients with ESR < 35 mm/hr at start of leflunomide showed better 
leflunomide survival at complete follow-up (Hazard ratio [95CI] 1.38 [1.01-1.88]) compared 
with patients with ESR ≥ 35 mm/hr. The attending rheumatologist was associated with 
leflunomide drug survival. From all rheumatologist, the rheumatologist with the median 
number of included patients was used as the reference rheumatologist for calculating 
maximal contrasts within the group of attending rheumatologists in this study. 
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Table 2. Univariate analysis for predictors for longer leflunomide drug survival. 
 
Factor Univariate analysis Multivariate analysis 
 p-value Hazard ratio 
(95CI) 




0.05  0.006  
No  1 (reference)  1 (reference) 
Yes  1.35 [1.00-1.83]  1.58 [1.14-2.21] 
ESR start (mm/hr) 0.04  0.03  
≥35  1 (reference)  1 (reference) 
<35  1.38 [1.01-1.88]  1.42 [1.03-1.96] 
Rheumatologist 0.095 0.60-2.661 0.02 0.54-2.301 
Legend: 95CI = 95% confidence interval, ESR start = erythrocyte sedimentation rate at the start of leflunomide therapy.  
1




Multivariate analysis showed attending rheumatologist, concomitant systemic 
corticosteroid use and an ESR < 35 mm/hr at start of leflunomide to be related to 





Predicting which patients will benefit from leflunomide is a challenge in optimising 
leflunomide treatment. Our data show that attending rheumatologist, concomitant systemic 
corticosteroid use and ESR at the start of leflunomide treatment to be predictors for survival 
of leflunomide in an outpatient population with RA in the setting of care-as-usual.  
At the time we started our study no information on the predictors for longer survival of 
leflunomide was published. Wolfe et al [5], defining treatment failure as a combination of 
withdrawal or addition of a second DMARD, recognized adverse effects and clinical status 
prior to starting methotrexate or leflunomide as predictors for treatment failure. For obvious 
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reasons adverse events occurring during treatment were not part of our analysis. Contrary to 
Wolfe et al. [5] corticosteroid use was found to be of predictive value.  
Wolfe et al report the exclusive use of self-reported data and the absence of laboratory 
data to predict discontinuation as one of the limitations of their study. In our study we used 
laboratory data as far as they are part of routine rheumatological care. Lower ESR, in 
contrast to CRP, was found to be a significant predictor of leflunomide survival.  
Our data suggest that the individual rheumatologist influences leflunomide survival 
significantly. A recent publication on the long term survival of methotrexate also concluded 
that attending rheumatologist was a predictor for long term methotrexate survival [8]. Our 
findings are in accordance with this result and again suggest that remarkable heterogeneity 
exists in the treatment strategies of individual rheumatologists. Although the prescription of 
leflunomide was not prospectively standardised in our study, leflunomide was not 
considered the option of first choice in the study period. Clinical guidelines aim to reduce 
variations in practice and to promote uniform and consistent best practice. Whether 
development of guidelines on the application of leflunomide in RA will lead to more uniform 
strategies and improvement of treatment outcomes remains to be determined. 
Siva et al. [7] found age < 44 or > 75 years, annual family income < $60.000 and the use 
of a 3-day 100-mg loading dose to be predictive for leflunomide discontinuation. In our study 
age was not found to be predictive. Annual income is not part of routine rheumatological 
care in our practices and therefore could not be scored in our study. Since all but three 
patients in our study started leflunomide using the dosing schedule advised in the Summary 
of Product Characteristics, the absence of a loading dose could not be recognized as a 
predictor in our study.  
In this study a limited dataset was collected. Therefore, some predictors for leflunomide 
survival may have been missed in the current analysis. Retrospective data collection may 
have introduced a bias and therefore may have influenced results. However, no patients 
were excluded from the study, the dataset was complete and the data collected were not 
subject to observer bias. This suggests that if any bias was present this may have had only 
a limited influence. 




Concomitant systemic corticosteroid use, ESR at the start of treatment and attending 
rheumatologist were found to be predictive for leflunomide survival. Whether specific 
interventions based on this information, for example by more frequent follow-up of patients 
with a higher risk of treatment withdrawal, will lead to improved treatment outcomes remains 
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Leflunomide is a disease-modifying antirheumatic drug, which is bioactivated by formation of 
A77 1726. In this study a rapid and simple quantitative assay using a reversed phase HPLC-
UV method is validated for detection of A77 1726 in human serum.  
Methods 
The HPLC-UV method uses a mobile phase consisting of methanol and a KH2PO4-buffer 
(45mM, pH=3) (50:50,v/v), at a flow rate of 1 mL/min. A77 1726 is detected by UV-
absorption at 295 nm with a retention time of 8.9 minutes. Demoxepam is used as internal 
standard.  
Results 
Validation showed lower and upper limits of quantitation of 0.5 and 100 mg/L, respectively. 
The assay was linear over the concentration range of 0.5-100 mg/L (r2 > 0.999). Intra- and 
inter-day precision showed coefficients of variation within 15% over the complete 
concentration range; accuracy was within 8%. Commonly prescribed drugs to treat 
rheumatoid arthritis, like disease-modifying antirheumatic drugs, analgesics and 
corticosteroids, and their main metabolites, are separated from A77 1726 with a resolution > 
2. Serum levels of A77 1726 in 37 patients on leflunomide therapy were determined using 
this HPLC-UV method. Measured serum A77 1726 serum concentrations in patient samples 
showed large variability with a range of 3 to 176 mg/L.  
Conclusion 
We developed an easy-to-operate and validated HPLC-UV method for determination of A77 
1726, the active metabolite of leflunomide, in human serum. The proposed method can be 
employed for the assay of A77 1726 in rheumatoid arthritis patient samples. 





Leflunomide is a disease-modifying antirheumatic drug (DMARD) of the isoxazole class. 
After oral administration leflunomide is rapidly, non-enzymatically and completely converted 
into its long-acting, active metabolite A77 1726 (2-cyano-3-hydroxy-N-(4-
trifluoromethylphenyl)-crotonamide; Figure 1) [1]. A77 1726 has antirheumatic activity 
through inhibition of the enzyme dihydro-orotate dehydrogenase (DHODH), a key enzyme in 
the de novo production of pyrimidines in T-lymphocytes, a process essential for T-
lymphocyte proliferation. 
Leflunomide showed antirheumatic activity which is comparable to methotrexate and 
sulfasalazine in randomized controlled trials using an oral dosage regimen starting with 100 
mg once daily for three days followed by a maintenance dose of 20 mg once daily [2]. 
Overall in these trials 50-67% of patients reach efficacy end points during 12 month follow-
up, with some patients reaching clinical efficacy 4-6 months after start of leflunomide 
therapy. Adverse events most frequently reported are gastrointestinal complaints (diarrhea, 
abdominal pain). The combination of late onset of efficacy, the high incidence of adverse 
events early in therapy and the uniform dosing schedule limit drug survival rates of 
leflunomide in populations with rheumatoid arthritis [3-5]. On the basis of these results 
optimization of leflunomide therapy is needed. 
An option for treatment optimization is dose adjustment on the basis of A77 1726 steady 
state serum concentrations. In preregistration pharmacokinetic population modelling studies, 
a relationship between steady state A77 1726 serum concentrations and the probability of 
clinical success is suggested [6]. Leflunomide is rapidly and completely metabolized after 
oral administration, for that reason serum concentrations are unmeasurable. Furthermore, 
no clinically relevant inhibition of DHODH by leflunomide is supposed, leaving the 
antirheumatic activity of leflunomide negligible. Therapeutic drug monitoring therefore should 
focus on the major active metabolite A77 1726. 
Earlier, published methods for determination of A77 1726 had several drawbacks. For 
example these methods lack information on interference of detection and quantitation of the 
analyte, A77 1726, by co-medication frequently used in patients with rheumatoid arthritis [7]; 
did not consider hydrolysis of leflunomide in extraction solvents containing potassium 
carbonate [8]; or had a upper limit of quantitation (due to loss of linearity) that did not cover 




Figure 1. Chemical structures of leflunomide (left; CAS 75706-12-6) and its major 





Moreover, information on the stability of A77 1726 in serum kept under refrigerated 
conditions for more than one month [7] was lacking. 
To study the potential value of therapeutic drug monitoring of A77 1726 in optimizing the 
treatment schedule a validated method of analysis in human serum is needed. In this study 
we present a rapid and simple, validated HPLC-UV method for A77 1726 in human serum. 
Moreover, data are presented on the range of steady state serum concentrations of A77 
1726 in a population of patients with rheumatoid arthritis on 10 to 20 mg leflunomide daily. 
 
 
Material and methods 
 
Equipment 
Chromatographic separation was performed using a Waters HPLC apparatus (Milford, 
MA, U.S.A.) consisting of a gradient pump and a column heater (model 2690) and a variable 
wavelength detector (model 996 PAD). Isocratic chromatographic separation was performed 
on a reversed-phase LiChrospher 100 RP-18e column (5 µm; 125 x 4 mm; Merck 
(Darmstadt, Germany)). The column temperature was maintained at 25°C.  
All samples and standard solutions were chromatographed using a mixture of methanol: 
KH2PO4 (45 mM, pH=3) (50:50, v/v) as the mobile phase (flow rate 1.0 mL min-1), and UV-
detection at 295 nm and an injection volume of 20 µL. Data from each chromatographic run 
were processed using Waters Millennium 32 software. Concentrations were calculated from 
the peak height ratios in relation to the internal standard. 
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Preparation of the mobile phase 
The mobile phase (methanol: KH2PO4 (45 mM, pH=3) (50:50, v/v)) was prepared by 
adding methanol and the KH2PO4-buffer and mixing well. The KH2PO4-buffer (45 mM, pH=3) 
was prepared by dissolving 6.124 g KH2PO4 in 1000 mL distilled water and correcting the pH 




Acetonitrile and methanol were purchased from Labscan Ltd (Dublin, Ireland). Ethanol, 
KH2PO4, demoxepam and phosphoric acid 85% were obtained from Merck (Darmstadt, 
Germany). Acetaminophen, azathioprine, celecoxib, diclofenac, hydroxychloroquine, 
ibuprofen, methotrexate, naproxen, rofecoxib, prednisolone, sulfapyridine, sulfasalazine, 5-
aminosalicylic acid, 6-mercaptopurine were purchased from Bufa (Uitgeest, The 
Netherlands). Leflunomide and A77 1726 were kindly provided by Aventis Pharma 
(Hoevelaken, The Netherlands). Human serum was derived from a pool of anonymous and 
unpaid, healthy volunteers. 
 
Preparation of standard solutions and samples 
For preparation of the stock standard solution, A77 1726 was dissolved in ethanol at a 
concentration of 1 mg/mL, placed in an ultrasonic water bath for 1 hour and subsequently 
diluted to 100, 10 and 1 mg/L by spiking blanc human serum. 
For the stock internal standard solution, demoxepam was dissolved at a concentration of 
2.5 mg/L in acetonitrile. 
Patient serum samples were prepared by adding 1.0 mL internal standard solution to 100 
µL serum. The tubes were capped, vortexed for 3 seconds and centrifuged at 3000 rpm for 5 
minutes. Two-hundred µL of the supernatant was transferred into a glass tube and 
evaporated to dryness under a gentle nitrogen stream at 40 °C. The residue was dissolved 
in 200 µL of the mobile phase. The reconstituted specimens were vortexed for 10 seconds 
and analysed with HPLC-UV. 
Serum calibration standards (0.5, 1, 10, 25, 50, and 100 mg/L) and quality control 
standards were separately prepared by spiking blanc pooled human serum with increasing 






Linearity was examined over the complete concentration range of A77 1726 (0.5-100 
mg/L) and using acceptable fit to linear regression by calculating regression coefficients and 
evaluation of sum of squares of residuals, tested with analysis of variance. 
Selectivity was examined by studying the interference of endogenous peaks and 
antirheumatic medication with the determination of A77 1726 and the internal standard. 
Criteria set for lack of interference were a resolution between the peak of A77 1726/internal 
standard and potentially interfering medication of > 2. Selection of potentially interfering 
antirheumatic drugs was based on UV-absorption spectra at 295 nm. These drugs were 
studied at serum concentrations reached with doses routinely used for rheumatoid arthritis. 
Drugs and their major metabolites studied were non-steroidal anti-inflammatory drugs 
(celecoxib, diclofenac, ibuprofen, naproxen, rofecoxib), DMARDs (azathioprine/6-
mercaptopurine, hydroxychloroquine, methotrexate, sulfapyridine, and sulfasalazine/5-
aminosalicylic acid) and acetaminophen. Since (methyl)prednisolone and prednisone do not 
have relevant absorption at 295 nm, these compounds are very unlikely to interfere with 
detection and quantitation of A77 1726. However, to confirm this, the major metabolite of 
prednisone, prednisolone, was studied for interference. 
The intra-day reproducibility was examined by analysing five independent preparations 
of each standard concentration, each injected twice, on the same day. Inter-day 
reproducibility was examined by analysing five independent preparations of each 
concentration, each injected twice, on three different days within a period of two weeks. For 
each day freshly prepared standard solutions were made. All standard solutions were 
prepared from an independent standard stock solution. The calibration curve used for 
calculating patient samples was the calibration curve determined from all data of the five 
separate repetitions of intra-day reproducibility testing. These data were fitted using least 
sum of squares analysis. Criteria for acceptance for each separate calibration curve were a 
regression coefficient of > 0.99 and a back-calculated concentration within 15% of the 
respective target concentrations. 
Stability of A77 1726 40 mg/L in human serum was studied by repeated, duplicate 
analysis. The solution was divided into 5 mL aliquots and kept frozen at -20 ºC until the 
moment of analysis. Samples were analysed at 0, 1, 2, 4 weeks and every 4 weeks for a 
period of 5 months, subsequently. Criteria for acceptable stability were differences between 
the baseline concentration and the concentration at follow-up < 5%. 
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Figure 2. Chromatogram of serum of a patient with a A77 1726 serum concentration of 















All consecutive patients visiting our outpatient department of rheumatology from January 
to October 2003, who were on stable, daily doses of leflunomide for at least 6 months were 
asked to participate in this part of the study. After obtaining written informed consent a single 
venous blood sample in anti-coagulant-free evacuated containers was taken for 
determination of A77 1726. After sampling, blood was directly centrifuged and serum was 
kept frozen at –20 ºC. Directly prior to analysis samples were processed as described 
above. In case of serum concentrations of A77 1726 above the upper limit of quantification, 
samples were diluted 1:1 with blanc human serum and re-analysed. All patient samples 
were injected twice, comparable to standard and control samples. 






With the described method resolution >2 of A77 1726 and the internal standard 
(demoxepam) was achieved (Figure 2). The retention times of demoxepam and A77 1726 
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Table 1. Intra- and inter-day reproducibility for A77 1726 in human serum. 
 










0.5 0.52 ± 0.03 8.1 4.4 0.53 ± 0.03 5.0 7.0 
1 1.08 ± 0.03 2.8 8.0 0.94 ± 0.12 13.2 -5.9 
10 9.95 ± 0.06 0.6 -0.5 10.03 ± 0.30 3.0 0.3 
25 24.5 ± 0.05 0.2 -1.9 24.6 ± 0.52 2.1 -1.8 
50 48.0 ± 0.03 0.1 -3.9 48.4 ± 0.73 1.5 -3.2 
100 100.2 ± 0.15 0.1 0.2 100.7 ± 0.61 0.6 0.7 




Chromatograms displayed no interference of endogenous peaks in spiked blanc human 
serum samples and patient samples. No interference of antirheumatic medication with peaks 
of demoxepam and leflunomide was detected, with all co-medication peaks having a 
resolution > 2 compared with the peaks of A77 1726 or the internal standard. 
The calibration curve for A77 1726 was linear over the full concentration range from 0.5 
mg/L to 100 mg/L, with a correlation coefficient of 0.9996. Correlation between the ratio as 
calculated from the chromatograms and the spiked concentrations is best described by: 
 
[Concentration A77 1726] (mg/L) = 11.5 x [peak height ratio] + 0.14 
 
Table 1 shows the results of the intra- and inter-day reproducibility, respectively. 
Coefficients of variation and accuracy for intra- and inter-day reproducibility are within 15% 
over the concentration range from 0.5 to 100 mg/L. On the basis of these results, the lower 
and upper limits of quantitation for A77 1726 with this analytical method are 0.5 mg/L and 
100 mg/L respectively. 
Results from the assays for studying stability of A77 1726 over the period of 5 months 
are shown in table 2. Until week 8 samples show acceptable stability, with differences 
between the baseline concentration and concentration at follow-up < 5%.  
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Table 2. Stability of A77 1726 40 mg/L in human serum. 
 
T (weeks) Measured concentration  
(mg/L; n=2 each) 
Deviation from T=0  
(mg/L) 
Devation from T=0  
(%) 
0 40.7 - - 
1 41.7 1.0 2.4 
2 42.6 1.9 4.7 
4 42.1 1.4 3.4 
8 40.9 0.2 0.5 
13 43.9 3.2 7.9 
17 41.3 0.6 1.5 




Thirty-seven blood samples were taken for determination of A77 1726 concentrations. 
Patient and treatment characteristics of the population are given in Table 3. Measured 
serum concentrations show large variability, ranging from 3 to 176 mg/L. For two patients 
(5%) A77 1726 serum concentrations were found to be > 100 mg/L, 133 and 176 mg/L, 
respectively. Mean[SD] concentrations for the 10 and 20 mg daily dose groups are 39[30] 





The current analytical method shows acceptable intra- and inter-day accuracy and 
precision over the A77 1726 concentration range from 0.5-100 mg/L. Endogenous serum 
peaks and antirheumatic medication did not interfere with the detection of A77 1726 in the 
current HPLC-UV method. Stability of A77 1726 in human serum kept frozen at –20 °C until 
the moment of analysis is shown up till 8 weeks after sampling. This enables analysing 
patient samples in one run up to 8 weeks after sampling in future studies. 
To study the applicability of the validated method in clinical practice a series of patient 
serum samples  were analysed for A77 1726  concentrations. The serum concentrations are 
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Number of patients 37 
Age (years) 70 [12] 
Duration of RA (years) 12 [10] 
Rheumatoid factor positive (%) 76 
Leflunomide prescribed as first DMARD (%) 16 
Number of DMARDs prior to leflunomide 2.0 [1.6] 
Duration of leflunomide use (days) 
       Range 
970 [237] 
214-1281 
Prescibed daily leflunomide dose (mg) 
       10 
       15 (alternating 10 and 20 mg) 










characterized by large interindividual variation. The validated concentration range covers 
95% of the concentration found in the patient samples in our study. 
As stated, previously published methods for determination of A77 1726 had several 
drawbacks concerning lack of information on interference of detection and quantitation of the 
analyte, A77 1726, by antirheumatic co-medication [7]; did not consider hydrolysis of 
leflunomide in extraction solvents containing potassium carbonate [8]; or had an upper limit 
of quantitation (due to loss of linearity) that did not cover the complete concentration range 
expected to be obtained in patient samples [9,10]. Moreover, information on the stability of 
A77 1726 in serum kept under refrigerated conditions for more than one month [7] was 
lacking. The HPLC-UV method described here, focuses on A77 1726 as the only analyte of 
interest, is validated for the absence of interference of other, commonly prescribed 
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antirheumatic medication on the determination of A77 1726 and studies stability of A77 1726 
in serum for a period up till 5 months.  
A77 1726 is the metabolite responsible for inhibition of DHODH and therefore 
antirheumatic activity. Moreover, reports on pharmacokinetics of leflunomide show that no 
detectable serum levels of leflunomide are reached in dose regimens for rheumatoid arthritis 
[1]. A77 1726 itself is excreted in faeces or metabolised further to 4-trifluoromethylaniline 
oxalinic acid [1]. The role of leflunomide and the metabolites of A77 1726 in antirheumatic 
activity are currently not clear and systemic exposure to these metabolites is minimal [1]. 
Therefore, quantitative assays for use in patient samples should focus on A77 1726 as the 
analyte of interest. 
A proportion of the patients with rheumatoid arthritis will be treated with combinations of 
DMARDs, analgesics and/or corticosteroids, within the current treatment paradigm of 
rheumatoid arthritis. Therefore, interference of concomitant medication with the quantitation 
of A77 1726 is of special interest in the patient group treated with leflunomide. Our method 
is validated for absence of interference of concomitantly prescribed antirheumatic drugs and 





We developed an easy-to-operate and validated HPLC-UV method for determination of 
A77 1726, the active metabolite of leflunomide, in human serum. The proposed method can 
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Leflunomide is the prodrug of the disease-modifying antirheumatic metabolite A77 1726. 
Over 50% of patients withdraw from leflunomide therapy within 1 year after start of 
treatment, mainly because of adverse drug reactions. Therapeutic drug monitoring of A77 
1726 may be useful to predict effectiveness of leflunomide treatment. We have studied the 
relationship between A77 1726 steady state serum concentrations and disease activity using 
28 joints (DAS28), respectively DAS28 response. 
Methods 
Outpatients with rheumatoid arthritis on a stable leflunomide dose > 4 months were 
included. DAS28 parameters and adverse drug reactions were registered. Blood samples 
were drawn for determination of the A77 1726 concentration.  
Results 
In fifty-two patients A77 1726 serum concentrations were determined. Concerning the 
primary end point, the relation of A77 1726 serum concentrations with DAS28-response 
category, the Receiver Operating Characteristics (ROC) curve shows an area under the 
curve (AUC) of 0.73 (95% confidence interval (CI95) 0.54-0.93; p<0.05), sensitivity 
exceeding 99% at concentrations below 16 mg/L. Concerning the secondary end point, 
DAS28 values at the moment of sampling show no relationship between A77 1726 
concentrations, with AUC of the ROC-curve 0.50 (CI95 0.33-0.67; NS).  
Conclusions 
A77 1726 steady state serum concentrations show a relationship with DAS28 response. 
Determination of A77 1726 serum concentrations for patients with insufficient response to 
therapy may offer clinically relevant information for decisions on treatment continuation or 
dose adjustment.  





Leflunomide is a disease-modifying antirheumatic drug (DMARD) of the isoxazole class. 
After oral administration leflunomide is rapidly, non-enzymatically and completely converted 
into its active metabolite A77 1726 (2-cyano-3-hydroxy-N-(4-trifluoromethylphenyl)-
crotonamide) [1]. A77 1726 has antirheumatic activity through inhibition of the enzyme 
dihydro-orotate dehydrogenase (DHODH). DHODH is a key enzyme in the de novo 
production of pyrimidines in T-lymphocytes, a process essential for T-lymphocyte 
proliferation. A77 1726 has a long mean plasma half life of 15.7 days (range 14-18 days) in 
patients with rheumatoid arthritis [1-3]. 
Leflunomide has antirheumatic activity comparable with methotrexate and sulfasalazine 
[4]. Although an antirheumatic effect can be observed within a few weeks, in some patients 
onset of effectiveness takes up to 6 months [5]. Moreover, a high incidence of adverse 
events, possibly explained by the uniform dosing schedule with only few options for dose 
adjustments, is noted. These factors limit drug survival rates and effectiveness of 
leflunomide in populations with rheumatoid arthritis [6-8]. Therefore, optimization of 
leflunomide treatment is warranted. 
Therapeutic drug monitoring based on A77 1726 steady state serum concentrations may 
allow individualised dose adjustment and consequently increase clinical effectiveness. In 
phase II pharmacokinetic population modelling studies, a relationship between steady state 
A77 1726 serum concentrations < 13 mg/L and a reduced probability of clinical success is 
described [9]. 
In this study we investigated the relationship between rheumatoid arthritis disease 







Patients with rheumatoid arthritis, visiting the outpatient department of rheumatology 
from the 4 participating centres in the period of January 2003 to January 2004, who were on 
fixed, doses of leflunomide for at least 4 months were asked to participate. After obtaining 
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written informed consent a single venous blood sample was taken for determination of A77 
1726. Further, patient-, rheumatoid arthritis- and medication-characteristics and the 4 
parameters for calculation of the Disease Activity Score using 28-joint counts (DAS28) were 
recorded; tender and swollen joint counts, erythrocyte sedimentation rate and a 100 mm 
visual analogue scale for general health status as estimated by the patient. Further, DAS28 
at the time of starting of leflunomide was retrieved from the patients record. All DAS28 
parameters were scored for every patient by the same rheumatologist at every visit. DAS28 
was calculated from the four parameters at the end of the study to prevent influence of the 
DAS28-value on treatment decisions. 
Exclusion criteria were participation in another study, concomitant use of daily doses of 
>10 mg prednisone-equivalents or pharmacokinetically interacting medication. Interacting 
drugs were detected by checking medication histories for the prescription of rifampicin, 
activated charcoal and cholestyramine [3]. 
Since non-compliance to leflunomide therapy influences exposure to leflunomide and 
therefore steady state serum concentrations of A77 1726, an effort was made to gain insight 
into therapy compliance. For this purpose the local pharmacies of the patients were asked 
for leflunomide-refill data. Tracking of virtually complete prescription data is possible since in 
The Netherlands patients usually register with one pharmacy only and local pharmacies 
keep a computerised, detailed record of all delivered prescriptions. From the refill data the 
refill rate is calculated: 
 
Refill rate = (number of tablets delivered/number of days since leflunomide start) 
 number of prescribed tablets per day 
 
Refill rates under 1.0 represent underconsumption, above 1.0 overconsumption. Refill 
rates from 0.9-1.1 were categorised as good compliance [10].  
The human medical-ethics research committee approved the study. 
 
Determination of A77 1726 
Blood samples were analysed for A77 1726 by means of a validated high-pressure liquid 
chromatography method [11]. Mean [SD] A77 1726 serum concentration and the percentage 
of patients with a steady state A77 1726 serum concentration < 13 mg/L, the previously 
reported cut-off A77 1726 concentration for optimal clinical success [9], were calculated. 
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End points 
The primary end point was to determine the relationship between A77 1726 serum 
concentration and the DAS28-responder category. DAS28-responder category was 
determined comparing the DAS28 at the start of leflunomide therapy with DAS28 at the 
moment of sampling. Responders were categorised according to EULAR criteria [12,13]. 
Since in clinical rheumatological practice moderate response is insufficient as a goal for 
therapy, for analysis the comparison of good versus moderate or non responders was made. 
The null hypothesis for this end point was that low A77 1726 serum concentrations will 
predict poorer response. All patients for whom the A77 1726 serum concentration, DAS28 at 
the start of leflunomide therapy and DAS28 at the moment of sampling were recorded, were 
included for determination of this end point. Since disease activity is directly influenced by 
concomitant use of DMARDs, patients on leflunomide in combination with other DMARDs 
were excluded from this analysis. 
The secondary end point was to determine the relationship between A77 1726 serum 
concentration and disease activity at the moment of sampling. DAS28 was categorised in low 
(≤3.2) or high (>3.2) disease activity, according to EULAR criteria [12,13]. The null 
hypothesis for this end point was that lower A77 1726 serum concentrations are associated 
with high disease activity. All patients for whom the A77 1726 serum concentration and 
DAS28 at the moment of sampling were recorded, were included for analysis. As for the 
primary end point concomitant use of DMARDs other than leflunomide was an exclusion 
criterion for this analysis. 
 
Statistical analysis 
SPSS 12.0.1 for Windows was used for data collection, data validation, data selection, 
and statistical analysis. Normality of the distribution of A77 1726 serum concentrations per 
dose group is tested according to Kolmogorov-Smirnov. Differences in mean A77 1726 
serum concentrations between the leflunomide dose groups are studied using Students t-
test. Receiver operator characteristics (ROC) curves and chi-square analysis were used to 
determine the relationship of A77 1726 serum concentrations with disease activity and 
DAS28 responder category, respectively. The relationship between disease activity or 
response and corticosteroid- or NSAID-use was tested using chi-square analysis. 
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Table 1. Demographic and clinical characteristics.1 
 
Characteristics  
Number of patients 52 
Age (years) 69 [12] 
Female (%) 67 
Period since diagnosis of rheumatoid arthritis (years) 11 [10] 
Rheumatoid factor positive (%) 71 
Leflunomide prescribed as first DMARD (%) 21 
DMARDs prior to leflunomide (n) 
       Range 
2.0 [1.7]  
0-6 
Duration of leflunomide use (days) 
       Range 
       Patients > 1 year of leflunomide therapy 





Prescribed daily leflunomide dose (%) 
       10 mg 
       20 mg 





Concomitant corticosteroid use (%) 44 
Concomitant other DMARD use (%) 8 
Concomitant NSAID use3 (%) 58 
Legend: DMARD = disease-modifying antirheumatic drug, NSAID = non-steroidal anti-inflammatory drug. 1Mean 
[standard deviation] unless stated otherwise. 2Range 5-15 mg leflunomide daily. 3At least one active prescription at the 





In 52 patients the A77 1726 steady state concentration was determined (Table 1). A77 
1726 steady state concentrations showed large inter-individual variability, with 
concentrations ranging from 3 to 150 mg/L (Figure 1). In 6 patients (12%) A77 1726 
concentrations were < 13 mg/L, all on daily leflunomide doses of 20 mg. 
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Figure 1. Box-whisker plots for A77 1726 serum concentrations for 10 and 20 mg 
leflunomide daily dose. 




In 2 patients A77 1726 plasma concentrations exceeded 100 mg/L, with both patients on 
20 mg leflunomide daily. Mean [SD] A77 1726 serum concentrations in the 10 and 20 mg 
dose were 33[24] (range 15-98) and 42[35] (range 3-150) mg/L, respectively. The mean A77 
1726 serum concentrations in each dose group tended to differ although statistical 
significance was not reached (p=0.12). 
Seventy-one percent of the patients showed compliance with refill rates between 0.9 and 
1.1. Refill rates varied between 0.56 and 1.35, with 22% of the population having a refill rate 
lower than 0.9 and 7% of the population having a refill rate above 1.1. Refill rate and A77 
1726 serum concentration were not correlated (r < 0.008). Patients with A77 1726 



























Number of patients 25 
Age (years) 68 [13] 
Female (%) 72 
Period since diagnosis of rheumatoid arthritis (years) 8[7] 
Rheumatoid factor positive (%) 60 
DAS28 at baseline 
     DAS28 > 5.1 (n) 




Leflunomide prescribed as first DMARD (%) 24 
Concomitant corticosteroid use (%) 40 
Concomitant other DMARD use (%) 0 
Concomitant NSAID use2 (%) 38 
Legend: DAS28 = disease activity using 28-joint counts, DMARD = disease-modifying antirheumatic drug, NSAID = 
non-steroidal anti-inflammatory drug. 1Mean [standard deviation] unless stated otherwise. 2At least one active 




Primary end point: DAS28-response versus A77 1726 concentration 
In 25 patients DAS28 values at the start of leflunomide treatment and at the moment of 
sampling were recorded (Table 2). Figure 2 shows the ROC-curve for DAS28 response in 
relation to the A77 1726 concentration. The area under the curve is 0.73 (CI95 0.54-0.93; 
p<0.05). Sensitivity is 90,9% at the 18 mg/L A77 1726 concentration level. At the 16 mg/L 
level sensitivity is 100%; that is, patients with good response, according to EULAR criteria, 
are not recorded below this A77 1726 serum concentration.  
Table 3 shows the 2x2 table for test results (positive test: A77 1726 serum concentration 
≥16 mg/L) versus response (positive response: good responder according to DAS28 criteria). 
Chi-square analysis shows a significant dependence of DAS28-response and A77 1726 
plasma concentration using 16 mg/L as cut-off point for the dichotomy (p=0.02).  
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Figure 2. ROC-curve for DAS28 -response versus A77 1726 concentration (AUC 0.73 
(CI95 0.54-0.93)). 
Legend:  ROC-curve;  Reference line. 
 
 
Figure 3. ROC-curve for DAS28 versus A77 1726 concentration (AUC 0.50 (CI95 0.33-
0.67)).  
Legend:  ROC-curve;  Reference line. 
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Table 3. 2x2 table for response versus A77 1726 plasma concentration (n (%)). 
 
  DAS28 response category  
  Good Non or moderate Total 
A77 1726 plasma concentration ≥ 16 mg/L 10 (40%)a 8 (32%)b 18 (72%) 
 <16 mg/L 0 (0%)c 7 (28%)d 7 (28%) 
 Total 10 (40%) 15 (60%) 25 (100%) 
Legend: a-d = notes for the calculation of the PPV, NPV and likelihood ratios. 
PPV = positive predictive value = a/(a+b) 
NPV = negative predictive value = d/(c+d) 
Likelihood ratio for positive test result = (a/(a+c))/(b/(b+d)) 
Likelihood ratio for negative test result = (c/(a+c))/(d/((b+d)) 
 
 
The positive predictive value, a high A77 1726 serum concentration (≥ 16 mg/L) and 
response (good response according to DAS28 criteria) is 56% (CI95 33-79%); an A77 1726 
serum concentration of ≥ 16 mg/L in 56% of the patients correctly predicts that they have 
responded well. The negative predictive value, a low A77 1726 serum concentration (<16 
mg/L and ‘no response’) is 100% (CI95 not calculated since good responders were not 
recorded at A77 1726 serum concentrations < 16 mg/L); an A77 1726 serum concentration 
<16 mg/L is associated with non-response in each case were this low A77 1726 serum 
concentration is found. The likelihood ratio for a positive test result, i.e. the ratio of a positive 
test result (A77 1726 serum concentration ≥ 16 mg/L) for good versus moderate or non 
responders, is 1.9 (CI95 1.1-2.9). The likelihood ratio for a negative test result, i.e. the ratio 
of a negative test result (A77 1726 serum concentration < 16 mg/L) for good versus non- or 
moderate responders, is 0 (CI95 0.0-1.5).  
DAS28-response was not significantly related to corticosteroid- (p>0.1) nor NSAID-use 
(p>0.1). 
 
Secondary end point: DAS28 versus A77 1726 concentration 
Data from 45 patients, of the 52 patients included in the study, were used for this end 
point. Five patients were excluded because of combination therapy with a DMARD other 
than leflunomide (3x methotrexate, 2x hydroxychloroquine), 2 patients were excluded since 
no DAS28 could be calculated due to missing data (VASgeneral health). Figure 3 shows the 
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ROC-curve for DAS28 in relation to the A77 1726 concentration. Area under the ROC-curve 
is 0.50 (95% confidence interval (CI95) 0.33-0.67; p>0.1). Disease activity was not 





Although our data show no association between serum concentrations of A77 1726 and 
disease activity, none of the patients with low A77 1726 concentrations had a good 
response according to EULAR criteria. 
 
Criteria for therapeutic drug monitoring 
The International Association for Therapeutic Drug Monitoring and Clinical Toxicology 
defines therapeutic drug monitoring as ‘.. the measurement made in the laboratory of a 
parameter which, with appropriate interpretation, will directly influence prescribing 
procedures ..’ [14]. Ensom et al [15] have defined criteria for drugs for which therapeutic 
drug monitoring may have additional value. These criteria are: the drug has to be part of the 
standard of care for the indication, the drug can be easily determined in biological matrices, 
the pharmacological effect of the drug is not directly measurable, the drug has a small 
therapeutic window, and the therapy with the drug has to be continued for a period long 
enough to be able to determine the effect of therapy adjustments based on therapeutic drug 
monitoring. Further, Ensom et al state that there has to be a large inter- or intra-individual 
variability in pharmacokinetics and that there has to be a relationship between drug 
concentration levels and clinical effectiveness. When translating these criteria into our data 
on leflunomide, therapeutic drug monitoring for leflunomide/A77 1726 may be an interesting 
option for improving effectiveness: leflunomide is one of the DMARD-options for long-term 
treatment of RA with dose-limiting toxicity, the effectiveness of leflunomide cannot be 
determined early after therapy initiation or dose adjustments, and A77 1726 serum 
concentration can be determined using a relatively simple chromatographic technique. 
Concerning the last criterion mentioned by Ensom, the large variability of drug 
concentration levels, data from clinical studies are scarce. Large inter-individual variability of 
A77 1726 concentrations in a RA-population was shown in a recently published study, with 
A77 1726 concentrations varying from 5 to 93 mg/L (n=12) [16]. Large inter-individual 
variability of A77 1726 serum concentrations is also reported by Mladenovic et al [2]. Our 
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data correlate well with these results. It can be concluded that this criterion, as set by 
Ensom, is met for the leflunomide case.  
It would be interesting to know whether the variability in A77 1726 concentrations can be 
reduced by individualised dosing, based on patient characteristics. However, one study on 
the influence of demographic variables found that none of the variables studied, affected 
A77 1726 steady state concentrations substantially [9]. This leaves the possibility of 
adjusting the leflunomide treatment regimen post hoc on the basis of therapeutic drug 
monitoring. 
In 1997, based on data from phase I and II studies, a pharmacokinetic/ 
pharmacodynamic model for predicting therapeutically active serum concentrations of A77 
1726 was published [9]. Using follow-up results after 6 months of leflunomide therapy and 
Paulus criteria as the efficacy end point, the authors conclude that the maximum probability 
of clinical success would be obtained by a dose rate which maintains the steady state A77 
1726 serum concentration above 13 mg/L. On the basis of this model the authors state that 
a daily leflunomide dose of 20 mg would result in A77 1726 steady state concentrations 
above 13 mg/L in > 99% of the patients. However, our data show that 12% of the patients 
reach A77 1726 concentrations < 13 mg/L despite good therapy compliance, defined as 
pharmacy refill rates between 0.9 and 1.1. Using the previously reported model [9] we 
conclude that in a significant proportion of the RA-population, a daily leflunomide dose of 20 
mg does not lead to steady state A77 1726 concentrations which are related with a 
maximum probability of clinical success.  
On the other hand, our data support the conclusion [9] that a certain steady state 
concentration has to be exceeded in order to obtain clinical success. The target 
concentration was previously determined to be 13 mg/L [9], our results suggest a target 
concentration exceeding 18 mg/L for > 90% sensitivity or > 16 mg/L for >99% sensitivity. 
Twenty-eight percent of our patients have steady state A77 1726 plasma concentrations < 
16 mg/L representing approximately 50% of the patients with inadequate response, that is 
non- or moderate responders according to EULAR-criteria.  
Some remarks on the current study and the interpretation of the results have to be made. 
Our study was retrospective in design and included a relatively small study population for 
study of the relationship between A77 1726 steady state serum concentrations and 
response. For this reason the results of our study necessitate confirmation in a larger, 
prospective study. Whether the current design and sample size has had an influence on the 
study findings, besides statistical power, is unclear. Some considerations point to the fact 
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that this may not be the case. Attending rheumatologists were not aware of the A77 1726 
serum concentration at the moment of blood sampling and collecting parameters for 
calculation of the DAS28, making bias in estimating disease activity less obvious. Further, as 
discussed earlier, our data are in accordance with the results of Weber et al [9]. Both studies 
found an A77 1726 serum concentration cut-off point for response to therapy and at 
approximately the same concentration level.  
In our study 44% and 58% of the patients concomitantly used corticosteroids and 
NSAIDs, respectively. Since both corticosteroids and NSAIDs may influence individual 
DAS28-parameters these concomitant medications may have influenced the results of our 
study. Although no relationship between corticosteroid- nor NSAID-use and disease activity 
or response was determined, our study was not designed to correct for this potential 
confounder.  
No correlation between disease activity at the moment of sampling and A77 1726 serum 
concentrations was found. One possible explanation for this result is the fact that disease 
activity at the moment of sampling is not stratified for baseline disease activity. DAS28 
responders categories which, besides disease activity at the moment of measurement, holds 
in it the change of disease activity from baseline as well, is an appropriate and validated end 
point for this analysis. In absence of published data on the potential, direct relationship 
between A77 1726 serum concentrations and disease activity we performed this analysis. 
Furthermore, in our study no specific efforts were made to  optimize patient compliance 
with leflunomide therapy, besides routinely exercising good clinical practice. Structural 
deviations in medication intake from the prescribed daily dose are likely to influence steady 
state A77 1726 serum concentrations. However, no influence on study results from 
deviations in therapy compliance, that is refill rates outside the range of 0.9-1.1, are 
expected for several reasons. Firstly, no correlation between refill rate and A77 1726 serum 
concentration over the complete concentration range was detected. Secondly, patients with 
A77 1726 serum concentrations <13 mg/L and > 100 mg/L all show refill rates between 0.93 
and 1.06. Therefore, low or high refill rates also are not associated with A77 1726 serum 
concentrations in the lower or upper concentration ranges.  
 
Clinical implications 
Our data demonstrate that disease activity according to DAS28 criteria is not correlated 
with A77 1726 serum concentrations. When disease activity at baseline is taken into account 
one has a measure of response which enables an evaluation of leflunomide-induced DAS28-
Chapter 3.2 
86 
responder categories. Interestingly, our data on the relationship between A77 1726 
concentrations and DAS28-response reveal perspectives regarding future clinical 
applications for therapeutic drug monitoring of A77 1726.  
It would be interesting to know whether early decisions on therapy withdrawal or 
continuation are improved when unblinded, i.e. whether decisions can be based on the 
combination of insufficient response and a low A77 1726 steady-state serum concentration. 
Under the assumption of therapy compliance and stable dosing, a direct relationship 
between duration of therapy, A77 1726 serum concentration at that moment and the A77 
1726 steady state serum concentration exists. This leads to the hypothesis that a non-
steady state A77 1726 serum concentration determined early in leflunomide therapy, for 
example after 4 weeks of treatment, may well predict patients response to therapy later on. 
Applying this hypothesis to leflunomide therapy, theoretically, offers the opportunity to make 
early decisions based on non-steady state A77 1726 serum concentrations and may prevent 
delay before therapy is switched to more efficacious alternatives for the individual patient. To 
what extent this approach will lead to improvements in leflunomide treatment outcomes has 
to be subject of further studies. 
Secondly, one could speculate whether patients with inadequate clinical response to 
leflunomide treatment and a low, sub-therapeutic A77 1726 serum concentration (< 16 
mg/L), 28% of the whole population in our study, will show improved response at increased 
daily leflunomide doses. Since A77 1726 shows linear pharmacokinetics (a linear relation 
between dose rate and steady state serum concentrations), an increased dose will lead to 
higher serum concentrations. With a positive predictive value of 56%, not all patients at A77 
1726 serum concentrations ≥ 16 mg/L will become good responders according to DAS28-
response criteria. To put the potential role of therapeutic drug monitoring on the basis of our 
results into perspective: from the fraction of patients with non or moderate response 
according to DAS28-criteria, approximately 50% will have a A77 1726 serum concentration < 
16 mg/L. When increasing the dose for these patients, we expect 56% of them to become 
DAS28 good responders.  
A remark has to be placed with this approach. Comparative studies on leflunomide in 
rheumatoid arthritis so far have used a narrow dose range varying from 5 to 25 mg daily [2]. 
Despite increased efficacy a daily dose rate of 25 mg is found to be correlated with a higher 
incidence of ADR [2,9]. Whether toxicity at leflunomide doses > 20-25 mg/day remains a 
problem when leflunomide doses are increased selectively for those patients with A77 1726 
serum concentrations below 16-18 mg/L, has not yet been the subject of clinical studies. 
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Information on higher dose rates is available from studies in the field of rheumatology 
[17,18], transplantation medicine [19] and oncology [20]. Recently, results of 11 patients with 
rheumatoid arthritis treated with 40 mg leflunomide daily for at least 3 months were 
published [17]. These patients previously tolerated the 20 mg daily dose but still had active 
disease on this dose. The authors conclude that a daily dose of 40 mg increased 
effectiveness of the treatment in 6 of 11 patients. Four of 11 patients encountered mild and 
reversible adverse events after dose escalation. Metzler et al [18] describe a prospective 
study of leflunomide in 20 patients with Wegener’s granulomatosis. Daily doses were 
increased stepwise to a maximum of 40 mg. These authors conclude that the safety profile 
of leflunomide was comparable with that found in clinical trials despite the, compared with 
RA treatment, higher dose levels. Williams et al. [19] describe a retrospective review of 53 
liver or kidney transplant recipients receiving leflunomide at maintenance doses of 40-60 mg 
daily, after receiving loading doses of 1200-1400 mg over 7 days to achieve steady state 
A77 1726 serum concentrations of 100 mg/L. In their review leflunomide was well tolerated 
and dose-limiting side effects occurred in less than 15% of patients when drug serum levels 
were less than 80 mg/L. At these dose rates the authors conclude that patients can be 
safely dosed during more than 300 days follow-up. Although not directly applicable to a 





We have shown that in a steady state there is no association between disease activity 
and A77 1726 serum concentration. However, lower subtherapeutic A77 1726 serum 
concentrations are related to absence of response on leflunomide therapy. These results 
support the conclusion that determination of A77 1726 serum concentrations may influence 
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For reasons of insufficient quality of the raw material, aurothioglucose was withdrawn from 
the Dutch market at the end of 2001. Aurothiomalate became available as an alternative 
preparation. We followed a cohort of patients during the first year after switching from 
aurothioglucose to aurothiomalate to study effectiveness and safety. 
Methods 
Patients were observed at baseline, and at 3 and 12 months after switching. At each visit, 
data on adverse drug reactions (ADR) , withdrawal and disease activity were collected.  
Results 
120 patients (age 63[15] years, 68% female, 93% rheumatoid arthritis, duration of disease 
15[9] years, 82% IgM rheumatoid factor positive, 9[9] (range 0.1-45) years of previous 
aurothioglucose therapy) were included. Nineteen patients (16%) reported an ADR on 
aurothiomalate not previously experienced on aurothioglucose; pruritus, dermatitis/stomatitis 
and chrysiasis/hyperpigmentation being most frequently reported. Twenty-nine patients 
(24%) patients withdrew from aurothiomalate within 12 months follow-up for reasons of 
ineffectiveness (14%), adverse drug reactions (7%) or disease in state of remission (3%). 
Kaplan-Meier estimates show aurothiomalate survival rates of 78.5% after 12 months. No 
statistically significant differences between the disease activity parameters during follow-up 
visits compared with the baseline visit were detected for the patients remaining on 
aurothiomalate.  
Conclusions 
Within the first 12 months after switching from aurothioglucose 24 percent of patients 
withdrew from aurothiomalate. Sixteen percent of patients reported novel adverse drug 
reactions. For the population remaining on aurothiomalate no clinically relevant changes in 
disease activity were recorded after switching. 




Since 1943, in the Netherlands aurothioglucose (ATG; Auromyose®) was the only 
parenteral gold preparation available. For reasons of insufficient quality of the raw material, 
ATG was withdrawn from the Dutch market at the end of 2001. This withdrawal from the 
market resulted in an estimated 1000 to 1500 patients in the Netherlands switching from 
ATG to another treatment option.  
Although intramuscular gold currently is not the first choice option for rheumatologists in 
treating patients with rheumatoid arthritis (RA), these preparations remain a part of the 
treatment paradigm [1]. Studies show effectiveness of intramuscular gold to be similar with 
methotrexate in different settings [2-4]. Rheumatologists requested for ongoing availability of 
a parenteral gold salt for prescription purposes. The Dutch Medicines Evaluation Board, 
after an accelerated procedure, licensed aurothiomalate (ATM; Tauredon®) as an alternative 
gold preparation as requested. 
Both ATG and ATM are studied in over 50 randomized, controlled trials each. 
Comparable effectiveness of ATG and ATM was shown in a 2-year follow-up study in 125 
patients [5]. Results from research studying the switch from ATM to ATG show the latter to 
be tolerated well after switch [6] or prevent post-injection reactions related to ATM-injections 
[7]. Although never formally studied, some publications suggest that switching from ATG to 
ATM may introduce clinical problems. Differences in toxicity have been observed in a study 
comparing ATM and ATG [5].  
To study earlier suggestions of negative safety of the aqueous ATM preparation, we 
monitored patients switching from the oily ATG preparation Auromyose® to the aqueous 






At the moment of withdrawal of ATG (August 2001) rheumatologists in The Netherlands 
were asked to participate in the study. Patients switching from ATG to ATM were eligible for 
inclusion. Data analysis was carried out for patients with a complete 12-month follow-up, 





Baseline data consisted of patient-, disease- and treatment characteristics. Follow-up 
visits took place at 3 and 12 months. ADR on therapy were recorded on a standard form, 
listing 34 different ADR known to be related to gold therapy. Novel ADR were defined as 
ADR not previously reported at the baseline visit with respect to the ATG treatment. In case 
of withdrawal from ATM, the time until withdrawal and the reason for withdrawal were 
recorded. Effectiveness of therapy was recorded as changes in erythrocyte sedimentation 
rate (ESR), C-reactive protein (CRP), a visual analogue score (VAS) of patients and 
rheumatologists estimation of disease activity, and a categorical (better, equal, worse) 




The ATG-dose was converted to the ATM-dose on a 1:1 milligram basis, since ATG and 
ATM contain a comparable fraction of elementary gold, 50.3% and 50.5%, respectively. 
Rheumatologists were allowed to adjust the ATM-dose as needed, adapting frequency of 
administration or dose per administration. 
 
Statistical analysis 
SPSS 12.0.1 for Windows was used for data collection, data validation, data selection, 
and statistical analysis. Student’s t-test was used for comparing mean values of disease 
activity parameters between visits. Kaplan-Meier estimates were used to calculate the 
cumulative probability of withdrawal from ATM. The relation between baseline variables and 







Since most hospitals did not run out of stock of ATG immediately, it lasted up to October 
2002 for the last patients to be included. One-hundred-twenty patients were included by 30 
rheumatologists in 18 hospitals. Mean [SD] age of the patients was 63[15] years, 68% were 
female and patients used ATG for 9[9] (range 0.1 - 45) years prior to switching to ATM.  The 
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Table 1. Treatment characteristics at baseline.1 
 
Treatment characteristics  
Parenteral gold prescribed as first DMARD (%) 21 
Number of DMARDs prior to parenteral gold 
         Range 
1.8[1.5] 
0-7 
Concomitant corticosteroid use (%) 12 
Concomitant other DMARD use (%) 
         Methotrexate 
         Sulfasalazine 
         Hydroxychloroquine 






Indications for gold therapy (%) 
         RA 
         JIA 
         AP 






Parenteral gold characteristics  
Duration of ATG treatment (months) 
        Median 




Weekly dose of ATG (mg; %) 
          < 10 
          ≥ 10-<25 





Cumulative ATG dose (mg) 
         Median 




Legend: AP= arthritis psoriatica, ATG=aurothioglucose, DMARD=disease-modifying antirheumatic drug, JIA =juvenile 




Table 2. Novel adverse drug reactions reported in relation to ATM therapy during 12 
month follow-up. 
 
Adverse drug reation N (%) 
Pruritus 8 (7) 
Dermatitis/stomatitis 6 (5) 
Chrysiasis/pigmentation 5 (4) 
Proteinuria 4 (3) 
Urticaria 2(2) 
Headache 2 (2) 
Vasomotor reactions 2 (2) 
Arthralgia/myalgia 2 (2) 
Palpitations 1 (1) 
Mild enterocolitis/upper abdominal complaints 1 (1) 




indication for gold therapy was rheumatoid arthritis in 93% of patients, with a mean duration 
of disease of 15[9] years. Eighty two percent of the patients with rheumatoid arthritis were 
positive for IgM rheumatoid factor. Table 1 shows the treatment characteristics of the 
population. Two patients died, respectively 3 and 4 months after switching to ATM, for 
reasons not related to gold treatment (brain tumor, cardiac arrest). No patients were lost to 
follow-up. 
 
Adverse drug reactions 
Nineteen patients (16%) reported one or more novel ADR during follow-up (Table 2). The 
patient group reporting a novel ADR during ATM did not statistically significant differ from 
the patient group not reporting a new ADR with respect to age, gender, IgM rheumatoid 
factor status, erosive disease, presence of rheumatoid noduli, duration of RA, weekly ATM 
dose, cumulative ATG dose or number of previous DMARDs. However, patients reporting a 
new ADR had a longer median duration of previous ATG therapy compared with patients 
not-reporting a new ADR, 117 and 66 months respectively (p=0.048). 
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Figure 1. Kaplan Meier estimate of ATM withdrawal.  





Twenty-nine (24%) patients withdrew from ATM, after a mean [SD] of 5.9[3.0] months. 
Reasons for ATM withdrawal were ineffectiveness (14%), ADR (7%), a combination of 
ineffectiveness and ADR (1%), and RA in remission (3%). Kaplan-Meier estimates for the 
probability of ATM survival are shown in Figure 1. 
 
Determinants for ATM withdrawal 
Of the variables studied age, gender, body mass index, duration of rheumatic disease, 
presence of rheumatoid nodules, erosive disease, IgM rheumatoid factor status and 
cumulative ATG dose were found not to be associated with withdrawal. However, duration of 
ATG therapy > 72 months (relative risk (RR) 3.0 95% confidence interval (CI95) 1.3-6.7) or 
pretreatment with 1 or 2 disease-modifying antirheumatic drugs (RR 3.3, CI95 1.4-7.6) were 
found to be predictive for lower withdrawal rates compared with patients on ATG therapy for 














































Legend: CRP = C-reactive protein (mg/L), ESR = erythrocyte sedimentation rate (mm/hr), VASpatient respectively 
VASrheum = visual analogue scale as recorded by patient respectively rheumatologist (mm, in a 100-mm scale). 





Completeness of data on disease activity at each visit was above 80% at every visit for 
ESR (range 83-100%), VAS as rated by patient (range 80-89%) and VAS as rated by the 
rheumatologist (range 81-94%). CRP data were recorded in 60-73% of the baseline and 
follow-up visits. Parameters of disease activity (Figure 2) did not significantly differ between 
baseline and the follow-up visit after 3 and 12 months, respectively. Patients and 
rheumatologists ratings of disease activity compared with the baseline visit are shown in 
Table 3. Patients’ ratings tend to worsen during follow-up, rheumatologists’ ratings have no 
tendency for better nor for worse. 
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Table 3. Patients’ and rheumatologists’ rating of disease activity compared with 
baseline visit (%). 
 
 Visit after 3 months Visit after 12 months 
Patients rating   
Better 17 7 
Equal 46 62 
Worse 371 321 
Rheumatologists rating   
Better 13 12 
Equal 71 73 
Worse 161 151 






Our study showed that 24% of patients switching from ATG to ATM during a 12-month 
period withdrew from ATM, mainly for reasons of ineffectiveness or adverse drug reactions. 
After switching 16% of patients reported novel adverse drug reactions. For the population 
remaining on ATM no clinically relevant changes in disease activity were recorded.  
A head-to-head comparison of ATG and ATM on effectiveness by Rothermich et al. [8] 
found no significant differences between both gold salts. Our data are in accordance with 
their study.  
Novel ADR most frequently reported on ATM therapy in our study were pruritis and 
dermatitis/stomatitis. This finding is in accordance with the results from previous studies, 
with skin eruptions and stomatitis having a 2.8 respectively 3.2-fold higher incidence in the 
ATM group compared with the ATG group [5,8]. It is important to realize that these results 
are derived from studies conducted in the 1970’s when requirements for study design, 
follow-up and publication were different compared with today.  
Can we explain the higher incidence of stomatitis/dermatitis and pruritis for ATM in 
comparison with ATG? Firstly, when the gold is involved in these sequelae, then the 
difference in the pharmacokinetic profiles of the two preparations may play a role. The 
absorption of ATM from aqueous solutions is known to be very rapid, with gold peak serum 
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concentrations between 10 minutes and 2 hours [8,9]. Applying the oily vehicle of ATG  
results in delayed gold peak serum concentrations, and these peak levels may not be 
reached for as long as 6 to 8 hours after injection. Although several authors conclude that 
serum gold levels and clinical effectiveness or ADR are not associated [10,11], the high 
unbound concentration directly after injection of the aqueous solution may explain for the 
negative safety profile of the aqueous preparations. 
Secondly, when thiomalate plays a role in these phenomena, the results of the study by 
Rudge et al. [12] may be important. They found no correlation between plasma levels or 
urinary excretion of free thiomalate between patients with and without ADR during ATM 
therapy, suggesting that thiomalate is not a relevant factor in the occurrence of ADR. 
Thirdly, Ernestam et al [13] showed in vitro production of IL-10 in peripheral blood 
mononuclear cells to be related with a lack of skin reactions in vivo. Whether ATM and ATG 
have differential effects on IL-10 production and whether they may be an explanation for the 
differences in the incidence of skin reactions remains to be studied. 
How can we interpret the survival rate of ATM after switching from ATG? ATG was 
withdrawn from the market suddenly and without prior warning to rheumatologists and 
pharmacists, leaving no opportunity to conduct a comparative, blinded trial for switching 
from ATG to ATM. Therefore, a comparison of the withdrawal rate, in our study 24% in 12 
months, with data from populations in other studies is necessary. When comparing data 
from other trials with our data two options remain. Firstly, when ATM after switching is 
considered as de novo gold therapy withdrawal data from follow-up of de novo gold 
populations are relevant. Results from these studies show that withdrawal from gold therapy 
within 12 months vary between 30% and 47% [2,14,15] in patients with rheumatoid arthritis. 
Secondly, ATM-therapy, after switching from ATG, can be considered a continuation of 
already installed gold therapy. Specific information on withdrawal rates from gold therapy 
after long-term follow-up, the mean duration of ATG therapy in our study was 75 months, is 
not available. However, some data can be derived from long-term follow-up studies in 
rheumatoid arthritis. Pincus et al [16] reported a withdrawal rate of 24% between 24 months 
and 60 months of therapy. Estimating an annual withdrawal rate of 8%, assuming an equal 
percentage of the population withdrawing each year. Galindo-Rodriguez et al [17] reported a 
withdrawal rate of 13% between 3 and 6 years of gold therapy, estimating an annual 
withdrawal rate of 4-5%.  
Therefore, on the basis of withdrawal rates, ATM therapy after switching from ATG in our 
study cannot be considered a de novo start of gold therapy since the incidence of withdrawal 
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is lower compared with control populations, nor can it be considered a continuation of gold 
therapy since the incidence of withdrawal is higher compared with long-term follow-up 
populations.  
At the moment of withdrawal of ATG from the market rheumatologists and their patients 
had to reconsider treatment options. Possible options were switching from ATG to ATM, 
withholding treatment or introduction of a non-gold-containing DMARD. Considering the 
efficacy of newly available options as leflunomide and tumor necrosis factor alpha blocking 
therapies, it is remarkable that only 24% of patients withdraw from ATM therapy in our study 
despite the occurrence of novel ADR in some patients. A certain degree of satisfaction with 






Twenty four percent of patients withdrew from aurothiomalate, mainly for reasons of 
ineffectiveness (14%) or adverse drug reactions (7%). Within the first 12 months after 
switching from aurothioglucose to aurothiomalate 16% of patients reported novel adverse 
drug reactions. For the population remaining on aurothiomalate no clinically relevant 
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Computerized drug interaction surveillance systems (CIS) may be helpful in detecting 
clinical significant drug interactions. Experience with CIS learns that they often yield alerts 
with questionable clinical significance, fail to provide relevant information on risk factors for 
the adverse reaction of the interaction and fail to detect all significant drug interactions. 
These problems stress the importance of transparency and selectivity in choosing the drug 
interactions to be included in CIS. In the Netherlands the Working Group on 
Pharmacotherapy and Drug Information is responsible for maintenance of the CIS of the 
Royal Dutch Association for the Advancement of Pharmacy (KNMP).  
Methods 
The Working Group developed an evidence-based procedure for structured assessment of 
drug-drug interactions and revised all drug interactions in the CIS accordingly.  
Results 
For every drug interaction four core parameters are assessed: evidence on the interaction, 
clinical relevance of the potential adverse reaction resulting from the interaction, risk factors 
identifying patient-, medication- or disease characteristics for which the interaction is of 
special importance and the incidence of the adverse reaction. On the basis of this 
assessment the drug-drug interactions for introduction in the CIS are selected. After revision 
of the drug combinations in the CIS of the KNMP the Working Group judged 24% of the 
combinations not to interact and another 12% to interact but not to require action.  
On the basis of this assessment the subset of drug combinations for which interaction alerts 
are generated and the information on management of a drug interaction alert for users of the 
CIS were adapted. When an alert is generated by the CIS, the user of the system is supplied 
with comprehensive information on the four core parameters, the mechanism of the 
interaction and critical information for management of the interaction for the individual 
patient.  
Discussion 
This structured procedure offers the possibility for transparent and reproducible assessment 
of the clinical relevance of drug interactions.  
Conclusion 
A CIS selectively generating interaction alerts based on this assessment may help in 
realizing good clinical practice and offers a methodology to further increase drug safety. 




Quality of pharmacotherapy is highly dependent on the process of choosing a drug in 
relation with the nature of the disease. In the process of choosing the optimal 
pharmacotherapeutical strategy, factors like route of administration, dosage, contra-
indications, the potential for adverse drug reactions and costs play an important role. The 
possibility of drugs to influence each others safety or effectiveness, a drug-drug interaction, 
is an additional variable in making the optimal choice for pharmacotherapy.  
Drug interactions increase morbidity and mortality and may lead to hospital admission [1-
4]. In primary health care 9-70% of patients are reported to be exposed to drugs with the risk 
of a drug interaction, with 1-23% of major relevance [5-10]. A French study reports an 
incidence of 27 per 10,000 prescriptions with contra-indicated drug interactions in an 
ambulatory outpatient population [11]. During hospital admission the number of drug 
interactions per patient increases, with potential clinically relevant drug interactions 
occurring in 1 out of 70 prescriptions [12,13]. 
Many sources for information of drug interactions are available for health care providers, 
ranging from the summaries of product characteristics and product leaflets to text books and 
internet sites (gsm.com, epocrates.com, fda.gov, arizonacert.org) [14-16]. However, 
knowledge of an interaction between two drugs is no guarantee for timely recognition of the 
interaction or for taking the appropriate action to prevent the risk of an adverse outcome 
[17,18]. Unless the major advances in our understanding of drug-drug interactions, our 
ability to appropriately apply this information to specific patients has lagged far behind 
[19,20]. 
Computerized drug interaction surveillance systems (CIS) may be helpful in detecting 
and preventing drug interactions with clinical significance [21]. However, many pharmacists 
and doctors experience these systems to yield a large number of drug interactions with 
questionable or unclear clinical significance, fail to provide identifiable patient and 
medication risk factors, fail to detect all relevant drug interactions and to include a variable 
set of interactions [18,22-25]. These shortcomings lead users to be uncertain on the quality 
of the system and to ignore drug interaction alerts [23,25]. Furthermore, one study shows 
that interpretation of drug interaction signals without clear information on background and 
clinical relevance leads to discrepancies in perception of seriousness of the interactions [26]. 
These problems stress the importance of transparancy and selectivity in choosing the 
drug interactions to be included in CIS. The Working Group on Pharmacotherapy and Drug 
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Information is responsible for maintenance of the CIS of the Royal Dutch Association for the 
Advancement of Pharmacy (KNMP). In this 22-member multidisciplinary Working Group 
internists, general practitioners, pharmacists, hospital pharmacists, clinical pharmacologists 
and (a member of) the Netherlands Medicines Evaluation Board are represented. The 
Working Group recently developed a procedure for structured assessment of drug-drug 
interactions. On the basis of this assessment, drug interactions for inclusion in the KNMP-
CIS, with widespread use by general practitioners and (hospital) pharmacists, are selected. 
In the Netherlands tracking of virtually complete prescription data is possible since 
patients usually register with one pharmacy only and local pharmacies keep a computerised, 
detailed record of all delivered prescriptions. For this reason electronic medication 
surveillance for the complete drug use profile of the individual patient is possible.  
In this manuscript we describe the procedures for structured assessment of drug-drug 
interactions and the translation of this assessment to the CIS of the Working Group on 
Pharmacotherapy and Drug Information in the Netherlands. Further, we present the results 
of the revision of the complete CIS of the Royal Dutch Association for the Advancement of 






To develop a system for structured assessment of drug interactions it is important to 
define the goal of drug interaction alerts. The Working Group defined this goal as ‘timely 
recognition of the opportunity to intervene in drug use in order to prevent an undesired effect 
as a result of a combination of drugs’. This definition clearly states that a drug interaction 
alert is useful only when an intervention is necessary and possible, for example prescribing 
and/or dispensing an alternative drug, dosage adjustment or adjusted monitoring of drug 
effects. The Working Group stated that users of the CIS should be presented drug 
interaction alerts requiring a potential intervention, accompanied with appropriate 
information on the relevance for their individual patient and with a clear proposal for potential 
interventions. Furthermore, the assessment procedure should facilitate quick updates of the 
CIS when new drug interactions are recognized or new information on existing drug 
interactions is published. 
 
Clinical relevance of drug-drug interactions: a structured assessment procedure 
113 
Table 1. Core parameters for assessing the clinical relevance of drug interactions. 
 
Core parameters 
Evidence on the drug interaction 
The clinical relevance of the potential adverse reaction resulting from the drug interaction 
Risk factors, the drug interaction may be of special importance in patients with the specific risk factor 





For the assessment of drug interactions the Working Group defined four core parameters 
(Table 1). When assessing these four parameters for every potential drug interaction, a 
complete and transparent set of information is collected which can be used as the basis for 
management of the drug interaction. Information on these parameters is collected and 
prepared by pharmacists from the Scientific Institute for Pharmacists in the Netherlands and 
presented to the Working Group every 6 weeks. In the Working Group, on the basis of these 
four core parameters, clinical relevance is discussed in a multidisciplinary way.  
 
Evidence 
The first suggestions that a drug interaction exists often comes from the registration file 
and summary of product characteristics of newly registered drugs. The importance of 
structured research on drug interactions in the pre-registration phase is stressed by the Note 
for Guidance on the ‘Investigation of drug interactions’, giving guidelines for studies on drug 
interactions [27]. Despite this research, problems arise in gaining insight in the background 
information to assess the clinical relevance of these drug interactions. Evidence on the drug 
interaction may be theoretical, or the evidence is derived from clinical research that is not 
published and not freely accessible (data on file). In assessing the clinical relevance of 
newly registered drugs the standard operating procedure of the Working Group is to ask the 
registration holder of the drug for detailed information on the drug interaction, besides 
searching a standard set of sources (Table 2).  
Once papers have been selected as potential sources of evidence on the drug 
interaction, the Working Group uses an 5-category scale for assessing the quality of the 
evidence for a drug interaction derived from [32] (Table 3). 
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Table 2. Sources for drug interactions referred to by the Working Group on 
Pharmacotherapy and Drug Information. 
 
Information sources 
Drug interaction text books [14,15] 
Pubmed database [28] 
Excerpta Medica database (EMBASE) [29] 
Iowa Drug Information System (IDIS) [30] 
European Public Assessment Reports (EPARs) [31] 
 
 
Some drug interactions lack evidence from studies or case reports but have theoretical 
considerations as the primary basis, for example in cases where an analogy is suspected 
with another representative of the same drug class which is known to have a drug 
interaction. For interactions suspected to be relevant on the basis of an analogy the Working 
Group requires detailed information on the mechanisms of the interaction to consider the 
drug interaction to be relevant. For example, the HMG-co-enzyme A-inhibitors (‘ statins’) are 
known to have differential inhibiting effects on the cytochrome P450 enzyme system. 
Handling the statins as a homogenous group when considering drug interactions and the 
cytochrome P450 system therefore, is incorrect. 
 
The potential adverse reaction 
The second core parameter considered by the Working Group is the clinical relevance of 
the potential adverse reaction from the drug interaction. 
The Note for Guidance on the investigation of drug interactions defines a drug interaction 
as clinically relevant ‘when the therapeutic activity and/or toxicity of a drug is changed to 
such an extent that a dosage adjustment of the medication or medical intervention may be 
required’ [27]. This relevance often strongly depends on individual patient- or disease-
characteristics. A dichotomous categorization of the drug interaction as relevant or irrelevant 
is an undesired oversimplification of drug interaction assessment. To obtain a useful, 
transparent and reproducible result the Working Group uses a 6-category scale for the 
seriousness of the adverse reaction of a drug interaction. The effect of the drug interaction 
as reported in the evidence on the drug interaction forms the basis of the classification of the 
effect. The categories, named A to F, are ordered at increasing seriousness (Table 4).  
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Table 3. Categories for quality of evidence. 
 
Category Description 
0 Pharmacodynamic animal studies; in vitro studies with a limited predictive value for the human in vivo 
situation; data on file  
1 Incomplete, published case reports (no re- or dechallenge, presence of other explaining factors for the 
adverse reaction) 
2 Well-documented, published case reports; retrospective analyses of case series 
3 Controlled, published interaction studies in patients or healthy volunteers with surrogate end points 
4 Controlled, published interaction studies in patients or healthy volunteers with clinically relevant end points 
  
Variable Posters and abstracts from scientific meetings: 0 or 1, depending on the information provided. When the 
information of the poster or abstract is not published in a peer reviewed journal within 3 years after the 
scientific meeting, this information is re-categorized as 0.  
Variable Information from the Summary of Product Characteristics/European Public Assessment Reports (EPAR): 
0, 1 or 2, depending on the information provided [31].  
Variable Retrospective case series: 2 or 3, depending on the information provided. 
 
 
The Working Group discusses for each new adverse reaction, in which category the 
reaction has to be placed. By categorizing effects of drug interactions and using earlier 
classifications of adverse reactions for assessment of new drug interactions, a reproducible 
system of categorization of drug interactions effect has been developed. 
Some adverse reactions, like changes in blood pressure, changes in International 
Normalized Ratios (for oral anticoagulants), can have different gradations in seriousness. 
For categorization of these effects the Working Group uses the Common Toxicity Criteria as 
developed by the National Cancer Institute (NCI-CTC) [33]. The NCI-CTC use a 6-step scale 
for dividing gradual adverse reactions of drugs, 0-5, which are translated to A-F in the 
system of the Working Group.  
 
Risk factors 
The risk of an adverse outcome from drug interactions may depend on patient- (e.g. age, 
gender), disease- (e.g. renal and hepatic function) and medication- (e.g. dose, route of 
administration)  characteristics. Information on these  risk factors is essential  information for 
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Table 4. Examples of effects per category of seriousness of adverse reactions due to 
drug interactions.1 
 
Category A - Clinically irrelevant effect 
- Failure of therapy with: digoxin 
- Ventricular premature beats, atrial ectopics 
- Increase of international normalized ratio up to 4.0 
Category B - Adverse reactions due to increased bio-availability of calciumantagonists of the 
   dihydropyridine class 
- Misscelaneous : amnesia, fatigue, headache, nausea 
Category C - Adverse reactions due to increased bioavailability of anti-epileptics, ciclosporin, tacrolimus,  
   sirolimus 
- Increased risk of failure of therapy: methadone, leflunomide, iron suppletion, levothyroxin,  
  antidepressants 
- Parkinsonism, tremor 
- Increased risk for upper gastro-intestinal bleeding 
Category D - Adverse reactions due to increased bioavailability of aminoglycosides, ciclosporine, lithium,  
  methotrextate, digoxin 
- Increased risk of failure of therapy for a serious, non-lethal disease; e.g. levodopa,  
  methyldopa, loop diuretics 
- Deep venous thrombosis 
- Convulsions 
Category E - Increased risk of failure of life-saving therapy; e.g. antiretroviral medication, quinidine,  
   rejection-prevention (ciclosporin, tacrolimus, sirolimus) 
- Misscelaneous: prolonged QT-interval, pulmonary embolism, rhabdomyolysis, multi-organ  
   failure 
Category F - Death 
- Torsades de pointes, ventricular tachycardia 
- Misscelaneous: increased risk for pregnancy with risk factors for the fetus/neonate, bone  
   marrow depression, serotonine syndrome 
 
1
 Per category examples of potential effects within the category are shown. In every effect category new events are 
added after assessment by the Working Group 
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the user of the CIS. The Working Group, while assessing the relevance of a drug interaction, 
gathers information on factors predictive for an adverse outcome. 
 
Incidence 
Not for every patient an interacting combination of drugs will lead to an adverse 
outcome. The Working Group, while assessing the relevance of a drug interaction, gathers 
information on the incidence of adverse outcomes. In many cases information on the 
incidence of the adverse outcome is lacking, due to the absence of interaction studies.  
 
 
Results of assessment 
 
Based on the information on the four core parameters the Working Group assesses 
whether the combination of drugs gives an interaction (interaction: yes or no) and whether 
this combination of drugs has to be alerted at the moment of recognition by the CIS (action: 
yes or no).  
 
Interaction yes-action yes 
A drug combination that the Working Group assesses to be interacting (interaction: yes) 
and for which direct alerts have to be generated (action: yes), is entered in the CIS.  
 
It is rare for the evidence to show clearly and unambiguously what the final assessment 
of the drug interaction should be. Consequently, it is not always clear to those who were not 
involved in the discussion, how the working Group was able to arrive at its recommendation. 
In order to address this problem, in accordance with the procedures adopted by the Scottish 
Intercollegiate Guidelines Network (SIGN; www.sign.ac.uk) the Working Group has 
introduced the concept of considered judgement. Under considered judgement, the Working 
Group summarises its view of the total body of evidence on the drug interaction. This 
summary covers the four core parameters of the assessment process. Besides this 
summary, when alerting a drug interaction, the surveillance system generates a text for the 
user to aid in the process of managing the interaction. Four different texts are provided by 
the Working Group: a prescriber text, a pharmacy counter text, a hospital text and a 




The prescriber text gives an alert and information for the prescribing physician. This text 
takes into account the possibility to prescribe an alternative medication or to adjust therapy 
monitoring. The pharmacy counter text gives information relevant at the moment of 
dispensing of the drug in the pharmacy. From our experience in the past years a third text 
dedicated to the clinical situation, the hospital text, is provided.  
 
Besides the prescriber-, pharmacy counter- and hospital text, all users of the CIS can 
consult a fourth text, the general background information text. This text offers information on 
the four core parameters as assessed by the Working Group, besides information on the 
mechanism of the interaction and a short review of the literature on the interaction. Quality of 
evidence on the drug interaction and the seriousness of the adverse outcome are 
transparently translated to the user as an alphanumeric code, 0A (evidence lacking, 
clinically irrelevant effect) to 4F (evidence consists of controlled, published interaction 
studies with a clinically relevant end point; the adverse outcome is clinically very relevant). 
Together with the risk factors and the incidence of an adverse outcome the user of the 
surveillance system is presented core information on the drug interaction in a transparent 
and concise manner in case of an alert. 
 
Interaction yes-action no 
When the Working Group assesses a combination of drugs to be interacting (interaction: 
yes) but requires no action (action: no) when the combination of drugs is prescribed this 
combination of drugs is entered in the surveillance system. However, for these interactions 
the CIS will not automatically generate an alert. Instead, these interactions are only logged 
by the system. The reason to enter these drug combinations in the interaction surveillance 
system is the possibility for users of the CIS to create a tailor-made system, that is they have 
the possibility to generate an alert for these combinations in their local situation. 
 
Interaction no 
When the Working Group assesses the combination of drugs not to be interacting 
(interaction: no) and no action is therefore required, the drug combination will not 
automatically generate an alert. In these cases users of the CIS do not have the possibility 
to generate an alert for the combination. 
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Table 5. Examples of drug interactions per category. 
 
A. Interaction yes, action no 
Bile salts binding resins + cholesterol-lowering fibrates 
Cimetidine + erythromycine 
Cimetidine + calcium antagonists of the dihydropyridin class 
Ciclosporin A + quinolone antibiotics 
Risperidone + selective serotonine reuptake inhibiting antidepressants 
 
B. Interaction no 
Bisacodyl (oral route) + antacids 
Linezolide + sertraline 
Lithium + trimethroprim 
Monoamine oxidase inhibitors + non-SSRI antidepressants 
Moclobemide + tramadol 
Pimozide + antimycotics of the azole-class 
Terfenadine + fluoxetine/fluvoxamine 




In a separate drug information system published by the Royal Dutch Association for the 
Advancement of Pharmacy, the Informatorium Medicamentorum, information on these drug 
combinations is gathered [34]. Publication in this medium provides the opportunity for users 
to detect whether a drug combination has been assessed by the Working Group and 
provides complete information on all four core parameters. 
 
Revision of the drug interactions the KNMP-CIS 
On the basis of this structured assessment the Working Group in 2002-2003 revised the 
complete set of drug combinations present in the CIS of the KNMP. Exceptions were made 
for the interactions concerning oral anticoagulants and antiretroviral medication since these 
interactions were assessed in close cooperation with the Federation of Thrombosis Services 
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in the Netherlands and experts in the field of treatment of HIV-infections, respectively. 
Revision of these combinations is currently ongoing. 
Before revising the CIS of the KNMP the system included 225 different drug 
combinations. After revision according to the structural assessment the Working Group 
judged 54 (24%) of these combinations not to be interactions. This subset of combinations 
was withdrawn from the CIS. Of the remaining 171 combinations, 26 (12%) were judged to 
be interactions but requiring no action. These combinations were left in the CIS but no alert 
is generated when the combination is recognized. For the remaining 145 combinations 
(64%) an alert is generated as soon as the combination is detected by the CIS. For 
combinations judged to be not interacting or interacting but without the necessity for direct 





We described the procedure for structured assessment of drug interactions by the 
Working Group on Pharmacotherapy and Drug Information of the Royal Dutch Association 
for the Advancement of Pharmacy and the procedures to inform the users of the CIS on the 
interpretation of the results of the assessment for their individual patients.  
The Working Group adopted the procedure for structured assessment of drug 
interactions in 2002 and revised the complete CIS accordingly. This resulted in 36% of the 
combinations being assessed as ‘not interacting’ or ‘interacting but not requiring any action’. 
This percentage is comparable with the results of a German group that concluded that the 
number of alerts would be reduced by approximately 30% when drug pairs were filtered out 
that do not require active management as a result of minor or unspecified severity [19].  
Since the revision all new drug interactions have been entered into the CIS only after 
completing the structured assessment procedure. Experience with the procedure since 2002 
shows that major goals for the assessment procedure are reached. Adverse reactions are 
reproducibly categorized, re-assessment of drug interactions on the basis of new information 
is a rapid process and the structured assessment facilitates the translation of the information 
from the four core parameters to clinical action.  
As the authors from a recently published study concluded, over 75% of major drug 
interactions with published evidence are manageable, that is adverse reactions can be 
prevented by taking specific actions [19]. Manageability is highly dependent on facilitation of 
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the process of adequately informing the users of the CIS and critically selecting the 
combinations for which alerts are of clinical significance. A CIS generating specifically 
clinically significant alerts, accompanied with adequate information, may offer a tool for 
further optimization of quality of pharmacotherapy. 
It is important to recognize that the quality of evidence supporting drug-drug interactions 
may differ between drugs registered before the publication of the ‘Note for guidance on the 
investigation of drug interactions’ and drugs registered after this Note for Guidance gave 
guidelines for research on interactions [27]. However, public availability of the information 
from drug-interaction studies is important, instead of these results remaining ‘data on file’ or 
short descriptions in the summaries of product characteristics and EPARs. 
It has to be taken into account that CIS are no substitute for the information in the 
product leaflets. However, since information in the product leaflet often is too comprehensive 
to assess the relevance of a drug interaction for the individual patient, an alert from the CIS 
provides additional information to the text of the product leaflet.  
Theoretically, information on pharmacogenetic testing, for example on enzyme and 
receptor mutations, may introduce benefits in recognizing patients at increased risk of 
adverse reactions due to drug-drug interactions. However, at the moment pharmacogenetic 
testing is not part of routine clinical practice and therefore not applicable. When this 
information becomes important in daily practice, inclusion in the assessment procedure as 





The procedure for assessment of clinical relevance of drug interactions as described in 
this manuscript offers the possibility for transparent and reproducible assessment of the 
clinical relevance of potential interacting drug combinations. A CIS selectively generating 
interaction alerts based on this assessment may help in realizing good clinical practice and 
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Drug-drug interactions (DDI) may adversely influence treatment outcomes in patients with 
rheumatic diseases. To prevent adverse drug reactions or therapeutic failure timely 
recognition and adequate management of clinically relevant DDI is required. The objective of 
this study is to give an overview of drug-interactions with disease-modifying antirheumatic 
drugs (DMARDs), to assess the clinical relevance of potential drug-interactions with 
DMARDs and to study the uniformity in assessment of clinical relevance between 
rheumatologists and hospital pharmacists. 
Methods 
Potential DDI were selected from product leaflets and search of the medical literature. For 
every potential interaction, data on the evidence of the DDI, the severity of the adverse 
reaction from the DDI, risk factors for and incidence of adverse reactions as a consequence 
of the DDI were collected. Based on this information two observer groups, rheumatologists 
and hospital pharmacists, independently assessed whether the individual combinations 
interacted. As a marker for clinical relevance the panel judged whether the combination 
required immediate intervention.  
Results 
A total of 40 drug combinations with a DMARD were selected, of these 17 (43%) were 
judged to be interacting and to require immediate intervention, 13 (32%) were judged not to 
be interacting or to be interacting but not to require immediate intervention and for 10 
combinations (25%) hospital pharmacists and rheumatologists did not agree. Observer 
agreement between groups for the assessment of the drug combinations to be interacting or 
requiring immediate intervention showed good (κ= 0.80) and fair (κ= 0.39) agreement, 
respectively. Rheumatologists tended to require immediate intervention more often for DDI 
based on increased toxicity of the DMARD as the major adverse reaction, while hospital 
pharmacists tended to judge DDI with an increased risk of DMARD failure more often to 
require immediate intervention. 
Discussion 
Alerts generated by computerized drug interaction alert systems (CIS) have to be specific 
(generated only when relevant), sensitive (generated in all relevant situations) and have to 
be accompanied by information for adequate management for the individual patient. In our 
study for 25 percent of the drug combinations with DMARDs the observer groups did not 
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agree as to whether the combination required immediate intervention. Due to differences in 
perception of severity of the effect of a DDI, perceived specificity and sensitivity of alerts 
generated by CIS may be suboptimal.  
Conclusion 
For a subset of 10 of 40 DMARD combinations, rheumatologists and hospital pharmacists 
differed in the assessment of clinical relevance. Multidisciplinary discussion as the basis for 






Pharmacotherapy is the mainstay of the treatment of rheumatoid arthritis. Due to higher 
age and the presence of comorbidity in the population treated, many patients are prone to 
be treated with multiple drugs and therefore are at risk for the adverse reactions due to drug-
drug interactions (DDI) [1,2]. To prevent these adverse reactions prompt recognition and 
adequate management of clinically relevant DDI is required.  
Although information on potential DDI is available from reviews [3-6], product leaflets, 
textbooks [7,8] and medical literature, a number of problems exist concerning recognition of 
DDI. Manual recognition of potentially relevant DDI, in contrast to computer-generated 
alerts, has shown to yield incomplete results, with large variety between individual observers 
[9]. Although computerized drug interaction alert systems (CIS) may improve sensitivity of 
the recognition of potential relevant DDI, they have a number of major drawbacks [10-14]. 
Many pharmacists and doctors experience these systems to yield a large number of DDI 
with questionable or unclear clinical significance, but on the other hand fail to detect all 
relevant DDI. Further, these systems are reported to fail to provide identifiable patient and 
medication risk factors. These shortcomings lead users to be uncertain of the quality of the 
system and to ignore DDI alerts [12,14]. 
For these reasons a transparent and reproducible assessment of potential DDI is 
essential before drug combinations are entered into CIS. The Working Group on 
Pharmacotherapy and Drug Information, responsible for the maintenance of the CIS of the 
Royal Dutch Association for the Advancement of Pharmacy, developed a structured 
assessment for DDI to reach this goal. The assessment is based on evaluation of four core 
parameters of an interacting drug combination: the quality of the evidence on the DDI, the 
severity of the adverse reaction of the DDI, patient-, medication- or disease characteristics 
increasing the risk of adverse reactions to the combination and the incidence of the adverse 
reactions when the combination is given [15]. On the basis of this assessment drug 
combinations are selected for incorporation in the CIS. 
Although the perception of sensitivity and specificity of the alerts generated by the CIS 
may improve using a structured assessment procedure, differences in assessment of clinical 
relevance between medical and pharmacological specialties may exist. When these 
differences are not considered the specificity and sensitivity of the CIS alerts may be 
perceived as suboptimal. Studies on differences in the assessment of clinical relevance of 
DDI in rheumatology between observer groups have not been published, to our knowledge.  
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We performed a study comparing rheumatologists’ and hospital pharmacists’ 






Selection of potential drug-drug interactions 
From product leaflets and text books on DDI [7,8] potential DDI with drugs used as 
DMARDs were selected. Medical literature was searched using Medline [16] and EMBase 
[17], using the following search terms for the key word, title and abstract sections of the 
publications: ‘interaction(s)’, ‘DMARD’, ‘disease-modifying antirheumatic drug(s)’, 
‘antirheumatic’, ‘rheumatology’, ‘rheumatoid arthritis’ or the names of the individual DMARDs 
of interest (anakinra, IL1-RA, auranofin, aurothioglucose, aurothiomalate, azathioprine, D-
penicillamine, etanercept, gold, (hydroxo)chloroquine, infliximab, leflunomide, methotrexate, 
sulphasalazine/sulfasalazine). Reference lists of the retrieved publications were searched 
for further information on potential DDI. 
 From all potential DDI with DMARDs the following were excluded: 
1. combinations of 1) two DMARDs, 2) DMARDs and systemic corticosteroids and 3) 
DMARDs and non-steroidal anti-inflammatory drugs, since in the majority of cases 
these medications are combined intentionally, in order to obtain a better clinical 
response. Although we were well aware of the existence of the potentially clinically 
relevant DDI between methotrexate and non-steroidal anti-inflammatory drugs, 
especially when two different physicians prescribe these medications for the same 
patient, this combination is not assessed in this study, 
2. potential DDI with ciclosporine A. These combinations generally are well-studied, 
pharmacokinetic DDI and require therapeutic drug monitoring as intervention to manage 
potential adverse reactions or therapy failure, 
3. combinations where the evidence on a potential DDI is based on dose levels far higher 
than used in the treatment of rheumatoid arthritis. For example, potential DDI with MTX 
or azathioprine in doses used in oncology or chloroquine as an antimalarial agent, 
4. combinations of DMARDs and food-supplements, phytotherapeutic/homoeopathic 
preparations, 
5. pharmaceutical DDI, i.e. (in)compatibilities in pharmaceutical containers. 
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Table 1. Quality level of evidence. 
 
Category Description 
0 Pharmacodynamic animal studies; in vitro studies with a limited predictive value for the human in vivo 
situation; data on file  
1 Incomplete, published case reports (no re- or dechallenge, presence of other explaining factors for the 
adverse reaction) 
2 Well-documented, published case reports; retrospective analyses of case series 
3 Controlled, published interaction studies in patients or healthy volunteers with surrogate end points 
4 Controlled, published interaction studies in patients or healthy volunteers with clinically relevant end points 
  
Variable Posters and abstracts from scientific meetings: 0 or 1, depending on the information provided. When the 
information of the poster or abstract is not published in a peer reviewed journal within 3 years after the 
scientific meeting, this information is re-categorized as 0.  
Variable Information from the Summary of Product Characteristics/European Public Assessment Reports (EPAR): 
0, 1 or 2, depending on the information provided [31].  




Assessment of potential drug interactions 
 
Standard information set per interaction 
For every potential DDI a standard dataset was prepared containing comprehensive 
information on four core parameters of the DDI:  
1. Quality of the evidence on the combination, categorized 0-4 (Table 1). 
2. Description of the adverse reaction of the combination and the mechanism of the DDI. 
3. When the risk of an adverse reaction from the potential DDI is dependent on patient- 
(e.g. age, gender), disease- (e.g. renal and hepatic function) and medication- (e.g. 
dose, route of administration) characteristics, these risk factors are given.  
4. The incidence of the adverse reaction when the combination is administered. 
 
Further, the standard dataset contained the main publications on the DDI. These 
publications could be supportive for or deny the existence of the DDI. 




On the basis of the standard dataset per potential DDI, three rheumatologists and three 
hospital pharmacists were all asked to assess the DDI independently. The rheumatologists 
and hospital pharmacists were selected on the basis of > 5 years of clinical experience and 
current involvement in clinical practice. The rheumatologists and hospital pharmacists all 
worked in large, non-academic teaching hospitals spread throughout the Netherlands.  
Assessment took place according to two questions that had to be answered with yes or 
no. 
1. On the basis of the information on the DDI do you assess this combination of drugs to 
interact? In other words: does anything happen when the two drugs are combined in 
comparison with the situation were both drugs are administered alone? 
2. When you judge this combination to be an interaction, is any immediate intervention 
required? Immediate intervention is defined as any action required at the moment the 
combination is recognized, to assure safe and effective use of the combination. 
Potential immediate interventions include, adjusted monitoring of therapy effectiveness 
or safety in the near future, adjusted patient information, appointments for therapeutic 
drug monitoring, dose adjustments or prescription of an alternative drug.  
 
Data analysis 
For both observer groups, rheumatologists and hospital pharmacists, the data from the 
assessment were pooled separately. Outcomes per group were based on the opinion of the 
majority. On the basis of these assessments the potential DDI were divided into 3 groups: 
1. Combinations judged by both observer groups as DDI that require immediate 
intervention. 
2. Combinations judged by both observer groups a) to be not interacting and therefore not 
to require immediate intervention and b) combinations judged to be interacting but 
require no immediate intervention. 
3. Combinations where rheumatologists and hospital pharmacists disagreed on whether 
the combination interacted or whether immediate intervention had to be taken.  
 
The adverse reaction of each individual drug combination was prospectively categorized 
in one of five categories: increasing toxicity of the DMARD or the non-DMARD, decreased 
effectiveness of the DMARD or the non-DMARD, or other. When the adverse reaction of the 
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DDI was increased toxicity, and this toxicity was also associated with the DMARD and the 
non-DMARD individually, this toxicity was categorized as ‘increasing toxicity of the DMARD’.  
 
Statistical analysis 
Assessments of the drug combinations per observer group were presented using 2x2 
tables. From these, to assess the interobserver variability, Cohen’s kappa was calculated. 
Kappa values <0.20, 0.21-0.40, 0.41-0.60, 0.61-0.80 and 0.81-1.00 were classified as poor, 
fair, moderate, good or very good agreement between the two observer groups, respectively 
[19]. Differences in assessments of clinical relevance between observer groups per adverse 
reaction category were analysed using the nonparametric McNemar test. A p-value < 0.05 





Selection of potential DDI 
Forty potentially interacting drug combinations with DMARDs were found within the 
selection criteria. For the newer DMARDs in use during the last five years, none of the 
combinations concerned the group of ‘biologicals’ (anti-tumor necrosis factor therapy, IL-1-
RA-therapy). For leflunomide 4 potential interacting combinations were found. 
The highest level of evidence found for the selected drug combinations was 3, 2, 1, and 
0 for 57, 5, 18 and 20%, respectively. For none of the drug combinations interaction studies 
with clinical end points, level 4 evidence, was found.  
 
Assessments 
Table 2 shows the 2x2 table for the assessment by the two observer groups whether or 
not the drug combinations are interactions. The results represent good agreement between 
observer groups (κ= 0.80±0.11). Within the observer groups the 40 combinations were 
judged unanimously in 29 (73%) and 26 (65%) of the cases by hospital pharmacists and 
rheumatologists, respectively. 
Table 3 shows the 2x2 table for the assessment by the two observer groups whether or 
not the drug combinations required immediate intervention. The results represent fair 
agreement between observer groups (κ= 0.39 ± 0.15). Within observer groups the 40 combi- 
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No 8 3 11 Hospital pharmacists 
Yes 0 29 29 










No 13 5 18 Hospital pharmacists 
Yes 5 17 22 




nations were judged unanimously in 27 (69%) and 17 (43%) of the cases by hospital 
pharmacists and rheumatologists, respectively. 
Tables 4-6 show specific information per drug combination judged to require immediate 
intervention, not to require immediate intervention or combinations where both observer 
groups disagreed.  
Rheumatologists tended to require immediate intervention more often for drug 
combinations with an increased risk of toxicity of the DMARD compared with hospital 
pharmacists. Rheumatologists and hospital pharmacists tended to differ in their 
assessments of individual drug combinations where the adverse reaction is decreased 
effectiveness of the DMARD, with the hospital pharmacists more often judging the 
combination to require immediate intervention (Table 7). 
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Table 4. Drug combinations assessed to be interactions requiring immediate 
intervention. 
 
DMARD Combining agent Level of 
evidence 
Adverse reaction Ref. 
Azathioprine Allopurinol 3 ↑ azathioprine toxicity [20,21] 
 Doxorubicin 3 ↑ hepatotoxicity [22] 
 Oral anticoagulants 2 ↓ anticoagulant activity [23] 
Chloroquine Praziquantel 3 ↓ AUC praziquantel by 65% [24] 
 Drugs that increase the 
QT-interval 
0 ↑ cardiac arrhythmia  - 
D-penicillamine Digoxin 3 ↓ AUC digoxin by 40-64% [25] 
 Iron-salts 3 ↓ AUC D-penicillamine by 35-60% [26] 
Hydroxychloroquine Cardiac glycosides 2 ↑ Cmax digoxin by 4-fold [27,28] 
Leflunomide Activated charcoal/ 
resins 
3 ↓ plasma half life of A77 1726, 10-fold [29] 
 Warfarin 1 ↑ anticoagulant activity [30] 
Methotrexate Acitretin/retinoids 3 ↑ hepatotoxicity due to ↑ AUC MTX [31,32] 
 Cotrimoxazole/ 
trimethoprim 
3 ↑ bone marrow depression [33-35] 
 Isoniazid 3 ↑ hepatotoxicity [36] 
 Probenecid 3 ↑ C24h MTX 3-4 fold [37,38] 
Sulfasalazine Digoxin 3 ↓ AUC digoxin by 50% [39] 
 Isoniazid 3 ↑ hepatotoxicity [35] 
 Talinolol 3 ↓ AUC talinolol by 90% [40] 
 
 
Legend: ↑ = increase or increased risk, ↓ = decrease or decreased risk, A77 1726 = active metabolite of leflunomide, 
AUC = area under the curve as a measure of bioavailability, Cmax = maximal plasma concentration, C24h = 
concentration at 24 hours after administration, MTX= methotrexate, Ref. = references. 
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Table 5. Drug combinations assessed NOT to require immediate intervention. 
 
 
DMARD Combining agent Level of 
evidence 
Adverse reaction Ref. 
Aurothiomalate ACE-inhibitors 1 Nitritoid reactions [41,42] 
Azathioprine Lamivudine 1 ↑ pancreatitis [43] 
 Mycofenolate mofetil 0 ↑ haematological toxicity [44] 
 ACE-inhibitors 3 ↑ neutropenia and ↑ anaemia [45,46] 
Chloroquine Codeine None ↓ analgesic effectiveness of codein [44] 
 Metronidazole 1 Acute dystonia [47] 
 Neuromuscular blocking 
agents 
0 ↑ neuromuscular blockade [48] 
 Mefloquine 0 ↑ QT-interval prolongation, ↑ convulsion,  
↑ mefloquin plasma concentrations 
[49] 
D-penicillamine Clozapine 0 ↑ agranulocytosis [50] 
 Oral contraceptives 1 ↑ macromastia [51] 
 Tricyclic antidepressants 0 ↑ myasthenia gravis [52] 
Gold salts Chelating agents  0 Changes in gold distribution and 
elimination 
[44] 











Table 6. Combinations were rheumatologists and hospital pharmacists disagreed on 
whether immediate intervention had to be taken. 
 
DMARD Combining agent Evidence Adverse reaction Immediate intervention ? Ref. 





Azathioprine Co-trimoxazole 3 ↑ neutropenia/ 
thrombocytopenia 
Yes No [54] 
Chloroquine Cimetidine 3 ↓ elimination chloroquine No Yes [55] 
 Mg-trisilicate/ 
kaolin 
3 ↓ AUC chloroquine Yes No [56] 
D-penicillamine Antacids 3 ↓ AUC D-penicillamine 
by 30-40% 
Yes No [57] 
 L-dopa 1 ↑ AUC L-dopa by 50% No Yes [58] 
Leflunomide Itraconazole 1 ↑ hepatotoxicity No Yes [59] 
 Rifampicin 3 ↑ Cmax A77 1726 by 
40% 
No Yes [60] 
Methotrexate Penicillins 3 ↑ MTX toxicity No Yes [61,62] 
Sulfasalazine Ampicillin/ 
rifampicin 
3 ↓ AUC sulfapyridine  
by 60-65% 
Yes No [63,64] 




Legend: ↑ = increase or increased risk, ↓ = decrease or decreased risk, A77 1726 = active metabolite of leflunomide, 
AUC = area under the curve as a measure of bioavailability, Cmax = maximal plasma concentration, C5h = 
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Table 7. Assessment for immediate intervention per adverse reaction category. 
 







Increased toxicity DMARD 19 9 14 0.13 
Decreased effectiveness DMARD 7 6 2 0.13 
Increased toxicity non-DMARD 4 1 2 1.00 
Decreased effectiveness non-DMARD 6 5 5 1.00 
Other 4 1 1 1.00 




Considering the combinations for which both observer groups agreed on immediate 
intervention plus the combinations for which the observer groups disagreed, as 
combinations for which an alert from the CIS may be relevant, 27 of the 40 combinations 
remain. Each observer group has a sensitivity of 81% for these combinations, i.e. both 
groups identify 22 out of 27 combinations to require immediate intervention. Specificity for 
both groups is 81%, i.e. for 5 of the 27 combinations both observer groups would generate 






Our literature search yielded 40 potentially interacting drug combinations involving 
DMARDs within the predefined criteria. For 30 (75%) of these DDI rheumatologists and 
hospital pharmacists agreed regarding the requirement of an immediate intervention or not. 
Overall, rheumatologists tended to require immediate intervention more often for those 
combinations that increased the risk of toxicity of the DMARD, while hospital pharmacists 
more often required immediate intervention for combinations with an increased risk of 
ineffectiveness of the DMARD. 
Of all possible drug combinations with DMARDs that could occur in clinical practice, for 
only 40 combinations information is found. A recent study concluded that for only 7.5% of 
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the total number of prescribed drug combinations in a general population participating in a 
health-screening program, information on the existence of a potential DDI was present [66]. 
When translating these results to the RA-population underreporting of potential clinically 
relevant DDI with DMARDs may be expected. Guidelines for research on potential DDI for 
newly registered drugs [67] may expand the knowledge on potential DDI. However, drugs on 
the market for several years often lack this information. This is reflected by the 43% of 
combinations in our study with evidence quality categorized as 0 to 2, and the lack of the 
highest level of evidence (grade 4) for any of the combinations. 
Alerts generated by CIS have to be specific, sensitive and have to be accompanied by 
information for adequate management for the individual patient. In routine medical practice 
both physicians and pharmacists have the ability to respond to DDI alerts when using a CIS. 
In our study for 25 percent of the drug combinations the observer groups did not agree as to 
whether the combination required immediate intervention. Both observer groups especially 
diverged in their judgement whether or not immediate intervention is required based on the 
adverse reaction category. Due to these differences in perception of severity of the effect of 
a DDI, perceived specificity and sensitivity of the CIS may be suboptimal. Therefore, a 
multidisciplinary discussion as the basis for uptake of DDI in a CIS may increase clinical 
applicability of the alert generated by the CIS. 
In our study ‘immediate intervention’ was broadly defined as any action to assure safe 
and effective use of the combination or to avoid the combination. Perception of the degree in 
which the DDI can be controlled, i.e. to what extent it may be possible to take action to 
prevent the adverse reaction, may be a source of differences in judgement between both 
observer groups. For example, when the combination shows an interaction based on 
decreased absorption from the gastrointestinal tract due to complexation 
(chloroquin/magnesiumtrisilicate, D-penicillamine/antacids, D-penicillamine/iron salts, D-
penicillamine/digoxin, sulfasalazine/iron salts), the DDI can be controlled by spacing oral 
gifts of both medications by several hours. Hospital pharmacists judged that all these DDI 
should have required immediate intervention, while rheumatologists only judged immediate 
intervention required for 2 of these interactions. This stresses the differences in points of 
view between the observer groups and the necessity to assess the relevance of a 
combination through a multidisciplinary approach. Since approximately 75% of all DDI can 
be controlled [66], differences in opinion on the degree on which DDI can be controlled may 
introduce potential differences in assessment of requirement of immediate intervention for 
most DDI.  
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Some limitations of the current study need to be pointed out. Firstly, the differences 
between observer groups in our study may be specific for the field of rheumatology. Since, 
to our knowledge, no studies on this subject are published in other fields of medicine this 
has to be subject of study in the future. Secondly, no effort was made to reach consensus 
between both groups, implying that maximum contrast between observer groups is 
presented here. Despite these limitations our study is the first to provide valuable 
information on the differences in the assessment of the clinical relevance of DDI between 





For 40 drug combinations including a DMARD clinical relevance was assessed by two 
observer groups, rheumatologists and hospital pharmacists. For a subset of 10 of these 
DMARD combinations rheumatologists and hospital pharmacists differed in the assessment 
of clinical relevance. Multidisciplinary judgement as the basis for uptake of DDI in a CIS may 
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The field of rheumatology has changed in the past years. New treatment options are 
added to the pharmacotherapeutical armamentarium of the rheumatologist, outdated 
treatment options have disappeared. In this rapidly changing field the adequate 
implementation of new information for treatment of the individual patient is of great 
importance to obtain optimal treatment outcomes. From this point of view, the critical 
evaluation of outcomes in day-to-day care is obligatory to reach the goal of optimal therapy 
for every patient. This thesis studies different aspects of safety and efficacy of 
pharmacotherapy in the treatment of rheumatoid arthritis (RA). Studies in this thesis focus 
on leflunomide, parenteral gold and the clinical relevance of drug-drug interactions with 
disease-modifying antirheumatic drugs (DMARDs). 
 
 
Leflunomide in daily clinical practice, options for treatment 
optimization 
 
Summary and discussion 
In chapter 2 different studies concerning the treatment of rheumatoid arthritis with 
leflunomide in clinical rheumatological practice are described. In chapter 2.1 we 
prospectively studied withdrawal from leflunomide, the incidence of adverse drug reactions 
and effectiveness of leflunomide in an outpatient population with RA. In this study 136 RA 
patients were included. We found that during follow-up 76 patients (56%) withdrew from 
leflunomide treatment, mainly because of adverse drug reactions (29%) or lack of 
effectiveness (13%). Sixty-five percent of patients experienced at least one adverse drug 
reaction related to leflunomide. Within a 12 month period after start of leflunomide treatment 
76% of the evaluable patients were classified as moderate or good responder according to 
the disease activity counting 28 joints (DAS28) response criteria. From the results of this 
study it was concluded that leflunomide offers an efficacious treatment option although the 
incidence of withdrawal from leflunomide therapy, mainly for the reason of adverse drug 
reactions, was high. The results of this study stress the importance of critical evaluative 
studies in the positioning of a novel DMARD in the setting of care-as-usual and demand 
optimization of the leflunomide treatment schedule and better recognition for patients at risk 
for treatment failure. 
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One of the adverse drug reactions of leflunomide which caught the attention was 
hepatotoxicity, mainly because of reports of several fatal events. Although rare, these events 
started the discussion on whether or not leflunomide had to be withdrawn from the market. 
Eventually, the discussion on hepatotoxicity led to adaptations in the product leaflet of 
leflunomide, with guidelines for close montoring of serum liver enzyme activities as marker 
for potential hepatotoxicity. Discussions on the safety of leflunomide following reports of 
rare, fatal hepatotoxic reactions are important in optimizing safe drug use. A critical 
evaluation of the magnitude of hepatotoxicity as detected trough clinical chemical testing in 
routine rheumatological practice is complementary to this discussion. 
To gain insight in the timing, frequency and severity of elevated liver enzymes, a study 
on the incidence and severity of hepatotoxicity during leflunomide treatment in a cohort of 
RA patients in a setting of ‘care-as-usual’ is conducted. The results of this study are 
described in chapter 2.2. To categorize the severity of the liver enymze activities the 
Common Toxicity Criteria of the National Cancer Institute were used. According to these 
criteria elevated enzyme activities, compared with the activities regarded as the upper limit 
of normal activities, were categorized as moderate (grade 2), severe (grade 3) or life 
threatening (grade 4). In a population of 101 patients we found grade 2 or 3 elevations in 
any liver function blood test for 9 patients (8.9%). No grade 4 elevations and no clinical signs 
of serious hepatotoxicity were recorded. Due to grade 2 hepatotoxicity one patient (1%) was 
withdrawn from leflunomide treatment, and one patient continued leflunomide in a reduced 
dose. In eight of nine patients with grade 2-3 liver function blood tests, these elevated liver 
function tests occurred within 6 months after starting leflunomide. None of the patients with 
grade 2 or 3 toxicity had a history of hepatic disease, eight patients concomitantly used 
potential hepatotoxic co-medication. Eight (8%) patients used leflunomide in combination 
with methotrexate, one of these patients developed hepatotoxicity. From this study we 
concluded that, under conditions of continued monitoring of liver functions, hepatotoxicity 
during leflunomide use does not seem to be a major problem in our population.  
As was concluded from the long-term observation described in chapter 2.1, early 
recognition of patients at risk for leflunomide treatment failure may be important for 
improvement in obtaining treatment goals. In chapter 2.3 we describe the results of a study 
to determine predictors for leflunomide survival in an outpatient population with RA. A large 
dataset from two rheumatological practice in the regions of Friesland and Twente, was 
analysed to determine predictors for leflunomide survival. The dataset in this study consisted 
of 279 patients, of whom 173 patients (62,0%) withdrew from treatment during follow-up. 
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Univariate analysis showed concomitant systemic corticosteroid use and an erythrocyte 
sedimentation rate < 35 mm/hr at start of leflunomide to be predictive for better leflunomide 
survival. Furthermore, the attending rheumatologist was correlated with leflunomide drug 
survival. These variables were also found to be predictive for leflunomide survival in 
multivariate analysis. From this study we concluded that information on these predictors at 
the start of leflunomide therapy may offer opportunities for treatment optimization.  
Following the high withdrawal rate from our observational study, ways for improving 
treatment outcomes were sought. One of the options in this context is the implementation of 
therapeutic drug monitoring: the determination of the serum concentrations of the active 
component of leflunomide as a means to adapt clinical practice when necessary.  
 
In chapter 3 the potential role for therapeutic drug monitoring in leflunomide therapy is 
studied. In chapter 3.1 a high-performance liquid chromatography method with ultraviolet 
detection (HPLC-UV) was technically and clinically validated, to obtain a method for 
determination of A77 1726, the active metabolite of leflunomide. The method showed 
acceptable performance on all major aspects of the validation (linearity, intra- and inter-day 
precision, accuracy, specificity and lower/upper limits of quantitation). For clinical validation 
the serum A77 1726 concentrations in 37 RA patients on leflunomide therapy were 
determined using this HPLC-UV method. Measured serum A77 1726 serum concentrations 
in patient samples showed large variability with a range of 3 to 176 mg/L, with >95% of 
samples yielding A77 1726 serum concentrations within the validated range of the analytical 
method. From these results we concluded that the proposed method could be employed for 
the assay of A77 1726 in RA patient samples.  
Using this assay we studied the relationship between A77 1726 steady state serum 
concentrations and DAS28, respectively DAS28 response. The results of this study are 
described in chapter 3.2. For this study, fifty-two outpatients with RA on a stable 
leflunomide dose > 4 months were included. We concluded that A77 1726 steady state 
serum concentrations show a relationship with DAS28 response. More precisely, patients 
with A77 1726 serum concentrations < 16 mg/L did not show good response according to 
DAS28 criteria. This opens the option of determination of A77 1726 serum concentrations for 
patients with insufficient response to therapy, to gain clinically relevant information for 
decisions on treatment continuation or dose adjustment.  
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Future perspectives 
From the first three studies in these chapters the main results are the high withdrawal 
rate within the first year after start of leflunomide treatment and the high percentage of 
patients experiencing adverse drug reactions, with hepatotoxicity being manageable under 
conditions of strict monitoring. This leads to the conclusion that further optimization of 
leflunomide therapy is warranted, to obtain the expected treatment outcomes.  
Recognition of characteristics predictive for treatment failure may seem a rather basal 
strategy to obtain improvement in treatment outcomes. However, whether knowledge of the 
presence of a predictive factor for leflunomide survival in an individual patient will indeed 
lead to improvement in treatment outcomes, has to be the subject of future, prospective 
studies. One major factor in these future analyses will be the way in which this information is 
used in clinical practice. Do patients at higher risk of leflunomide withdrawal have to visit 
their rheumatologist more often compared with patients without an increased risk? And, 
when this is an option, what kind of information is collected during these visits to indeed 
improve clinical outcomes? Do patients at higher risk of withdrawal need to be treated with 
adapted dosing schedules, for example by leaving the loading dose or therapy maintenance 
with lower or higher daily doses than recommended in the product leaflets? These and other 
questions have to be answered to implement the predictive factors for therapy survival in 
daily rheumatological decision making. 
One possibility for leflunomide treatment optimization is studied in the chapter 
concerning therapeutic drug monitoring. As stated in the discussion of this chapter, it would 
be interesting to know whether early decisions on therapy withdrawal or continuation are 
improved when decisions can be based on the combination of insufficient response and a 
low A77 1726 steady-state serum concentration. Under the assumption of therapy 
compliance and stable dosing, a direct relationship between duration of therapy, A77 1726 
serum concentration at that moment and the A77 1726 steady state serum concentration 
exists. This leads to the hypothesis that a non-steady state A77 1726 serum concentration 
determined early in leflunomide therapy, for example after 4 weeks of treatment, may well 
predict patients response to therapy later on. Applying this hypothesis to leflunomide 
therapy, theoretically, offers the opportunity to make early decisions based on non-steady 
state A77 1726 serum concentrations and may prevent delay before therapy is switched to 
more efficacious alternatives for the individual patient. To what extent this approach will lead 
to improvements in leflunomide treatment outcomes has to be subject of further studies.  
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Confirmation of the results from our ‘therapeutic drug monitoring’ study in a larger, 
prospective study with patients on de novo leflunomide therapy is the proposed first step for 
future studies. Secondly, randomized studies comparing de novo leflunomide patients with 
RA, with and without information on the A77 1726 serum concentrations, have to be 
conducted. In these studies attention has to be given to the clinical decisions to be made 
when insufficient response, with or without information on the A77 1726 serum 
concentration, is encountered by patient and rheumatologist. 
 
 
Switching parenteral gold preparations 
 
Summary and discussion 
After withdrawal of aurothioglucose from the Dutch market aurothiomalate was 
presented as the alternative preparation. Considering the active component of 
aurothiomalate, gold, this is not a remarkable choice for an alternative preparation. 
However, from the point of view of evidence based medicine, this view was remarkable, 
since no large studies for patients switching between both treatments were published.  
Therefore, at the moment that aurothioglucose was withdrawn from the market a critical 
evaluation of the outcomes of gold therapy after switching from aurothioglucose to 
aurothiomalate was conducted. In this study, described in chapter 4.1, we followed a cohort 
of patients during the first year after switching from aurothioglucose to aurothiomalate to 
study effectiveness and safety. A total of 120 patients were included, from whom 19 patients 
(16%) reported an adverse drug reaction on aurothiomalate, not previously experienced on 
aurothioglucose. Twenty-nine patients (24%) patients withdrew from aurothiomalate within 
12 months follow-up for reasons of ineffectiveness (14%), adverse drug reactions (7%) or 
disease in state of remission (3%). No statistically significant differences between the 
disease activity parameters during follow-up visits compared with the baseline visit were 
detected for the patients remaining on aurothiomalate. When comparing our data on 
withdrawal from aurothiomalate with data from other studies, we concluded that the 
withdrawal rate was lower compared with patients starting gold therapy de novo, but higher 
compared with patients on gold therapy for several years. The higher withdrawal rate and 
reports of novel adverse drug reactions, i.e. adverse drug reactions not previously reported 
on aurothioglucose treatment, suggest the introduction of a treatment with different 
characteristics compared with aurothioglucose. On the other hand we concluded from these 
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data that it is remarkable that only 24% of patients withdraw from aurothiomalate therapy in 
our study despite the occurrence of novel adverse drug reactions in some patients. A certain 
degree of satisfaction with current gold therapy may have played an important role in 
deciding to continue parenteral gold therapy.  
 
Future perspectives 
The results from this study learn us that critical evaluation of outcomes when choosing 
alternative treatments in case of withdrawal from already installed therapy, may provide 
insight in pitfalls in effectiveness or safety of the new treatment. 
 
 
Clinical relevance of drug-drug interactions 
 
Summary and discussion 
In our studies in the field of drug-drug interactions we defined the goal of generating drug 
interaction alerts as ‘timely recognition of the opportunity to intervene in drug use in order to 
prevent an undesired effect as a result of a combination of drugs’. This definition clearly 
states that a drug interaction alert is useful only when an intervention is necessary and 
possible, for example prescribing and/or dispensing an alternative drug, dosage adjustment 
or adjusted monitoring of drug effects.  
In an ideal situation the information necessary to take the appropriate actions is present 
at the moment of registration of the new drug, in scientific publications. However, this 
situation rarely exists. In most instances information on drug-drug interactions in product 
leaflets is too comprehensive to be of practical use and specific drug-drug interaction studies 
are absent. With the introduction of legislative guidelines concerning obligatory studies on 
the field of drug-drug interactions as part of the registration files, this situation may be 
improved.  
Despite this improvement, the correct interpretation of the potential severity of an 
adverse effect resulting from a drug-drug interaction for the individual patient will remain a 
responsibility for health care providers. To fullfill this responsibility health care providers 
have to be informed, clearly and completely, on the relevant factors for making this 
interpretation.  
In this context, electronic drug interaction surveillance systems can fullfill an important 
role, complementary to the informing and alerting function of the product leaflets. In chapter 
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5.1 a structured procedure for assessing the clinical relevance of a drug-drug interaction 
based on the evaluation of four core parameters is described. This procedure is developed 
and implemented by the Working Group on Pharmacotherapy and Drug Information in the 
maintenance of the electronic drug interaction surveillance system of the Royal Dutch 
Association for the Advancement of Pharmacy. On the basis of this assessment the 
complete database is reviewed resulting in 36% of the interacting combinations to be 
assessed as ‘not interacting’ or ‘interacting but not requiring any action’. On the basis of 
experience with this procedure in the last few years, we concluded that this procedure offers 
the possibility for transparent and reproducible assessment of the clinical relevance of 
potential interacting drug combinations.  
This assessment procedure is used for assessing the clinical relevance of drug-drug 
interactions with disease-modifying antirheumatic drugs. Results of this study are described 
in chapter 5.2. Two observer groups, rheumatologists and pharmacologists, independently 
assessed whether the individual combinations interacted and whether the combination 
required immediate intervention. From a total of 40 DMARD-drug combinations, 17 (43%) 
were judged to be interacting and require immediate intervention, 13 (32%) were judged not 
to require immediate intervention and for 10 combinations (25%) pharmacists and 
rheumatologists did not agree. Rheumatologists tended to require immediate intervention 
more often for drug-drug interactions with increased toxicity of the DMARD as the adverse 
reaction, while pharmacologists more often judged drug-drug interactions with an increased 
risk of DMARD failure to require immediate intervention. We conclude that due to 
differences in perception of severity of the effect of a DMARD-drug interaction, perceived 
specificity (generating an alert only when relevant) and sensitivity (generating an alert 
whenever relevant) of alerts generated by electronic drug interaction surveillance systems 




A structural assessment of potential drug interactions for selection for electronic drug 
interaction surveillance systems, can be considered to be a starting point for further 
research. It is to be expected that electronic interaction surveillance systems yielding alerts 
with high specificity and high sensitivity, as a result of multidisciplinary discussion, will 
support clinical decision making better, compared with systems with low specificity and 
sensitivity. However, this has to be subject of future studies. These studies, for example, 
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could focus on the acceptance of alerts from these systems by physicians and pharmacists. 
How often are alerts overruled without taking notice? How often is clinical decision making 
influenced due to an interaction alert? On the other hand, these studies could focus on the 























Het werkterrein van de reumatologie is de laatste jaren door het beschikbaar komen van 
nieuwe behandelopties sterk veranderd. In dit snel veranderende veld is het van groot 
belang nieuwe informatie adequaat te implementeren en kritisch te evalueren om optimale 
behandeluitkomsten voor de individuele patiënt te realiseren.  
Dit proefschrift bestudeert diverse aspecten van veiligheid en effectiviteit van 
farmacotherapie bij de behandeling van reumatoïde artritis (RA). De onderzoeken in dit 
proefschrift richten zich op leflunomide, parenteraal goud en de klinische relevantie van 
geneesmiddel-geneesmiddel interacties met de zogenaamde ‘disease-modifying 
antirheumatic drugs’ (DMARDs). 
 
 
Leflunomide in de reumatologische praktijk 
 
Samenvatting en discussie 
In hoofdstuk 2 worden onderzoeken betreffende de behandeling van RA met leflunomide 
in de dagelijkse reumatologische praktijk beschreven. In hoofdstuk 2.1 wordt prospectief 
het staken van de behandeling met leflunomide, het optreden van bijwerkingen en de 
effectiviteit van leflunomide onderzocht in een poliklinische populatie patiënten met RA. In 
dit onderzoek zijn 136 patiënten geïncludeerd. Tijdens de observatieperiode stopten 76 
patiënten (56%) met leflunomide, met name in verband met het optreden van bijwerkingen 
(29%) of het ontbreken van (voldoende) effectiviteit (13%). Vijfenzestig procent van de 
patiënten meldde tijdens de observatieperiode minimaal 1 bijwerking die werd gerelateerd 
aan het gebruik van leflunomide. Binnen een periode van 12 maanden na start van de 
leflunomidebehandeling kon 76% van de populatie geclassificeerd worden als ‘moderate’ of 
‘good’ responder, op basis van de ziekteactiviteit beoordeeld aan de hand van 28 
gewrichten (disease activity score 28; DAS28). Naar aanleiding van de resultaten van dit 
onderzoek werd geconcludeerd dat leflunomide een effectieve behandeling voor RA biedt, 
maar dat de kans op staken van de leflunomidebehandeling, met name door het optreden 
van bijwerkingen, hoog is. De resultaten van het onderzoek benadrukken het belang van 
kritisch evaluerende, observationele onderzoeken ter bepaling van de plaats van nieuwe 
DMARD-behandelopties in de dagelijkse reumatologische praktijk. Daarnaast wijzen de 
resultaten op de noodzaak om de behandeling met leflunomide te optimaliseren en te 
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komen tot een betere herkenning van patiënten die een groter risico hebben op 
therapeutisch falen. 
Een van de bijwerkingen van leflunomide die veel aandacht heeft gekregen in de 
medische literatuur en de lekenpers was hepatotoxiciteit, met name door het optreden van 
enkele fataal verlopen incidenten. Hoewel zeldzaam, hebben deze incidenten de aanzet 
gegeven tot een discussie over de wenselijkheid van het op de markt houden van 
leflunomide voor de behandeling van RA. Uiteindelijk heeft deze discussie geleid tot 
aanpassingen in de productinformatie van leflunomide betreffende een striktere controle van 
de leverenzymactiviteiten, als maatstaf voor leverfunctiestoornissen. Discussies over de 
veiligheid van leflunomide naar aanleiding van enkele ernstige gevallen van hepatotoxiciteit 
zijn van groot belang om veilig geneesmiddelgebruik te optimaliseren. Een kritische 
evaluatie van de frequentie en ernst van hepatotoxiciteit zoals vastgesteld door klinisch-
chemische bepaling van leverenzymactiviteiten in de dagelijkse reumatologische praktijk zijn 
op deze discussies een aanvulling. 
Om inzicht te verkrijgen in de frequentie, de ernst en het moment van optreden van 
verhoogde leverenzymactiviteiten, is een onderzoek in een populatie patiënten met RA 
gedurende leflunomidetherapie uitgevoerd. De resultaten van dit onderzoek zijn beschreven 
in hoofdstuk 2.2. Om de ernst van de hepatotoxiciteit te kunnen categoriseren worden 
stijgingen van de leverenzymactiviteiten volgens de Common Toxicity Criteria van het 
National Cancer Institute ingedeeld. De Common Toxicity Criteria maken gebruik van een 
indeling van de ernst van bijwerkingen in moderate (graad 2), ernstig (graad 3) of 
levensbedreigend (graad 4), afhankelijk van de mate van stijging ten opzichte van de 
bovenste grens van de referentiewaarden. In een populatie van 101 patiënten vertoonden 9 
patiënten (8,9%) een graad 2 of graad 3 stijging van de leverenzymactiviteit. Graad 4 
stijgingen en klinische verschijnselen van hepatotoxiciteit werden in de observatieperiode 
niet vastgesteld. In verband met graad 2 leverenzymstijgingen is 1 patiënt (1%) gestopt met 
de leflunomidebehandeling, bij 1 patiënt werd de dagdosering leflunomide verlaagd. In 8 van 
de 9 patiënten met een graad 2 of graad 3 stijging trad deze stijging binnen 6 maanden na 
start van de leflunomidebehandeling op. Geen van de patiënten met een graad 2 of graad 3 
stijging had een voorgeschiedenis waarin sprake was van leverziekten. Acht van de negen 
patiënten gebruikten naast leflunomide ook andere medicatie waarvan bekend is dat 
leverfunctiestoornissen kunnen optreden. Acht patiënten (8%) gebruikten leflunomide in 
combinatie met methotrexaat, 1 van deze patiënten ontwikkelde leverfunctiestoornissen. 
Naar aanleiding van de resultaten van dit onderzoek werd geconcludeerd dat, onder de 
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voorwaarde van strikte controle van de leverfuncties, in onze populatie hepatotoxiciteit 
gedurende het gebruik van leflunomide geen groot probleem lijkt. 
Zoals geconcludeerd is naar aanleiding van de resultaten van de langetermijnobservatie 
die in hoofdstuk 2.1 is beschreven, kan vroege herkenning van patiënten met een grote 
kans van falen van de leflunomidebehandeling een handvat bieden voor verdere verbetering 
in het behalen van de beoogde behandeldoelen. Het continueren van de 
leflunomidebehandeling kan als maat voor het slagen of falen van de behandeling gebruikt 
worden. In hoofdstuk 2.3 wordt een onderzoek beschreven waarin voorspellende factoren 
voor het continueren van de leflunomidebehandeling worden gezocht. Als basis voor dit 
onderzoek is gebruik gemaakt van een databestand van patiënten met RA, die in de regio’s 
Friesland en Twente poliklinisch door een reumatoloog met leflunomide werden behandeld. 
Het databestand bevatte 279 patiënten, van wie er 173 (62%) het gebruik van leflunomide 
tijdens de observatieperiode staakten. Uit univariate en multivariate analyse bleek dat het 
gelijktijdig gebruik van systemische corticosteroïden en een bezinkingssnelheid < 35 mm/uur 
bij start van de leflunomidebehandeling voorspellend waren voor een langere periode van 
continueren van de leflunomidebehandeling. Verder werd naar aanleiding van de univariate 
en de multivariate analyse vastgesteld dat er tussen de behandelende reumatologen 
verschillen in de duur van continueren van de leflunomidebehandeling bestonden. Naar 
aanleiding van de resultaten van dit onderzoek werd geconcludeerd dat er factoren zijn die 
een voorspellende waarde ten aanzien van het continueren van de leflunomidebehandeling 
hebben. Informatie over deze voorspellende factoren kan mogelijkheden bieden voor 
verdere optimalisatie van leflunomidebehandeling. 
Op basis van de hoge frequentie waarmee patiënten de behandeling met leflunomide 
beëindigen, werd onderzoek gedaan naar een manier om de uitkomsten van de 
leflunomidebehandeling te verbeteren. Een van de opties was implementatie van 
zogenaamde ‘therapeutic drug monitoring’; dat wil zeggen de bepaling van de concentraties 
van de werkzame stof in het bloed en het gebruiken van de uitkomsten van deze bepaling 
als handvat voor het aanpassen van het therapeutisch beleid.  
 
In hoofdstuk 3 wordt de potentiële rol van ‘ therapeutic drug monitoring’ bij behandeling 
met leflunomide onderzocht. In hoofdstuk 3.1 wordt een bepalingsmethode technisch en 
klinisch gevalideerd om de serumconcentraties van de werkzame metaboliet van 
leflunomide, A77 1726, te kunnen bepalen. De bepalingsmethode voldeed op alle 
onderdelen van de technische validatie (lineariteit, intra- en interday precisie, juistheid, 
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specificiteit en de bovenste en onderste grenzen voor kwantificering van de concentratie) 
aan de gestelde voorwaarden. Voor de klinische validatie werden met behulp van deze 
bepalingsmethode de serumconcentraties van A77 1726 bepaald bij 37 RA patiënten die 
gedurende minimaal 4 maanden met leflunomide werden behandeld. De gemeten A77 1726 
serumconcentraties vertoonden een grote variatie, met een spreiding van 3 tot 176 mg/liter. 
Van 95% van de patiënten viel de gemeten concentratie binnen het gevalideerde 
concentratiegebied van de bepalingsmethode. Op basis van deze resultaten wordt 
geconcludeerd dat de gevalideerde methode kan worden toegepast bij de bepaling van de 
A77 1726 serumconcentraties bij patiënten met RA die worden behandeld met leflunomide. 
Met behulp van deze bepalingsmethode werd het verband tussen de A77 1726 
serumconcentraties en de DAS28 en de DAS28-respons onderzocht. De serumconcentraties 
werden bepaald op een moment tijdens de behandeling waarop de maximale, constante 
serumconcentratie bereikt is, de zogenaamde ‘steady state’ concentratie. De resultaten van 
dit onderzoek worden beschreven in hoofdstuk 3.2. In dit onderzoek werden 52 patiënten 
met RA en gedurende minimaal 4 maanden een stabiele dosering leflunomide geïncludeerd. 
Dit onderzoek toonde dat er een verband is tussen de A77 1726 steady state 
serumconcentratie en de respons op basis van de DAS28-criteria; patiënten met een A77 
1726 steady state serumconcentratie < 16 mg/L vertoonden geen goede respons op basis 
van de DAS28-criteria. Deze resultaten wijzen op de mogelijkheid voor bepaling van de A77 
1726 serumconcentratie voor die patiënten die onvoldoende respons vertonen op de 
leflunomidebehandeling om klinisch relevante informatie te verkrijgen voor het continueren 
van de behandeling of het aanpassen van de dosering.  
 
Toekomstperspectieven 
De belangrijkste resultaten van het eerste hoofdstuk zijn de hoge frequentie waarmee de 
leflunomidebehandeling in het eerste jaar na start van de behandeling wordt gestaakt en het 
grote percentage patiënten dat bijwerkingen meldt. Dit leidt tot de conclusie dat verdere 
optimalisatie van de leflunomidebehandeling is aangewezen om optimale 
behandeluitkomsten voor de individuele patiënt te realiseren.  
Herkenning van karakteristieken die de kans op therapiefalen kunnen voorspellen, lijkt 
een basale strategie om behandeluitkomsten te verbeteren. Echter, of kennis van deze 
voorspellende factoren inderdaad kan leiden tot verbetering van de behandeluitkomsten 
voor de individuele patiënt, dient te worden onderzocht in toekomstige, prospectieve 
onderzoeken. Op welke wijze kennis van de voorspellende factoren kan worden toegepast 
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zal een belangrijke factor zijn in deze toekomstige onderzoeken. Dienen patiënten met een 
hoger risico op therapiefalen frequenter te worden gecontroleerd door hun reumatoloog? Zo 
ja, op basis van welke informatie, naast de kennis van de voorspellende factoren, kunnen de 
behandeluitkomsten dan worden verbeterd? Dienen patiënten met een hogere kans op 
therapiefalen te worden behandeld met een afwijkend behandelschema, bijvoorbeeld door 
het weglaten van de oplaaddosis of door hogere of lagere onderhoudsdoseringen dan 
momenteel worden geadviseerd in de bijsluiter? Deze en andere vragen dienen te worden 
beantwoord om de voorspellende factoren voor therapiefalen te kunnen implementeren in 
het therapeutisch beleid.  
Een mogelijkheid voor optimalisatie van leflunomidebehandeling is onderzocht in het 
hoofdstuk aangaande ‘therapeutic drug monitoring’. Zoals al gesteld in de discussie bij dit 
hoofdstuk, zou het interessant zijn te weten of beslissingen over continueren of stoppen van 
de leflunomidebehandeling vroeg in de therapie, kunnen worden gebaseerd op de 
combinatie van onvoldoende respons en een lage A77 1726 serumconcentratie. Onder de 
aannames van therapietrouw en stabiele dosering, bestaat er een duidelijke relatie tussen 
de duur van de therapie, de A77 1726 serumconcentratie op dat moment en de te bereiken 
‘steady state’ serumconcentratie. Dit leidt tot de hypothese dat een niet-steady state A77 
1726 serumconcentratie die vroeg in de behandeling is bepaald, bijvoorbeeld na 4 weken 
behandeling, zou kunnen worden gebruikt ter voorspelling van de respons later in de 
therapie. Toepassing van deze hypothese zou kunnen leiden tot de mogelijkheid om vroeg 
in de behandeling beslissingen te nemen over het continueren, aanpassen of staken van de 
leflunomidebehandeling en daarmee vertraging te voorkomen voordat wordt overgestapt op 
effectievere alternatieve behandelingen voor de individuele patiënt. In welke mate deze 
benadering zal leiden tot verbeterde uitkomsten van de behandeling zal onderwerp dienen 
te zijn van verder onderzoek.  
Bevestiging van de resultaten van ons ‘therapeutic drug monitoring’ onderzoek in een 
groter, prospectief onderzoek met patiënten op de novo leflunomidetherapie is de 
voorgestelde eerste stap voor toekomstig onderzoek. De tweede stap kan bestaan uit een 
gerandomiseerd onderzoek waarin uitkomsten van de novo leflunomidebehandeling bij RA 






Wisselen van preparaten voor parenterale toediening van goudzouten 
 
Samenvatting en discussie 
Na het terugtrekken van aurothioglucose (Auromyose®) van de Nederlandse markt werd 
aurothiomalaat (Tauredon®) als alternatief preparaat geadviseerd. Op basis van de actieve 
component van Auromyose® en Tauredon®, goud, is deze keuze niet opvallend. Vanuit het 
oogpunt van ‘evidence based medicine’ is dit advies echter wel opvallend, daar geen grote 
vergelijkende onderzoeken tussen beide preparaten op het gebied van veiligheid en 
effectiviteit zijn gepubliceerd.  
Om deze reden is een kritische evaluatie van de uitkomsten van aurothiomalaat 
behandeling, na wisselen van aurothioglucose, aangewezen. Onderzoek naar deze 
uitkomsten is beschreven in hoofdstuk 4.1. In dit onderzoek is een populatie patiënten 
gedurende het eerste jaar na wisselen van aurothioglucose- naar 
aurothiomalaatbehandeling gevolgd, om effectiviteit en veiligheid van de behandeling te 
bestuderen. De geïncludeerde populatie bestond uit 120 patiënten, waarvan er 19 (16%) 
een bijwerking meldden die niet eerder tijdens de behandeling met aurothioglucose was 
gemeld. Gedurende de 12 maanden durende observatieperiode staakten 29 patiënten 
(24%) het gebruik van aurothiomalaat in verband met onvoldoende effectiviteit (14%), 
bijwerkingen (7%) of ziekte in remissie (3%). Er werden geen statistische significante 
verschillen gevonden in de parameters voor ziekteactiviteit ten opzichte van deze 
parameters bij start van de aurothiomalaatbehandeling voor die patiënten die de 
behandeling continueerden gedurende 12 maanden. Uit vergelijking van de frequentie van 
staken van aurothiomalaat in ons onderzoek en andere onderzoeken, blijkt dat de in dit 
onderzoek gevonden frequentie van staken lager is dan bij patiënten die de novo starten 
met parenterale goudbehandeling, maar hoger is dan bij patiënten op langdurige (jaren) 
goudtherapie. De hogere frequentie van therapiestaken en de meldingen van bijwerkingen 
die niet eerder gemeld zijn tijdens aurothioglucosebehandeling, suggereren dat met de 
behandeling met aurothiomalaat een behandeling is gestart met andere karakteristieken dan 
de aurothioglucosebehandeling. Dat slechts 24% van de patiënten het gebruik van 
aurothiomalaat binnen 12 maanden staakt, weerspiegelt mogelijk een zekere mate van 






De resultaten van dit onderzoek leren ons dat een kritische evaluatie van 
behandeluitkomsten bij het kiezen van alternatieve behandelingen in geval van het 
terugtrekken van een reeds gestarte behandeling, inzicht kan geven in effectiviteit en 
veiligheid van de nieuwe behandeling.  
 
 
Klinische relevantie van geneesmiddel-geneesmiddel interacties 
 
Samenvatting en discussie 
In de onderzoeken op het gebied van geneesmiddelinteracties is het doel van het 
signaleren van een geneesmiddelinteracties gedefinieerd als ‘de tijdige herkenning van de 
mogelijkheid om te interveniëren in geneesmiddelgebruik met als doel te voorkomen dat een 
ongewenst effect ten gevolge van combinaties van geneesmiddelen optreedt.’ Deze definitie 
maakt duidelijk dat een geneesmiddelinteractiesignaal alleen bruikbaar is als een interventie 
mogelijk en nodig is, bijvoorbeeld door het voorschrijven van een alternatief geneesmiddel, 
het aanpassen van de dosering of een aanpassing in de monitoring van het 
geneesmiddeleffect. In de ideale situatie is alle informatie die nodig is om de vereiste 
interventie te plegen, aanwezig op het moment dat het nieuwe geneesmiddel geregistreerd 
wordt. Helaas is deze situatie slechts zelden realiteit. In de meeste gevallen is de informatie 
over geneesmiddel-geneesmiddelinteracties in de bijsluiter te beknopt om direct toe te 
passen in het klinische beslisproces en ontbreken gepubliceerde onderzoeken op het 
gebied van geneesmiddelinteracties. Met de introductie van regelgeving op het gebied van 
verplichte onderzoeken naar geneesmiddelinteracties als onderdeel van het 
registratiedossier kan deze situatie verbeteren. 
Ondanks deze mogelijke verbetering, blijft de correcte interpretatie van de relevantie van 
de geneesmiddelinteractie voor de individuele patiënt de verantwoordelijkheid van de 
zorgverleners, met name artsen en apothekers. Om deze verantwoordelijkheid vorm te 
kunnen geven, dienen deze zorgverleners volledig en duidelijk te worden geïnformeerd over 
de kritische factoren betreffende de geneesmiddelinteractie om zich de juiste interpretatie te 
kunnen vormen.  
Een elektronisch geneesmiddelinteractie begeleidingssysteem kan vanuit deze optiek 
een belangrijke rol vervullen, aanvullend aan de informatie in de bijsluiter. In hoofdstuk 5.1 
wordt een gestructureerde procedure beschreven voor de beoordeling van de relevantie van 
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geneesmiddel-geneesmiddel interacties gebaseerd op de evaluatie van vier 
kernparameters: de kwaliteit van de bewijslast, de ernst van het potentiële effect, 
risicofactoren voor het optreden van het effect en de incidentie van het effect ten gevolge 
van de interactie. Deze procedure is ontwikkeld door de Werkgroep Farmacotherapie en 
Geneesmiddelinformatie en in het onderhoud van het elektronisch geneesmiddelinteractie 
begeleidingssysteem van de Koninklijke Nederlandse Maatschappij ter bevordering van de 
Pharmacie (KNMP) geïmplementeerd. Op basis van de beoordeling volgens deze procedure 
is de gehele bestaande database herzien. Deze herziening heeft ertoe geleid dat 36% van 
de interagerende combinaties als ‘geen interactie’ of ‘interactie, maar geen interventie nodig’ 
is beoordeeld. Op basis van de ervaring met het gebruik van deze procedure in de 
afgelopen jaren wordt geconcludeerd dat deze procedure de mogelijkheid biedt voor 
transparante en reproduceerbare beoordeling van de klinische relevantie van potentieel 
interagerende geneesmiddelcombinaties. 
Deze beoordelingssystematiek is voor bepaling van de klinische relevantie van 
geneesmiddel-geneesmiddel interactie met de DMARD’s gebruikt. De resultaten van dit 
onderzoek zijn beschreven in hoofdstuk 5.2. Twee groepen beoordelaars, reumatologen en 
farmacologen, beoordeelden onafhankelijk of er bij de individuele geneesmiddelcombinaties 
sprake was van een interactie en of deze interactie vervolgens een interventie vereiste. Van 
het totaal van 40 geselecteerde geneesmiddelcombinaties werden er 17 (43%) beoordeeld 
als interacties die een interventie vereisten, 13 (32%) als combinaties die geen interventie 
vereisten en voor 10 (25%) combinaties kwamen de beide beoordelaarsgroepen niet tot 
hetzelfde oordeel. Het onderzoek liet een trend zien waarbij reumatologen vaker dan 
farmacologen een interventie relevant achtten voor combinaties waarbij het effect een 
verhoogde kans op bijwerkingen van het DMARD betrof. Farmacologen bleken een 
interventie eerder relevant te achten voor die combinaties waarbij het potentiële effect een 
verminderde effectiviteit van het DMARD betrof. Op basis van deze resultaten wordt 
geconcludeerd dat door verschillen in de beoordeling van de relevantie van 
geneesmiddelinteracties, de beleving van specificiteit (alleen een interactiesignaal 
genereren indien vereist) en sensitiviteit (in alle vereiste gevallen een signaal genereren) 
van signalen die door elektronisch geneesmiddelinteractie begeleidingssystemen worden 
gegenereerd als suboptimaal worden ervaren, indien deze systemen niet worden gevoed 




Van een elektronisch geneesmiddelinteractie begeleidingssysteem dat signalen 
genereert met hoge specificiteit en sensitiviteit op basis van multidisciplinaire beoordeling, 
mag een betere ondersteuning van het klinisch beslisproces worden verwacht dan van een 
systeem met lagere specificiteit en sensitiviteit. Of deze verwachting ook bewaarheid wordt 
en of betere behandeluitkomsten worden gerealiseerd, dient te worden onderzocht in 
toekomstig onderzoek. Dit onderzoek kan zich op de acceptatie van interactiesignalen door 
artsen en apothekers richten. Hoe vaak en om welke redenen worden interactiesignalen 
genegeerd zonder adequate interventie? Hoe vaak wordt het klinisch beslisproces door een 
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Daar ligt het dan, een afgerond proefschrift. Bij het schrijven van dit dankwoord valt me 
op dat naast de aandacht voor het verzamelen, analyseren en opschrijven van alle 
gegevens er een ander belangrijk aspect aan het promoveren is: je leert er een grote groep 
bijzondere, interessante en aardige mensen mee kennen.  Zoveel mensen hebben een 
waardevolle bijdrage aan dit proefschrift geleverd dat het risico bestaat iemand in dit 
dankwoord te vergeten. Mocht dit onverhoopt gebeurd zijn, dan hoop ik dat diegene mij dat 
kan vergeven. 
Koos Brouwers en Mart van de Laar, mijn beide promotoren, wil ik bedanken voor de 
prettige en stimulerende manier waarop de samenwerking heeft plaatsgevonden. Door jullie 
bijdrage en creatieve ideeën voor vervolgonderzoek heeft het nooit aan momentum 
ontbroken. Jullie uitgebreide collegiale netwerken hebben er voor gezorgd dat creatieve 
ideeën niet strandden in schoonheid, maar ook konden worden uitgevoerd. Hoewel dit 
proefschrift een mooie afsluiting is van een periode, stopt het samenwerken hier gelukkig 
niet. De ideeën die we voor gezamenlijk onderzoek in de toekomst hebben, vormen een 
mooie basis voor een vervolg waar ik naar uitkijk. 
De basis voor mijn interesse in geneesmiddelenonderzoek is tijdens mijn opleiding tot 
ziekenhuisapotheker gelegd. Onder meer om deze reden kijk ik terug op een enorm fijne tijd 
in mijn opleidingsziekenhuizen in Tilburg. Bertil, Toine, Jacques, Hans en Kathleen bedankt 
voor jullie inzet om mijn opleiding tot een succes te maken.  
Bob, als hoofd van onze bovenlokale ziekenhuisapotheken, is je agenda meer dan 
gevuld met allerlei beleidsmatige zaken en dagelijkse beslommeringen. Dat je daarnaast 
altijd tijd vond om mij aan te horen als ik ‘even wat kwijt moest’ of ‘even met je wilde 
overleggen over een vraagje in het onderzoek’ waardeer ik enorm. Met een rake 
helikopterview kun jij de zaken weer in perspectief zetten, een gave waarvan ik in het kader 
van dit proefschrift meermalen dankbaar gebruik heb gemaakt. Een treinreis naar Mainz in 
2002 is daarvan, zoals je je ongetwijfeld herinnert, een sprekend voorbeeld.  
Mijn collega’s in Heerenveen en Leeuwarden zijn van groot belang geweest om het 
onderzoek mogelijk te maken. Het feit dat jullie het jarenlang opgevangen hebben dat ik één 
dag per week aan het promotieonderzoek heb besteed, zegt wat dat betreft genoeg. Romke, 
Rients, Jan Peter, Karen, Mark, Nicole, Lina, Michiel, Jennifer en Jan, bedankt!  
De voortdurende aandacht en inzet van studenten van de farmacieopleiding is voor het 
behalen van het resultaat van groot belang geweest. Wietse Baars, Judith Kohne, Marjolijn 
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van Wanrooij, René Keuper, Mei Din Wu en Froukje Idzinga, bedankt voor jullie inzet tijdens 
de bijvakonderzoeken.  
Nella Houtman, Mathijs Janssen, Marijn Kruijsen, George Bruyn, Hein Bernelot Moens, 
Anneke Spoorenberg, Ed Griep en de andere betrokken reumatologen in Nederland ben ik 
dankbaar voor hun voortdurende medewerking om de data voor de onderzoeken te 
verzamelen. Naast vele andere verzoeken in het kader van mijn onderzoek, klinkt het ‘even’ 
verzamelen van de parameters voor een DAS28-score bij elke visite als eenvoudig, maar 
kost het veel tijd in de drukke dagelijkse routine en is cruciaal voor het welslagen van 
klinisch praktijkonderzoek. Dat dit proefschrift voor jullie ligt, is het bewijs van een inzet 
waarvoor ik jullie enorm dankbaar ben.  
Monique Hoekstra, als kersverse doctor hebben jij en ik in dezelfde tijd ons proefschrift 
geschreven. De Twents-Friese samenwerking vond ik erg prettig en jouw verdediging was 
een mooi voorbeeld dat ik graag volg. 
Hilde Tobi, bedankt voor je enthousiasme bij de dagen van gezamenlijke data-analyse in 
Groningen. Ik heb er veel van geleerd.  
Jelly, Hieke, Femy, Sjoukje, Ankie, Henk en Martin bedankt voor de inzet waarmee jullie 
de bijvakstudenten hebben begeleid, waar het ging om de bepaling van de A77 1726 
plasmaconcentraties.  
De leden van de Werkgroep Farmacotherapie en Geneesmiddelinformatie wil ik hartelijk 
bedanken voor de vele, vele, vele uren die we samen hebben gediscussieerd om te komen 
tot een nieuwe systematiek van interactiebeoordeling. Ik ben er van overtuigd dat we aan 
het einde van de lijn een instrument in handen hebben, dat een verschil kan maken in dit 
aspect van de farmaceutische zorg voor de aan ons toevertrouwde patiënten.  
De leden van de leescommissie, prof. dr. A.F.A.M. Schobben, prof. dr. P.L.C.M. van Riel 
en prof. dr. K. Poelstra, wil ik op deze plaats bedanken voor hun bereidheid het manuscript 
te beoordelen en te voorzien van hun waardevolle commentaar.  
Twee mensen verdienen in dit dankwoord een aparte plaats in de schijnwerpers: Tim 
Jansen en Patricia van den Bemt. 
Tim, vanaf het moment dat ik in het Medisch Centrum Leeuwarden een voet over de 
drempel zette, heb ik onze samenwerking enorm gewaardeerd. Toen dat in de loop van 
2000 zelfs de vorm van een promotietraject kreeg, bleek die samenwerking nog een extra 
dimensie te krijgen. Vanaf het eerste moment heb jij herkend dat de ideeën die we hadden 
een proefschrift konden gaan vormen en heb je een belangrijke rol gehad in de realisatie 
van die ideeën. De snelheid waarmee jij reageert op conceptpublicaties evenaart die van 
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een snelle printer. De inkt is eigenlijk nog niet droog, maar de correcties en aanpassingen 
staan er al bij. Ik denk met plezier terug aan de avonden waarop we met een goed glas rode 
wijn boomden over lopende en toekomstige onderzoeken. Wat mij betreft zetten we dat in 
de toekomst onverminderd voort. Bedankt voor je inspanning om dit proefschrift te maken 
tot wat het is geworden. 
Patricia, al vanaf 1995 werken we onophoudelijk samen, eerst als directe collega’s 
binnen dezelfde vakgroepen en momenteel op verschillende locaties als noordzuidas dwars 
door Nederland. De wijze waarop jij invulling hebt gegeven aan het beroep van 
ziekenhuisapotheker en aan je eigen promotietraject zijn voor mij een voorbeeld dat 
navolging verdient. Ik ben er trots op dat jij paranimf bij dit voor mij zo belangrijke moment 
wilt zijn. 
Mijn familie en vrienden wil ik op deze plek bedanken voor de altijd aanwezige interesse 
voor de stand van zaken rond het proefschrift en voor de plezierige tijd die we hebben 
doorgebracht naast de voor iedereen drukke dagelijkse bezigheden.  
Lieve pa en ma, niet alleen een eigen gevoel van voldoening maar ook de waardering 
die je er voor van anderen ontvangt maken veel activiteiten in je leven waardevol. De 
aandacht, interesse, liefde en voortdurend stimulerende aanwezigheid van jullie zijn voor mij 
een belangrijke bron van inspiratie. Bedankt voor de kansen die jullie me hebben gegeven 
en de steun bij de keuzes die ik maak. 
Lieve Fenny, het zit er op! De afgelopen jaren heb je het schrijven van een proefschrift 
voor me mogelijk gemaakt door een warm ‘thuis’ voor me te zijn. Ons mooie leven kan weer 
meer in het teken komen te staan van samen dingen ondernemen. Bedankt voor je liefde en 
ondersteuning. 
 
Eric. 
 
